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Purpose, Vision, Values
Purpose:
We help people live well through
innovative research.

Vision:
Offer more treatment choices and improve
patient outcomes through research and innovation

Values:
– Every patient and community deserves the best care
– Resources should be managed responsibly

The annual report is published
by the office of the president
of Aurora Research Institute,
which oversees the patientcentered research conducted
throughout Aurora Health Care.
Randall Lambrecht, PhD
Senior Vice President,
Aurora Health Care
President,
Aurora Research Institute
414-219-7838
randall.lambrecht@aurora.org
Joe Grundle
Scientific Writer & Editor
414-219-7323
joseph.grundle@aurora.org
Katie Klein
Scientific Writer & Editor
414-219-3428
katie.klein@aurora.org
Julie Walters
Multimedia Designer
414-219-7825
julie.walters@aurora.org

– A healthy workplace is built through accountability,
teamwork and respect

Value Proposition:
Innovative research centered on improving
choices and outcomes for patients
•A
 premier destination health care system offering
more treatment options for patients
• Research that is patient-centered and held to the
highest standards of quality and ethics
• Attract talented and innovative clinicians focused on
finding better ways to help patients
• Educational outreach that not only touches individuals,
but transforms the health of communities
• National recognition and reputation for innovative
research through scholarly publication and presentations

The information presented in
this annual report is intended
for general information and
educational purposes. It is not
intended to replace the advice
of your own physician. Contact
your physician if you believe
you have a health problem.
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President’s welcome message
We are excited to present
the Aurora Research Institute
2014 Patient-Centered
Research Annual Report, a
gauge of recent innovative
research achieved throughout
Aurora Health Care.
Such achievements include
implantation of the first
leadless pacemaker in
Wisconsin and study of an
innovative way to remove
brain clots through coordination of a nationwide
clinical trial. Aurora was awarded several competitive
federal grants – one for participation in the National
Cancer Institute Oncology Research Program (NCORP),
which expands local access to clinical trials, and
another for the SMARTCare project, which aims to
advance cardiovascular care while saving costs. Other
highlights include receiving National Institutes of
Health funding to study genetic testing as a means
to offering precision (personalized) medicine, and
renewal of a U.S. Department of Defense grant to
continue our Knowledge-Based Nursing Initiative.
Through the partnership with Discovery World, our
cardiovascular researchers educated the community
in a direct, interactive way. Our philanthropic efforts

were returned as His Highness Sheikh Khalifa bin
Hamad Al Thani, Tim and Vivian Sullivan, and so many
others gave generous gifts to support research.
Our successes are too numerous to recount here.
Paging through this report, I trust you will be as proud
as I am of all the tremendous research at Aurora.
For our patients who span the globe, Aurora Research
Institute represents innovative research centered on
improving choices and outcomes that change not only
the lives of individuals, but transform the health of
populations. Our Journal of Patient-Centered Research
and Reviews helps advance scientific breakthroughs
to patients and medical professionals spanning more
than 70 countries and six continents.
On behalf of Aurora Research Institute and its newly
formed board of directors, I am pleased to provide
this highlight of our 2014 outcomes and, as always,
I welcome your feedback.
Helping people live well through innovative research,

Randall Lambrecht, PhD
Senior Vice President, Aurora Health Care
President, Aurora Research Institute

Aurora Research Institute

Board of Directors
Aurora Research Institute is governed by a board of directors that consists of Aurora Health
Care leaders who oversee the strategic and financial decisions that shape the institute’s future.
Gerard Colman, PhD
Chief Operating Officer

ASSISTANT SECRETARY
Rachelle (Shelly) Hart
General Counsel

Patrick Falvey, PhD
Executive Vice President
of Integration
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CONTRIBUTING TO

AURORA’S WAY FORWARD
2015 AND BEYOND

AURORA RESEARCH INSTITUTE ENGAGES …
Caregivers
• With regular learning opportunities
• Through relevant research-related news
Researchers systemwide and beyond
• Through quarterly publication of Journal of Patient-Centered Research and Reviews
• With more than 180 scientific journal articles/textbook chapters and more than 130 abstracts published last year
• By offering intramural grant opportunities totaling more than $530,000 annually for heart and cancer studies
• With recognition for outstanding research efforts
Patients and survivors
• With treatment options they can’t get elsewhere
• Through programs that lead to better outcomes and promote adoption of healthy lifestyles
Generous donors
• To enhance research on the aging heart and research performed by fellows
• To provide educational opportunities and advance medicine
Communities and stakeholders
• With the Aurora Health Satellite through a partnership with Discovery World
• Through public outreach, collaboration with American Heart Association
• At speaking engagements for the Clinical Trials Education Network of Wisconsin and others
Policymakers
• For development of SMARTCare software to improve care for patients with stable ischemic heart disease
• Through designation as a National Cancer Institute Community Oncology Research Program site to expand cancer
clinical trial offerings
• With nursing education through a U.S. Department of Defense grant

AURORA RESEARCH INSTITUTE ENHANCES …
• Care for the people Aurora serves by providing more choices and improved outcomes through innovative research
• Data analysis with digital analytics staff and biostatistician support
• Health care savings by managing finances responsibly

AURORA RESEARCH INSTITUTE GROWS …
• The Wisconsin First strategy by being the first in Wisconsin to offer the latest treatments through research like a
leadless pacemaker and stem cell therapies

AURORA RESEARCH INSTITUTE TRANSFORMS …
• Research into new treatment options for the people Aurora serves
• Populations through collaboration with Center for Urban Population Health

AURORA RESEARCH INSTITUTE INNOVATES …

X49140 (11/14) ©AHC

• New technologies and treatments of care delivery like the integrated surgical approach to remove brain clots
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Research Business Services
Kurt Waldhuetter
Vice President, Research Business Services
Waldhuetter leads the Research Business Services team, which is responsible for
Aurora Research Institute’s business operations and planning as well as pursuing
collaborative opportunities.

Research Business Services
Senior research business analyst Julie
Basquin, MS, serves as a liaison to the
Finance Department and helps facilitate
resource planning for Aurora Research
Institute, with budget planning and financial
monitoring and reporting services.

2014 expenditures: $16.5 million

Industry
contracts
$4,607,127

Foundation
support
$1,406,576

Grants and
awards
$2,152,504

Institutional
investment
$7,144,899

Clinical
programs
$837,361
Other
$400,287
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Biorepository and Specimen
Resource Center

Fostering innovation

Powered by ORBIT (Open-Access Robotic
Biorepository and Informatics Technology)

Led by Natalie Polinske, MS, the Biorepository
and Specimen Resource Center (BSRC) provides
leftover and prospectively collected tissue
and blood samples for research uses ranging
from Alzheimer’s disease to ovarian cancer to
congestive heart failure.
More than 100,000 patients
have consented for their
leftover biospecimens to be
used for research purposes.
The BSRC is powered
by ORBIT (open-access
robotic biorepository and
informatics technology) and
supported by the Research
Analytics team, led by Andy
Marek. Through Aurora
Health Care’s electronic
health record database,
Research Analytics aids in
the transformation of data
into new knowledge and
medical-decision support.

Aurora Health Care
caregivers often come
up with new ways that
could achieve better
health outcomes, reduce
costs or redefine the
patient experience.
Research business
innovation manager
Don Conrad reviews
intellectual property
for commercialization
consideration.

In 2014:

8

entrepreneurial
projects engaged

12

inventions disclosed

In 2014:

16

biospecimen
requests
fulfilled

868

biospecimens
distributed
Research associate Anne-Marie McAnelly works with a blood sample.

Clinical Trials Business Services and Grant Contracting
Contract services are vital to deliver investigational treatment options to patients.
Led by Katie Richter, the Clinical Trials Business Services team assists with contract budgeting, including
medical coverage analysis, and contract negotiations. Contract services also are necessary to facilitate the
acceptance of grant funding.

In 2014:

78
grant

contract
agreements
completed

46
clinical trial

contract
agreements
completed

64
confidentiality
disclosure
agreements
completed

The Clinical Trials Business Services team at work.

aurora.org/research
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Clinical Trials Department
Sara Planton, BSN
Director, Clinical Trials Department
Planton runs the Clinical Trials Department, which provides access to cardiovascular, oncology,
neuroscience and other investigational treatments before they are available elsewhere.
More than 300 active drug, device, procedure and registry clinical trials are supported by
over 70 caregivers, including managers, coordinators, specialists and educators.
More than 1,100 patients enrolled in a clinical trial throughout Aurora Health Care in 2014.

Cardiovascular team
Led by Wendy Schmidt, RN, the Clinical
Trials Department cardiovascular team
coordinates clinical trials in the areas of
cardiac surgery, interventional cardiology
and electrophysiology and for conditions
such as pulmonary hypertension,
peripheral vascular disease, structural
heart disease, heart failure and other
cardiovascular disease conditions.
“The most exciting experience for my
team is to have the opportunity to provide
cutting-edge technology to cardiovascular
patients and families and see many trial
outcomes advance to FDA approval for
commercial use,” Schmidt said.

Oncology team
The oncology team, led by
Jan DeBartolo, MSN, coordinates
clinical trials on breast, lung,
colorectal, prostate, gynecologic,
hematologic, renal cell and other
cancers.
“Aurora Health Care was the recipient
of an NCORP grant,” DeBartolo said.
“More trials will be opened in shorter
time frames. Thirty-three new cancer
trials were approved in 2014. There
were 28 more enrollments in cancer
clinical trials in 2014 over 2013. We
anticipate an even larger degree of
change in 2015.”
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304 open clinical trials
as of Dec. 31, 2014

1,113 clinical trial
enrollments in 2014

Clinical trial revenues:
$4.6 million in 2014
Neurosciences
$631,576

Oncology
184

Cardiovascular
82

Oncology
349

Cardiovascular
$2,371,769

Cardiovascular
623

Neurosciences
17
Other*
21

Neurosciences
18
Other*
123

Other*
$532,423
Oncology
$1,077,777

*includes humanitarian-use device, gastrointestinal, orthopedic, radiology and asthma clinical trials

Neurosciences team
Manager Carol Tutino, BSN, MS,
leads the neurosciences team, which
coordinates clinical trials on brain
cancer and surgery, stroke, epilepsy
and interventional radiology. She also
oversees AsthmaNet studies and
orthopedic and women’s health research.
“In 2014, stroke studies were opened to
support Aurora St. Luke’s certification
as a Comprehensive Stroke Center.
MiSPACE, a minimally invasive technique
to remove blood clots from the brain,
was opened as a multicentered registry
study with Aurora St. Luke’s as the
coordinating center,” Tutino said.

Green Bay team
A joint venture between BayCare
Clinic and Aurora Health Care, Aurora
BayCare Medical Center offers
the latest clinical trials, which are
held to the same high standards as
throughout the Aurora system. The
team is led by Annette Paul.
“2014 was a building year with a
push for innovative, physician-driven
studies that cover multiple specialties
and continued growth in orthopedics
research,” Paul said.

aurora.org/research
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Sponsored Programs Office/
Investigator-Initiated Research Department
Vani Nilakantan, PhD
Director, Sponsored Programs Office and Investigator-Initiated Research Department
Dr. Nilakantan directs the Sponsored Programs Office (SPO) and leads the InvestigatorInitiated Research (IIR) Department. The SPO serves as a central coordinating hub for
Aurora Health Care’s externally and internally funded research and other projects. The IIR
Department facilitates studies in which the researcher takes responsibility for all aspects of
the project as sponsor. Dr. Nilakantan also oversees the Animal Research and Care Program.

Sponsored Programs Office
The goal of the SPO team is to assist principal investigators in their
efforts to secure extramural research funding (pre-award) and ensure
compliance with regulations, terms and conditions (post-award).
In 2014, the SPO tracked awards totaling $5,161,750 – a success
rate of 30%, which is nearly double the pay line rate for National
Institutes of Health research projects. The SPO also is responsible
for administering three intramural grant award programs (two
cardiovascular and one cancer) and supported the funding of
14 pilot grants totaling $533,686 in 2014.
The team includes a dedicated program administrator to manage
Aurora’s National Cancer Institute Community Oncology Research
Program award of $3.87 million over five years. The funding will help
expand access to cancer clinical trials in Wisconsin (see page 39).

In 2014:

$5,161,750
in extramural grants awarded

Grants by sponsor type:
$5.7 million in 2014
Federal
$5,016,843
State
$143,907
Nonprofit
$1,000
Intramural
$533,686

143 open IIR studies
as of Dec. 31, 2014*
Neuroscience
4
Women’s
Health
14
Cardiovascular
57
Other
50
Oncology
18

Source: Aurora Health Care
*Institutional
Review Board
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Misc. (39)

Informatics (4)
GI (4)
Ortho (3)

Investigator-Initiated Research
Senior research scientists/Senior biostatisticians
Across the Aurora system,
researchers are engaged in
investigator-initiated research and
are invested in developing ideas
and studies that lead to patientcentered outcomes.

of Wisconsin’s Milwaukee and
Madison campuses, Harvard
University, Vanderbilt University,
Medical College of Wisconsin, etc.)
investigators, and conduct their
own investigator-initiated research.

The IIR Department facilitates
such research with senior research
scientists with diverse expertise
in areas of cancer, cardiovascular,
epidemiology, pharmacogenetics
and informatics. The scientists
and senior biostatisticians are
aligned with the clinical system
programs and collaborate with
internal (cancer, cardiovascular,
women’s health, neuroscience,
etc.) and external (University

The work done by the IIR
Department is supported by
intramural (cardiac awards,
cardiovascular surgery award,
cancer care award) and extramural
funding from federal (National
Institutes of Health, Department
of Defense), industry (Genentech
Inc.) and foundations (Rock River
Cancer Research Foundation).

In 2014:

16

manuscripts published

50+

abstracts presented/
accepted by the team

The IIR team also supports
investigators with development
of methods, study design and
execution of research.

Animal research
and care program
David Krum, MS,
oversees operation of the
Electrophysiology Basic
Research Laboratory and
the animal research and care
program.
The animal program abides
by the Institute for Laboratory
Animal Research standards
outlined in the Guide for the
Care and Use of Laboratory
Animals, the Public Health
Service policy for all
vertebrate animals and the U.S.
Department of Agriculture’s
Animal Welfare Act. All research
protocols are supervised by
Aurora’s Institutional Animal
Care and Use Committee.

Research regulatory specialist, associates and
coordinators
Available to all Aurora researchers,
the research regulatory
specialist ensures compliance of
investigator-initiated research
with federal regulations and helps
investigators with Institutional
Review Board and Institutional

Animal Care and Use
Committee submissions.
Project-dedicated research
associates and coordinators
support sponsored investigatorinitiated research studies.

Aurora Research Institute

Regenerative Medicine Center/
Laboratory Research
Nina Garlie, PhD
Director, Regenerative Medicine Center
Dr. Garlie leads the Regenerative Medicine Center. Research conducted through the center is
directed at using the body’s own healing and immune processes to develop new treatments
for life-threatening diseases. The center also includes translational research laboratories that
focus on a variety of specialties. Laboratory manager Bob Stoltz, MBA, MT, oversees lab
staff, which includes associates, assistants, technologists and technicians.

Regenerative Medicine Center
The Regenerative Medicine Center, located at
Aurora St. Luke’s Medical Center, integrates
research and clinical care in an environment
conducive to innovation. Physicians and
research scientists work together to develop
personalized approaches to treat diseases,
learning from the patient’s body and its
ability to recognize and fight disease, then
heal and regenerate.
The center houses the Autologous Stem Cell
Transplant Program, an accredited clinical
service providing expert coordinated care
and high-quality stem cells for patients with
cancer. The goal of this 20-year program is
to continually research and develop the best
treatment approaches to improve outcomes
for transplant patients.

Senior research associate Angela Timler, MS (left), observes research
associate Rob Talatzko prepare flow cytometry samples; research associate
Kate Dennert (right) processes stem cells for transplant.

Results from a research study conducted by this lab in 2014 suggests that the stem cell collection procedure
for patients undergoing stem cell transplantation can be shortened without affecting the ability to reach target
numbers of stem cells required for successful transplant.

Transplant and Histocompatibility
Led by Martin Oaks, PhD, the scientific focus of
the Transplant and Histocompatibility Research
Laboratory is to characterize the antigens and
antibodies that are relevant to long-term survival
of solid organ transplants.
A primary research area for the lab is the
characterization of the anti-inflammatory (healing)
properties of certain subpopulations of antibodies
found in transplant patients. These antibodies are
decorated with unique sugar structures that appear
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to engender them with the ability to suppress
rejection of the transplanted organ.
A second area of interest is characterization of
harmful versus innocuous antibodies that are
reactive with antigens present on transplanted
organs. Recent findings identified antibody
populations that are believed to be not harmful to
the transplant, and work continues to characterize
the reactivity and molecular targets of these
antibodies.

Endocrinology

Oncology

The focus of the Endocrine Research Laboratory,
led by Hershel Raff, PhD, is hypothalamicpituitary-adrenal function.

Targeted laboratory-based research includes
experimental cancer therapeutics and immunotherapy.

As part of a basic research study, investigators
are evaluating the development of neonatal
adrenal function and the role of the
hypothalamus and pituitary therein. The
pituitary-adrenal adaptation to critical illness
is a clinical research focus. New laboratory
approaches to evaluate endocrine function in
patients is another area of study for this lab.

Experimental cancer therapeutics

Neurosciences
The Neurosciences Research Laboratory was
developed in late 2014 to initiate a brain tumor
stem cell bank in collaboration with Aurora’s
Biorepository and Specimen Resource Center.
Tumor samples obtained from patients undergoing
brain surgery are analyzed in the lab to identify,
isolate and expand cancer stem cells. Testing of
these samples and expansion of this research
program will be the goals of this lab in 2015.

Cardiovascular
Laboratory-based research of the Sheikh Khalifa
bin Hamad Al Thani Center for Integrative
Research on Cardiovascular Aging is on pages
23 and 24. Clinical and preclinical cardiovascular
work with stem cells is on pages 25 and 26.

Researchers are working on new mechanism-based
drugs to treat various cancers. The goal is to develop
new approaches to prevent or treat cancers through
a better understanding of the genes and pathways
underlying their pathogenesis.
Research areas of interest include tumor proliferation,
invasion and metastasis, cell signaling, apoptosis,
angiogenesis, protein-protein and protein-DNA
interactions, and epigenetic alterations in the cancer.
The hope is to provide novel therapies that avoid or
overcome chemotherapeutic drug resistance and most
importantly, prolong the lives of cancer patients.

Immunotherapy
Monocytes may have both positive and negative roles
in cancer development and therapy. Researchers are
exploring the role of monocytes in killing cancer cells
when stimulated by antibodies. Findings show a necessity
for high levels of antigen expression for monocytes
to become activated. This may partially explain why
antibodies used against HER2/neu are not effective in
breast cancers that do not overexpress the antigen.
Monocytes also may inhibit the immune response, thus
assisting in tumor growth and spread. Researchers are
studying methods in which immune suppression may be
inhibited so we can improve immunotherapy of cancer.

aurora.org/research
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JPCRR goes global in its
inaugural year
First-Year Highlights
• Launched first issue in
February
• Indexed by U.S. Library
of Congress
• Featured in Milwaukee
Journal Sentinel, cited
by Milwaukee Magazine
• Launched interactive
website housed by
Digital Commons
• Ever-increasing global
readership (see map)
• >8,000 full-text articles
downloaded

The fourth issue of Journal of
Patient-Centered Research and
Reviews (JPCRR) capped off an
impressive first year for Aurora
Health Care’s scientific journal.
Largely funded by a generous
donation from the Robyn Temkin
Memorial Fund and led by Editorin-Chief Dennis Baumgardner,
MD, JPCRR was launched in
February with a melanomathemed issue overseen by guest
editor Michael Thompson, MD,
PhD, and immediately caught
the eyes of researchers around
the world, spurring well-received
submissions from health centers
in Oklahoma, Texas, Tennessee,
Canada and Italy.
The regional research community
also took note of Aurora’s entry
into publishing, and JPCRR
received praise from health
professionals across Wisconsin
in an April feature by Milwaukee
Journal Sentinel.

Capitalizing on that early
momentum, JPCRR launched an
interactive website and Twitter
feed (@JPCRR), resulting in
thousands of article downloads
over just a few months. An issue
focused on the burgeoning field
of cardio-oncology, overseen by
guest editors Charles Bomzer, MD,
and Bijoy Khandheria, MD,
provoked positive feedback from
readers in Ireland, India, Taiwan
and the Democratic Republic of
the Congo.
“The broad scope of topics
makes JPCRR an appealing
source of clinical guidance to
both primary care physicians and
multidisciplinary specialists,”
Dr. Baumgardner said.
Following its successful debut,
JPCRR plans to further grow
its author, audience and article
diversity in 2015. The journal’s
double-blind peer-review process
ensures unbiased evaluations of a
manuscript’s scientific strengths
and weaknesses.
It is important to recognize that
JPCRR is first and foremost
dedicated to improving patient
care. Everyone from patients to
students to clinicians can access
journal content from current
and archived issues at
www.aurora.org/jpcrr.

Snapshot of sites downloading
JPCRR articles over a 30-day period.
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Original submissions to JPCRR
are welcome at any time.

Caregivers recognized
for achievements in research
Recognizing achievements in research is one way Aurora Research
Institute engages researchers throughout Aurora Health Care.
The Research Awareness Committee coordinated the institute’s
fifth annual Greater Milwaukee Clinical Research Recognition Event
on Sept. 10, 2014, at Aurora St. Luke’s Medical Center. The event
highlights achievements in research by Aurora caregivers in the
Greater Milwaukee area.

2014 Greater Milwaukee
award recipients
Clinical Trials Research Award
Thomas Saphner, MD
Michael Thompson, MD, PhD
Investigator-Initiated Research Award
Anthony DeFranco, MD
Collaborative Research Award
Judy A. Tjoe, MD
Senior Investigator Award
Daniel O’Hair, MD
New Investigator Award
Michael Anderson, MD
Innovation Award
Amin Kassam, MD
Research Champion Award
A. Jamil Tajik, MD

Greater Milwaukee area award recipients: (back row, from left) Thomas Saphner, MD, and
Anthony Chambers, BSN, and (front row, from left) Maharaj Singh, PhD, Michael Anderson,
MD, Judy A. Tjoe, MD, Michael Thompson, MD, PhD, Daniel O’Hair, MD, Lisa Klement and Amin
Kassam, MD. (Not pictured: Anthony DeFranco, MD, and A. Jamil Tajik, MD.)

Aurora BayCare Medical Center held its sixth annual Fall Research
and Medical Education Reception on Oct. 15, 2014, at Aurora
BayCare Orthopedic and Sports Medicine Center. The event
highlights achievements in research and education by Aurora
and BayCare Clinic caregivers in the Green Bay area.

Research Service Award
Anthony Chambers, BSN
Lisa Klement
Maharaj Singh, PhD

2014 Green Bay
award recipients
Medical Educator of the Year Award
Erik Johnson, MD
Medical Education Curriculum
Development Award
Cardiology Department
Research Fellow in Sports Medicine
Rebecca Yde, DPT
Joe Woldt, DPT
Kate Jochimsen, DPT
Principal Investigator
of the Year Award
James Gapinski, MD

Paul Summerside, MD, BayCare Clinic’s chief
medical officer, Randall Lambrecht, PhD,
president of Aurora Research Institute, and
Richard Ludgin, MD, JD, vice president
of Medical Affairs for Aurora BayCare
Medical Center, network in Green Bay.

Before the ceremony in Green Bay,
Robert Limoni, MD, unveiled several
orthopedic innovations he is bringing
to market.

Innovation Award
Robert Limoni, MD
Research Support Award
Ashley Heesacker
Jean Dill, NP
Denise Barnes, RN

aurora.org/research
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Aurora Research Institute cultivates
future health care researchers

Aurora Research Institute summer student interns and their mentors.

Education and outreach are important tenets of
research.

on their resumes will open many doors for these
students.”

That’s why Aurora Research Institute offers many
research opportunities for students over the
summer.

Institute investigators also mentored five students
who were afforded a 10-week opportunity to gain
hands-on, biomedical research experience because
of the generosity of medical staff, who donate to
Aurora Health Care Foundation’s Medical Staff
Endowment Fund.

Seven talented student interns gained valuable
insights to the different components of the
institute and, in turn, offered support on a variety
of research initiatives during the Summer Student
Intern Program. The program accepts students
from around the country who spend 8-10 weeks
conducting patient-centered research projects.
“Our investigators value the support the students
provide to further the institute’s patient-centered
research,” said Vani Nilakantan, PhD, director of
Investigator-Initiated Research/Sponsored Programs
Office for Aurora Research Institute. “And having
the clinical research experience they gain at Aurora

“The researchers give their time to these students
to make a difference,” said Hershel Raff, PhD, of the
Endocrine Research Laboratory.
Not only does the institute provide these summer
student program opportunities, but it supports
inquisitive volunteers who benefit from working
with and learning from experienced investigators
at the Sheikh Khalifa bin Hamad Al Thani Center
for Integrative Research on Cardiovascular Aging
(CIRCA) at Aurora St. Luke’s Medical Center.

Summer students spend time working in the lab.
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Meet the summer student interns
THERESE (TESS) BATTIOLA

ALEX REDDY

Mentors: Arshad Jahangir, MD; Ekhson
Holmuhamedov, PhD
Year/University: junior/University of Wisconsin-Madison
Project: Evaluate the relative contribution of
anaerobic glycolysis and oxidative phosphorylation
to support motility of fibroblasts from diseased and
nondiseased hearts

Mentors: Andy Marek, John Klehm
Year/University: sophomore/University of
Wisconsin-Milwaukee
Project: Write an internal web application allowing
biorepository staff to access specimen metadata
and manage studies

ALESSANDRA DEFRANCO

JUSTIN ROUNTREE

Mentors: Arshad Jahangir, MD; Farhan Rizvi, PhD;
Ekhson Holmuhamedov, PhD
Year/University: junior/Mount Holyoke College,
South Hadley, Mass.
Project: Investigate the differential effect of
simvastatin on atrial and ventricular fibroblasts from
the human heart

Mentor: Ahmed Dalmar, MD
Year/University: junior/Carroll University,
Waukesha, Wis.
Project: Evaluate HER2/neu overexpression in women
with primary diagnosis of Stage IV breast cancer

LYDIA GARLIE

STEVE SAWYER

Mentors: Scarlet Shi, PhD; Vinay Thohan, MD
Year/University: junior/University of Wisconsin-Madison
Project: Review records for appropriate shocks in
patients who received an implantable cardioverterdefibrillator (ICD) and determine the possible
association of echocardiographic measures of cardiac
function to ICD shock

Mentors: Judy A. Tjoe, MD; Sanjay Kansra, PhD
Year/University: second year, Creighton University
School of Medicine, Omaha, Neb.
Project: Identify predictive biomarkers in early stage
breast cancer

ZACHARY GRESE

PAYDEN WHITE

Mentors: Natalie Polinske, MS; Anne-Marie McAnelly
Year/University: graduate/Marquette University,
Milwaukee, Wis.
Project: Examine the effects of long-term storage
at -20 C, multiple freeze thaw cycles and ambient
transport of blood specimens by identifying the
quantity and quality of DNA present

Mentors: Vicki Soerens; Julie Walters; Katie Klein;
Joe Grundle; Kurt Waldhuetter
Year/University: sophomore/University of
Wisconsin-Madison
Project: Update research website content, review
new Intellectual Property Policy and assist with a
multitude of clerical and administrative projects

MACK GUENTHER JABLONSKI

MELISSA WONG

Mentor: Hershel Raff, PhD
Year/University: junior/Lawrence University,
Appleton, Wis.
Project: Evaluate the function of the adrenal gland
in a rat model of premature birth

Mentor: John Richards, PhD
Year/University: senior/Washington University in
St. Louis, Mo.
Project: Evaluation of immune cell-mediated tumor
killing using herceptin as a model

SOIBHAN KELLEY
Mentors: Vani Nilakantan, PhD; Sara Planton, BSN
Year/University: senior/University of Rochester, N.Y.
Project: Compare postoperative acute kidney injury
rates between geriatric patients receiving cardiac
and abdominal procedures; set up templates for
quarterly clinical trials dashboard

CIRCA summer volunteers
• Esha Afreen, Marquette University, Milwaukee. Wis.
• Adil Bhatia, Brookfield Academy, Brookfield, Wis.
• Madeline Bireley, University of Wisconsin-Madison
• Zachary King, Johns Hopkins University, Baltimore, Md.

KINGSHUK MAZUMDAR
Mentors: Arshad Jahangir, MD; Ekhson
Holmuhamedov, PhD
Year/University: sophomore/Union College,
Schenectady, N.Y.
Project: Evaluate differences in sensitivity of naïve and
activated fibroblasts to apoptotic cell death stimuli

• Nate Kluge, University of Wisconsin-Madison
• Nick Kluge, University of Minnesota, Minneapolis
• Kennedy Ringelberg, University of Wisconsin-Madison
• Ramail Siddiqui, University of Wisconsin-Madison
• Fong Wang, Concordia University Wisconsin, Mequon, Wis.
• Callie Weers, Northwestern University, Evanston, Ill.
Carl Kaiser (teacher), Marquette High School, Milwaukee

aurora.org/research
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Caregivers who care
In an organization dedicated to improving outcomes for patients, it’s not surprising to
find that Aurora Research Institute caregivers have big hearts.
Throughout 2014, in a variety of ways, those caregivers supported agencies and funds
with missions to change lives for the better.

Discovery World
(see page 21 for full story)
Aurora Research Institute’s Nina Garlie, PhD,
and Arshad Jahangir, MD, coordinated a unique
educational outreach opportunity, Aurora Health
Satellite: Your Mighty Heart, at Discovery World,
Milwaukee’s science and technology center.
From March through May, medical and research
experts invested countless hours, sharing their
knowledge as part of an interactive exhibit and
through heart health educational workshops
that featured innovative research and medical
procedures at the frontier of cardiovascular health.
Gary Neitzel, MD, explains heart anatomy using
animal hearts at the Aurora Health Satellite.
Photo courtesy of Discovery World

American Heart Association
Aurora Research Institute has strong ties with
American Heart Association. In September, Vani
Nilakantan, PhD, captained a walking team and
spearheaded a community outreach booth for the
Milwaukee Heart Walk
& Fun Run. More than
40 institute caregivers,
including Nina Garlie,
PhD, and Arshad
Jahangir, MD, and
their family members
and friends supported
the institute’s team
and booth. The booth
featured Aurora Health
Care volunteers teaching heart anatomy using pig
hearts, performing ECGs using AliveCor technology
and providing information on healthy foods.
Aurora Research Institute and its caregivers raised
$1,125 for AHA through the walk.
Cheryl Cerreto, RN, checks heart rhythms during the American
Heart Association Milwaukee Heart Walk and Fun Run.
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every gift can

Aurora Partnership Campaign

change
a life.

Donate to a cause you care about.
Aurora Research Institute caregivers contributed more than $23,500 to October
a variety of
agencies,
1 -public
November
30
including $18,588 to Aurora Health Care Foundation through its 2014 Aurora Partnership Campaign.
Available throughout October and November, the campaign
offers a way for Aurora caregivers to support
Aurora
With hundreds of causes to choose from, the
more than 1,600 charitable funds.
Partnership
Aurora Partnership Campaign allows you to donate

Campaign

Great Basket Events
One way to support the campaign
is to contribute a basket to one of
the hospitals’ Great Basket events.
Another way is to buy raffle tickets
for those baskets.
Sara Planton, BSN, collected
funds and created the Aurora
Research Institute basket, with
a building innovation theme, for
the Aurora Sinai Medical Center
event. The basket had a value of
$85 and featured Legos, K’nex,
Mega Bloks and Cra-Z-Art toys to
represent creative thinking. The
basket helped raise $1,341 for the
neonatal intensive care unit at
Aurora Sinai.

to charities and nonprofits in your community –
and within Aurora – that are important to you.

Innovation-themed
basket (left)

For the Aurora St. Luke’s
Medical Center event,
Jennifer Cooper, RN,
spearheaded the
Curl-up-with-a-goodCardiovascular and
book basket (below)
Gastroenterology
Research basket and
Diane Gentilini and Jill
Barz the Regenerative
Medicine Center
basket. The baskets
Donate to a cause you care about.
were valued at about
$100 each and featured items to October
enjoy a 1 - November 30
day snuggling on the couch and create an
Aurora They helpedWith hundreds of causes to choose from, the
Italian dinner, respectively.
Partnership
Aurora Partnership Campaign allows you to donate
raise $3,360 for Aurora
St. Luke’s Greatest
to charities and nonprofits in your community –
Campaign
Needs Fund and $380
for the Family-toand within Aurora – that are important to you.
Family Thanksgiving program.

every gift can

change
a life.

Penny Wars
For Aurora Sinai’s first-ever Penny War, Sara Planton, BSN, spearheaded a penny jar for the
institute in September. Twenty teams competed; team members put pennies in their team jar
and silver coins or paper money into other teams’ jars. In total, the initiative raised $856 for
the Milwaukee Homeless Veterans Initiative.

Townsend Street School Students
On behalf of Aurora Research Institute, Vicki Soerens
and Julie Basquin, MS, coordinated the adoption of
10 students who attend Townsend Street School for
Christmas to provide gifts to students who are less
fortunate. About 97% of the students at the school are
living at or below the poverty line or are homeless.
In total, Aurora adopted 276 students, the most since
the program began in 2009, fulfilling wishes for warm
clothes, action figures and dolls.

aurora.org/research
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research
A. Jamil Tajik, MD
President, Aurora Cardiovascular Services
Director, Aurora Cardiac Specialty Centers
Dr. Tajik leads a multidisciplinary team of specialists who
coordinate cardiovascular care at Aurora Health Care.

Cardiovascular
fellowship research

Cardiovascular Leadership Council
Research Committee

Suhail Allaqaband, MD

Suhail Allaqaband, MD

Mark Mewissen, MD

Program Director, Clinical Research
for the Cardiovascular Disease
Fellowship Program

Tanvir Bajwa, MD

Imran Niazi, MD

Indrajit Choudhuri, MD

Vani Nilakantan, PhD

M. Fuad Jan, MD

Anthony DeFranco, MD

Sara Planton, BSN

Associate Director, Clinical Research
for the Cardiovascular Disease
Fellowship Program

Arshad Jahangir, MD (CHAIR)

Wendy Schmidt, RN

M. Fuad Jan, MBBS, MD

Mia Stone, MS, BSN

Noreen Wynn

Bijoy Khandheria, MD

Nasir Sulemanjee, MD

David Kress, MD

A. Jamil Tajik, MD

David Krum, MS

Noreen Wynn

Aurora Cardiovascular Services
Fellowship Research Manager

Sara Walczak
Research Regulatory Specialist

>$1 million
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Randall Lambrecht, PhD

in external grant funding awarded in 2014 for
investigator-initiated cardiovascular research studies

Interventional/
medical
(23) 28%

Translational
(2) 2%
Pulmonary
hypertension
(7) 9%

Electrophysiology
(18) 22%

Congestive
heart failure
(7) 9%

623

Peripheral
vascular
(16) 19%

Surgery
(9) 11%

total cardiovascular clinical
trial enrollments in 2014

82

open cardiovascular clinical
trials as of Dec. 31, 2014

Peripheral vascular
(12) 2%
Surgery
(36) 6%
Pulmonary
hypertension
(11) 2%

Translational
(228) 37%

Electrophysiology
(164) 26%

Congestive
heart failure
(70) 11%
Interventional/
medical
(102) 16%

Jim McKinnon participated in a
clinical trial to extend his life. Feeling
“super” after surgery, he donned an
iconic cape. (See story on page 29.)

>25%

of Aurora’s research is
cardiovascular-related

~40%

of Aurora’s cardiovascular
research is investigator-initiated
aurora.org/research
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Connecting the community with cardiac
experts – Aurora Health Satellite provides
avenue for personal interaction
Aurora Health Care cardiac specialists volunteered
their time and shared their expert knowledge during a
unique partnership with Discovery World, Milwaukee’s
science and technology center.
As part of the Aurora Health Satellite, called Your
Mighty Heart, Discovery World visitors experienced
an interactive exhibit and participated in heart health
educational workshops featuring innovative research
and medical procedures that are the frontier of
cardiovascular health.
“The partnership between Aurora and Discovery
World provided an exciting opportunity for our
cardiovascular researchers and clinicians to work
directly with the community in an interactive way,
emphasizing wellness and prevention as well as
options for those with disease,” said Arshad Jahangir,
MD, director of the Sheikh Khalifa bin Hamad Al Thani
Center for Integrative Research on Cardiovascular
Aging. “The exhibit and workshops were well received
with attendees of all ages.”
The interactive exhibit,
accessible to more
than 75,000 people
during an 11-week
period, featured
a demonstration
arena for the public
that included
opportunities to
learn about
exciting research
being conducted
at Aurora and

Nicole Baecker, BSN, shows a workshop participant how
to thread a catheter through a vein to the heart.
Photos courtesy of Discovery World

hands-on experiences
with heart anatomy
and suture incisions
on animal hearts. The
displays highlighted
significant pioneering
medical technologies
exhibit visitors
and a timeline reflecting
Aurora’s dedication to
the Milwaukee community’s health. Aurora volunteers
staffed the exhibit Saturdays as a way to connect with
the public (more than 9,000 people) and showcase
Aurora’s cardiac expertise.

more than

75,000

The six workshops explored different cardiac topics
and provided nearly 500 registered participants with
hands-on opportunities led by Aurora’s medical experts
and research teams. Participants took on the role of
a researcher, conducting experiments, learning about
state-of-the-art technology and hearing personal stories
from such patients.
“Our cardiology staff was eager and enthused to
educate our community about the latest breakthroughs
in research and treatment of heart disease,” said
Nina Garlie, PhD, director of the Regenerative
Medicine Center, Aurora Research Institute.
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Session 1:

Cardiovascular Basic and
Translational Research
Led by:
Arshad Jahangir, MD
Mahek Mirza, MD

Session 2:

Electrophysiology
Led by:
Jasbir Sra, MD
Indrajit Choudhuri, MD
David Krum, MS

Session 3:

Cardiovascular Imaging
Led by:
Bijoy Khandheria, MD
Denise Spiegel, RDCS

Session 4:

Heart Failure,
Cardiomyopathies
and Valve Disease
Led by:
Frank Downey, MD
Nasir Sulemanjee, MD
Christina Rivera, NP

Session 5:

Cardiovascular Surgery
Led by:
David Kress, MD
Jonathan Howard

Session 6:

Interventional
Cardiology
Led by:
Tanvir Bajwa, MD
Suhail Allaqaband, MD
Anthony DeFranco, MD
Cindy Hoyt-Harvey, BSN
Theresa Briggs, RN
aurora.org/research
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Sheikh Khalifa bin Hamad Al Thani

Center for Integrative Research
on Cardiovascular Aging (CIRCA)
Arshad Jahangir, MD
Medical Director, Sheikh Khalifa bin Hamad Al Thani Center
for Integrative Research on Cardiovascular Aging
Dr. Jahangir leads a team of researchers devoted entirely to studying the molecular
mechanisms responsible for the aging heart’s decreased stress tolerance and enhanced
susceptibility to heart rhythm disorders.

Advancing research …
from bench to bedside
The Sheikh Khalifa bin Hamad Al Thani Center
for Integrative Research on Cardiovascular Aging
(CIRCA), so named because of a generous
$2 million donation from His Highness in 2014,
is one of a few research centers in the world
devoted entirely to study the effect of aging
on the cardiovascular system.
Supported by the National Heart, Lung, and
Blood Institute of the National Institutes of
Health throughout 2014, the center’s mission is
to support and conduct basic, translational and
clinical research on the biology of aging, and to
develop predictive, diagnostic and therapeutic
interventions to preserve wellness, prevent
age-related cardiovascular dysfunction and
improve the quality of life of older people.

Research scientist Gracious Ross, PhD, reviews samples with a
microscope in the Sheikh Khalifa bin Hamad Al Thani Center for
Integrative Research on Cardiovascular Aging (CIRCA). Dr. Ross won
an Aurora Cardiovascular Surgery Research Award (see sidebar).

Publications/presentations
In 2014, the CIRCA team shared its bench,
translational and clinical research through
manuscript preparation and publication in peerreviewed journals and abstract presentation at
national and international meetings, advancing
the collective understanding of the aging heart.

Research associate Milanka Cosic places
tubes in a centrifuge in the CIRCA lab at
Aurora St. Luke’s Medical Center.
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The esteemed meetings included the American
College of Cardiology Annual Scientific
Session, American Heart Association Basic
Cardiovascular Sciences and Annual Scientific
Sessions, and Society for Cardiovascular
Angiography and Interventions Annual
Scientific Sessions.

CIRCA in 2014:

9

manuscripts
published/
submitted

20

abstracts
presented/
accepted

Intramural funding
STUDY:
Biomarker-based risk
stratification to identify
patients at risk for
postoperative atrial fibrillation
AWARD:
$50,000, second-year funding
SOURCE:
Aurora Cardiovascular
Surgery Research Awards
PRINCIPAL INVESTIGATOR:
Mahek Mirza, MD

Research scientist Larisa Emelyanova, PhD,
works in the CIRCA lab. Dr. Emelyanova
received $20,000 in second-year funding for
her study on modulation of mitochondrial
function as a novel approach to prevent
myocardium injury in the diabetic heart.

Research scientist Farhan Rizvi, PhD, tests
samples in the CIRCA lab. Dr. Rizvi won an
Aurora Cardiovascular Surgery Research
Award (see sidebar).

STUDY:
A novel calcium entry
mechanism in myofibroblast
as a therapeutic target for
prevention of cardiac fibrosis
progression
AWARD:
$50,000 over one year
SOURCE:
Aurora Cardiovascular
Surgery Research Awards
PRINCIPAL INVESTIGATOR:
Gracious Ross, PhD

Findings on testosterone therapy provide
valuable bedside information for physicians
The interest of the CIRCA team
was piqued after several large
studies raised concerns that
testosterone therapy can negatively
affect men’s heart health.
Testosterone, a hormone that plays
a key role in the development
of male sexual characteristics,
is important for maintaining
health and well-being. Therapy
frequently becomes necessary
because testosterone decreases as
a man ages. Low testosterone can
impact cognition, muscle mass and
strength, bone density, metabolic
function and mood.
After analyzing demographic
and health data from 7,245 men
with low testosterone levels from
2011 to 2013, CIRCA researchers
found that the rate of adverse
cardiovascular events in men who
received testosterone therapy

versus those who did not was the
same – meaning the treatment is
not causing harm.
“In the absence of prospective
data, studies like ours will help ease
anxieties around this treatment
and provide some information on
which physicians can base their
prescribing decisions,” said
Arshad Jahangir, MD, CIRCA
medical director and senior
author of the abstract.
The other authors are: Zuber Ali,
MD, Danielle Greer, PhD, Robyn
Shearer, MS, Ali Gardezi, MD, and
Anil Chandel, MD.
The American College of
Cardiology invited CIRCA’s
researchers to present their
findings on testosterone therapy
and three other research studies at
the 64th Annual Scientific Session.

STUDY:
Circulatory biomarkers of
extracellular matrix turnover
and noncoding RNA as
predictor for postoperative
heart failure
AWARD:
$50,000, second-year funding
SOURCE:
Aurora Cardiovascular
Surgery Research Awards
PRINCIPAL INVESTIGATOR:
Farhan Rizvi, PhD
STUDY:
Cytokine-mediated fibroblast
activation increases
resistance towards cell death:
mechanistic insights and
therapeutic implications
AWARD:
$50,000 over one year
SOURCE:
Aurora Cardiovascular
Surgery Research Awards
PRINCIPAL INVESTIGATOR:
Ulugbek Negmadjanov, MD
aurora.org/research
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Clinical trials test uses of stem cells
Building on 20 years of experience
in cellular therapy, Aurora Health
Care investigators are studying
investigational treatment options
using stem cells to restore normal
heart and artery functions.
In the United States, both therapies
are limited by federal law to
investigational use.

20 years
of experience in
cellular therapy

Heart failure
As part of an international clinical
trial, investigators at Aurora St.
Luke’s Medical Center are studying
the safety and effectiveness of
delivering stem cells via a minimally
invasive approach to the lower
chambers of the heart, or ventricles,
in subjects with chronic heart
failure who are already taking
the most advanced medications
available (clinicaltrials.gov identifier:
NCT02032004).
The stem cells (CEP-41750, Teva
Pharmaceutical Industries, Petah
Tikva, Israel) are obtained from an
anonymous healthy volunteer and
then expanded in tissue culture
before delivery to the heart. The
Regenerative Medicine Center team
helps prepare the cells for injection.

and follow-up evaluations. They
will not know if a subject has
received the stem cells to minimize
bias in the study.
“Through numerous clinical and
preclinical studies, we have come
to realize the potential of stem
cells to help patients suffering
from cardiovascular disease,
especially in the treatment of
heart failure,” Dr. Sulemanjee
said. “This research will help us
to further investigate this
technology and therapy.”
Over five years, the research team
will monitor all enrolled subjects
for benefit and improvement in
their heart failure, as well as any
major adverse cardiac events.
Don Lobacz, RN, and Dena Burke,
BSN, are coordinating the clinical
trial for Aurora Research Institute.

principal investigators Tanvir
Bajwa, MD, and Richard Carballo,
MD, and their team are testing
the safety and effectiveness of
the investigational treatment for
critical limb ischemia compared
to a placebo (clinicaltrials.gov
identifier: NCT01049919).
The purpose of the research is to
establish whether the therapy can
prevent or delay major amputation
or death in subjects with critical
limb ischemia due to severe PAD.
During the single study procedure,
a medical oncologist withdraws
bone marrow from the subject’s
hip. Then, a technical specialist
from the Regenerative Medicine
Center concentrates the marrow
cells using MarrowStim PAD Kit.
Immediately thereafter, a vascular
surgeon injects the cells into the
muscle of the affected limb.

Critical limb
ischemia

Aurora St. Luke’s is the only site
in Wisconsin participating in this
prospective, multicenter trial.

Severe blockages in the arteries of
their legs, or critical limb ischemia,
is caused by a narrowing of the
arteries throughout the body, or
peripheral arterial disease (PAD).

“The ramifications of this study
could mean an alternate treatment
option for subjects facing
amputation and improved
quality of life,” Dr. Carballo said.

Through a clinical trial utilizing
the MarrowStim PAD Kit (Biomet
Biologics LLC, Warsaw, Ind.),

Valerie Williams, RN, is
coordinating the clinical trial
for Aurora Research Institute.

Co-investigator Suhail Allaqaband,
MD, and his team perform the stem
cell delivery procedures. Half the
subjects will receive the stem cells.
The other half will receive only
medication.
Principal investigator Nasir
Sulemanjee, MD, and his team
perform screening, study enrollment
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MarrowStim PAD Kit
MarrowStim PAD Kit is a trademark of Biomet Biologics LLC, Warsaw, Ind.
Caution: The MarrowStim PAD Kit limited by U.S. federal law to investigational use.
Images courtesy of Biomet Biologics LLC

Researchers study technique to deliver
stem cells for atrial fibrillation prevention
Scar tissue that develops as a result
of heart surgery can cause electrical
disturbances to the heart’s rhythm.
Patients may require permanent
pacemakers to treat these heart
rhythm disorders.
Stem cells delivered to the lower
chambers of the heart have reduced
scar and prevented further scarring
in patients with heart disease, but
their impact on the upper chambers,
or atria, hasn’t been studied.
In collaboration with researchers at
the University of Wisconsin-Madison,
Aurora Health Care principal
investigator Indrajit Choudhuri, MD,
is leading a preclinical study using
pigs to develop a safe, minimally
invasive technique that will allow
delivery of stem cells to the atria and
enable the researchers to track their
retention in the heart tissue.
The purpose of the study is to
establish the approach so it can be
applied to patients undergoing heart
procedures to prevent future heart
rhythm disorders and minimize the
need for permanent pacemakers.
Pigs are used because their
cardiovascular system is similar to
that of human. The study received
approval by the University of
Wisconsin Institutional Animal
Care and Use Committee and its
protocol is in accordance with the
committee’s guidelines.

Pigs are used
because their
cardiovascular
system is similar
to that of
humans.

Injection of porcine mesenchymal stem cells into the atrial appendage of a pig. This
was performed under Animal Care and Use Committee approval with full anesthesia.

The first experiments are testing
whether injections are feasible
during open-chest surgery. Future
experiments will test whether stem
cells can be injected from inside
the heart via catheter.
The researchers are using use
fluoroscopy and intracardiac
echocardiographic imaging to
deliver labeled stem cells, which are
tracked via the label with positron
emission tomography-computed
tomography, more commonly
known as PET-CT. Electrograms
are monitored during the procedure
for electrical disturbances.
About 6 hours after the stem
cells are injected, heart tissue
samples are evaluated by confocal
microscopy to track retention.
“The collaboration with Tim Hacker,
PhD, Eric Schmuck, PhD, and
Amish Raval, MD, at UW-Madison
has been very positive,” said Nina
Garlie, PhD, program director of
the Regenerative Medicine Center.
“Their team has been instrumental

in providing protocols, equipment
and pigs to move this important
project forward. We hope that
the knowledge gained from this
study will lead to further research
to determine whether injected
stem cells prevent or reduce atrial
tissue scarring.”
Aurora Research Institute
awarded $50,000 to this project
through the Cardiovascular
Surgery Research Awards.
___________________________

Principal investigators:
Indrajit Choudhuri, MD
Jayant Khitha, MD
Nina Garlie, PhD

Co-Investigators

(Aurora Health Care):
Arshad Jahangir, MD
Bijoy Khandheria, MD
David Kress, MD
Tanvir Bajwa, MD
Jasbir Sra, MD
David Krum, MS
John Hare
Mamatha Pinninti, MD
aurora.org/research
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Institute awards nearly $400,000
for cardiovascular research studies
In 2014, Aurora Research Institute
awarded more than $200,000 to
Aurora Health Care investigators for
new cardiovascular-related research
studies.
The purpose of the grants is to
provide important seed funding
to promote future research of
cardiovascular disease, preferably
through competitive extramural
funding.
The Sullivan Cardiac Research
Award for Residents and Fellows
provides up to $30,000 per award
to residents and fellows under
mentorship guidance for patientcentered research of cardiovascular
diseases.
Interventional cardiologist Tanvir
Bajwa, MD, serves as mentor to all
winners of the Sullivan award, which
is funded thanks to the generosity
of Tim Sullivan, a member of
Aurora’s board of directors, and his
wife Vivian Sullivan. The Sullivans
donated $1 million to support
Dr. Bajwa’s cardiac research via
the fellowship program.
The Cardiac Research Award
provides up to $40,000 per award
and the Cardiovascular Surgery
Research Award up to $50,000
per award to basic and clinical

Mark Mewissen, MD, collaborates with Daniel Ortiz, MD, recipient of the
Sullivan Cardiac Research Award for Residents and Fellows.

investigators and fellows for
patient-centered research of
cardiovascular diseases.
Investigators can apply for
second-year funding to continue
their projects. Five renewals
totaling more than $175,000
were awarded in 2014.
Funds for the Cardiac and
Cardiovascular Surgery research
awards are available because
of the generosity of donors to
Aurora Health Care Foundation.

Daniel Ortiz, MD, in the catheterization
lab with mentors Mark Mewissen, MD, and
Tanvir Bajwa, MD.
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The Sponsored Programs Office
serves as the coordinating
hub for the intramural grant
program. Senior grant specialists
Mindy Waite, PhD, Juanita
Terrie Garcia, MEd, RN, Cristina
Gonzalez and Toby Wolf provide
award services.

The Scientific Review Committee,
which consists of researchers and
clinicians, scientifically evaluates
proposals based on overall
impact of the proposed study;
its significance, innovation and
approach; and the investigators
involved in the research.

Continuing
intramural funding
Through the Cardiovascular
Surgery Research Awards,
Martin Oaks, PhD, received
$37,250 in second-year
funding to analyze HLA
antibodies in patients with
ventricular assist devices.

Cardiovascular Surgery Research Award

Sullivan Cardiac Research Award
for Residents and Fellows

Cardiac Research Award

Principal investigator: Ulugbek Negmadjanov, MD
Co-investigators: E
 khson Holmuhamedov, PhD, Arshad
Jahangir, MD, A. Jamil Tajik, MD, David
Kress, MD, Frank Downey, MD, Larisa
Emelyanova, PhD, Farhan Rizvi, PhD,
and Hao Xu, PhD
Project: Determine how disease causes heart repair cells to
produce excessive scar tissue, which leads to complications
after heart surgery

Principal investigator: Vinay Thohan, MD
Co-investigator: Scarlet Shi, PhD
Project: Study whether Doppler imaging of heart function
can predict outcomes in patients with heart failure who will
undergo noncardiovascular surgeries

Principal investigator: Vinay Thohan, MD
Co-investigator: Scarlet Shi, PhD
Project: Identify clinical factors that may predict the
development of gastrointestinal bleeding in patients with
left ventricular assist devices (LVADs)

Principal investigator: Steven Port, MD
Co-investigator: Lily Honoris, MD
Project: Study whether computed tomography angiography
can identify plaque in the coronary arteries in patients with
end-stage kidney disease

Principal investigator: Nasir Sulemanjee, MD
Project: Determine whether and how kidney disease stages
in LVAD placement patients affects outcomes

Principal investigator: Daniel Ortiz, MD
Mentors: Tanvir Bajwa, MD, and Mark Mewissen, MD
Co-investigator: Maharaj Singh, PhD
Project: Implement a new tool to assess the possibility for
bleeding in patients who undergo treatment for blockages
in leg arteries

Two Aurora hospitals test SMARTCare
Aurora Health Care is collaborating with
the American College of Cardiology
on an innovative quality improvement
research project, SMARTCare (Smarter
Management and Resource Use for
Today’s Complex Cardiac Care).
The Centers for Medicare and
Medicaid Services in May 2014 awarded
the ACC Foundation $15.8 million to
test the SMARTCare software. The pilot
program incorporates the software
into the electronic health record to
improve care for patients with stable
ischemic heart disease by giving
treating physicians the most current
information available.
The purpose is to optimize quality
of care to improve health outcomes
while saving costs.

SMARTCare

Anthony DeFranco, MD, an Aurora
cardiologist and current governor
of the ACC’s Wisconsin Chapter,
helped secure the grant.
“To improve coordination of care
between specialists and primary
care physicians as well as reduce
costs without compromising care,
health systems need a practical way
of implementing rapidly advancing
practice guidelines at the bedside,”
Dr. DeFranco said. “SMARTCare will
enable Aurora to lead the way on
value-based care in a way that is
feasible for physicians and hospitals
and also better for patients.”
A portion of the grant will support
the project’s implementation at
Aurora St. Luke’s Medical Center and
Aurora Medical Center in Grafton.
Dr. DeFranco and Aurora executive
vice president Patrick Falvey, PhD,
will facilitate SMARTCare’s
implementation at Aurora as well as
for future Wisconsin participants.
Senior grant specialist Toby Wolf and
senior sponsored programs specialist
Lee Banfi, MBA, CPA, provide postaward grant services on behalf of
Aurora Research Institute.

Additional
extramural funding
STUDY:
Severe blood transfusion
reactions, including
pulmonary edema (STRIPE)
AWARD:
$309,032 over 21 months
SOURCE:
National Heart, Lung,
and Blood Institute (via
BloodCenter of Wisconsin)
PRINCIPAL INVESTIGATOR:
Michael Michalkiewicz, PhD
STUDY:
Using system science
methods to study cardiac
risk in the Somali community
AWARD:
$19,065 first-year funding
SOURCE:
National Heart, Lung,
and Blood Institute (via
HealthPartners Institute for
Education and Research)
PRINCIPAL INVESTIGATOR:
Ahmed Dalmar, MD
aurora.org/research
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Continuing his journey:
Patient receives LVAD as destination
therapy via clinical trial
Because he felt so
good and it was
close to Halloween.
That’s why Jim
McKinnon, 81,
of East Troy,
Wis., donned a
Superman cape in
his hospital room
at Aurora St. Luke’s
Medical Center,
where he was
recovering from
heart surgery.
“Superman symbolizes strength
and energy,” said McKinnon, who
was just starting to feel stronger.
McKinnon, through participation in
a clinical trial, received a HeartWare
left ventricular assist device (LVAD)
as destination therapy, meaning he
had exhausted all other advanced
heart failure treatment options and
was ineligible for a heart transplant.
Aurora St. Luke’s is the only site in
Wisconsin offering the HeartWare®
Ventricular Assist System
(Framingham, Mass.) as destination
therapy.

Limited options
Five million Americans a year
experience a level of heart failure
at varying degrees.
For 14 years, McKinnon suffered
with heart failure. During that time,
the retired State of Wisconsin
Department of Transportation
employee underwent two bypass
surgeries, received multiple stents
and developed a heart rhythm
disorder – his kryptonite that
caused his heart failure to worsen.
Suddenly, drugs stopped working
against the disease.
29
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Aurora St. Luke’s is the

only site
in Wisconsin offering
the HeartWare®
Ventricular Assist
System as
destination therapy.

“I was at death’s door,” said
McKinnon, who could hardly
walk at the time.
His cardiologist Ali Khan, MD,
referred McKinnon to John
Crouch, MD, a cardiovascular
and thoracic surgeon. Crouch
and Frank Downey, MD, principal
investigator for the HeartWare
clinical trial at Aurora St. Luke’s,
discussed McKinnon’s eligibility
for the trial.
“He is a very outgoing and
positive individual,” Dr. Crouch
said. “He was an ideal patient.”
Dr. Crouch and his team presented
McKinnon with his options, which
were limited due to his age. He
could continue with medication,
try a U.S. Food
and Drug
Administrationapproved LVAD
(HeartMate II,
Thoratec Corp.,
Pleasanton, Calif.),
which weighs
about 10 oz., or
enroll in the clinical
trial for the possibility
to receive the HeartWare
LVAD as a destination
therapy.

Taking a chance
Because of his small stature,
McKinnon chose enrollment in
the clinical trial (clinicaltrials.gov
identifier: NCT01966458) with
hopes of receiving the HeartWare
LVAD, which is half the weight
of the FDA-approved model.
Through randomization, he
had a 66% chance of receiving
the miniature device, which
is limited by U.S. federal law
to investigational use for the
destination therapy indication.
“That was a lifetime decision, a
life-saving decision,” McKinnon said.

HeartWare Ventricular Assist System
Caution: The HeartWare Ventricular Assist System
is limited by U.S. federal law to investigational use
for the destination therapy indication.
Image courtesy of HeartWare Inc.

McKinnon was randomized to receive the HeartWare
device, and Crouch performed the surgery. Aurora
St. Luke’s has performed more LVAD procedures than
any other hospital in Wisconsin.
McKinnon will need the device, which is connected
to his heart, for the rest of his life. The LVAD system
pumps blood from the left side of the heart into the
aorta, the large blood vessel that carries blood from
the heart to the rest of the body.
McKinnon must carry the system’s controller in
a small carrying case around his waist. Ralph, as
McKinnon calls his controller in memory of his late
father who died of a heart attack at 49, is connected
to the LVAD by a small cable that passes through
McKinnon’s skin above his stomach. All three of his
children are trained to change the wound’s dressing,
which must be done every other day.

McKinnon and his wife Faye in Florida enjoying a sunset.

“As part of his follow-up for the study, I need to see
Jim at 3 months, 6 months and 1 year and then every
6 months for the study,” said Cheryl A. Zywicki, RN,
who is coordinating the clinical trial for Aurora
Research Institute.

The controller runs the pump and provides text
messages and audible alerts to help better manage
the system. The controller is powered by two small
batteries or can pull energy from a wall outlet.

He may not be as fast as a speeding bullet, but he
is able to breathe easier when walking across a
room. Considering how he felt before the surgery,
it’s almost as if he really could leap a tall building in
a single bound.
____________________________________________

Feeling super

McKinnon’s results should not be used to predict outcomes
of the clinical trial. Researchers are documenting incidence of
stroke. Data collection is ongoing.

About a month after receiving the LVAD, McKinnon
wanted to celebrate how well he was feeling. So as
part of an inside family joke, his daughter brought
him a Superman cape.
“It means I can get to my grandson’s wedding next
October,” McKinnon said of his new lease on life.
“It’s a joy to see my (younger) grandchildren and
have them call me ‘bapa.’”
Though he still needs to return to Wisconsin for
regular follow-up visits, the snowbird met his goal
and made it to Florida for the holidays.

Clark Kent, aka Jim
McKinnon, 81, of East Troy,
Wis., dons a Superman
cape while recovering
from heart surgery at
Aurora St. Luke’s
Medical Center.
Photos courtesy of the
McKinnon family

McKinnon, with his wife Faye, enjoying a “medicinal”
mini-Scope-bottle-sized Tanqueray martini at home.
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Miniature pacemaker
technology under review
Advances in technology have allowed pacemakers to shrink from the
size of a pocket watch to a AAA battery or vitamin capsule.
Aurora Health Care researchers were the first in Wisconsin to implant
these miniaturized pacemakers – that do not require leads – as part of
ongoing international clinical trials. In the United States, the Nanostim™
leadless pacemaker (St. Jude Medical Inc., St. Paul, Minn.) and Micra™
Transcatheter Pacing System (Medtronic Inc., Minneapolis, Minn.) are
limited by federal law to investigational use.
Instead of an incision to the skin of the chest, subjects undergo a
minimally invasive procedure via a vein in the leg, eliminating the
need for a surgical pocket under the skin.
The goals are to reduce complications, including device pocketrelated infection and lead failure, and improve quality of life.

1st
First in
Wisconsin
Richard Kasprowicz, 71, of
Union Grove, was the first person
in Wisconsin to receive the
Nanostim leadless pacemaker as
part of a clinical trial for the new
device at Aurora Health Care.
“After a couple of hours, I was
ready to go,” said Kasprowicz,
who remained in the hospital
overnight.

Anthony Chambers, BSN, is coordinating both clinical
research trials for Aurora Research Institute.

Nanostim™ clinical trial
Principal investigators Imran Niazi, MD, and M. Eyman
Mortada, MD, and their team are studying the safety
and effectiveness of the Nanostim™ leadless pacemaker
in subjects indicated for a single-chamber ventricular
pacemaker (clinicaltrials.gov identifier: NCT02030418).

2vs.g
40 g
Weight of leadless
Nanostim pacemaker
compared to traditional
pacemaker with leads

All subjects enrolled in this
prospective, multicenter
clinical trial will receive the
device, which is about the
size of a AAA battery and
weighs 2 grams.
“This is a revolutionary
technology,” Dr. Niazi
said. “By avoiding invasive
surgery and using
interventional techniques

Nanostim™ leadless pacemaker
Caution: The Nanostim™ leadless pacemaker is limited by U.S. federal law
to investigational use.
Image courtesy of St. Jude Medical Inc.

for implanting pacemakers, we could reduce patient
discomfort and cost significantly. Surgical risk – such
as infection – and recovery time in the hospital is
greatly reduced. This new technology has the potential
to have an enormous impact on cardiac care for
the nearly 700,000 people worldwide who receive
pacemakers each year.”
Drs. Niazi and Mortada and their team are documenting
complications, pacing thresholds, R-wave amplitudes,
and response during graded exercise testing.

Micra™ clinical trial
Principal investigators Jasbir Sra, MD, and Vikram
Nangia, MD, and their team are studying the safety
and effectiveness of the Micra™ Transcatheter
Pacing System in subjects who have a Class I or II
indication for a single-chamber ventricular pacemaker
(clinicaltrials.gov identifier: NCT02004873).
All subjects enrolled in this prospective, multicenter
clinical trial will receive the device, which is about the
size of a vitamin capsule.
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Micra™ Transcatheter Pacing System
Caution: The Micra™ Transcatheter Pacing
System is limited by U.S. federal law to
investigational use.
Image courtesy of Medtronic Inc.

Drs. Sra and Nangia and their team are documenting
major complications and pacing capture threshold
success.

FDA approvals
Aurora Research Institute was
instrumental in bringing the following
innovations to market through
participation in clinical trials.

CoreValve (Medtronic Inc.)
The first in Wisconsin to implant the
artificial aortic valve nonsurgically,
Aurora researchers refined the
transcatheter aortic valve replacement
approach with development of a TAVR
program and dedication of hybrid
cardiovascular operating rooms.
Though FDA approved for patients
who are not candidates for surgery,
clinical trial participation at Aurora
continues for patients at intermediate
to very high risk for surgery.

Turbo-Tandem System
(Spectranetics Corp.)
One of the first sites in the state to
participate in the EXCITE clinical
trial, Aurora St. Luke’s Medical Center
clinicians have the expertise to use
the FDA-approved Turbo-Tandem
System to treat narrowing of the
arteries in patients who had been
previously treated with stents. The
laser technology removes plaque that
causes arteries to narrow.

IN.PACT Admiral drug-coated
balloon (Medtronic Inc.)
The only site in Wisconsin to
participate in the IN.PACT SFA II
clinical trial, Aurora St. Luke’s Medical
Center has the ability to treat patients
who suffer from peripheral artery
disease with the drug-coated balloon.

Electrophysiologists
literally wrote the book
Aurora Cardiovascular Services
electrophysiologists Jasbir Sra,
MD, and Masood Akhtar, MD,
edited and contributed to a
textbook that uses cases to
keep readers engaged.
“Practical Electrophysiology,”
published by Cardiotext
Publishing (Minneapolis, Minn.),
features detailed discussion of
fundamental electrophysiology
aspects and includes more than
70 case studies with multiplechoice questions.
“It is difficult to stay current with the ever-changing field
of electrophysiology,” Dr. Sra said. “Despite that, there are
fundamentals that students of electrophysiology need to
understand. We hope this textbook proves a useful tool.”
The book includes contributions from other Aurora
physicians (see Cardiovascular Appendix, page 34) and
specialists from around the world.

Dr. Masood Akhtar
Cardiac Research Fund
To honor Aurora Health Care’s own electrophysiology
pioneer, the Aurora Health Care Foundation established
the Dr. Masood Akhtar Cardiac Research Fund in 2014.
Donors can advance cardiac research with contributions to
the fund, which will support Aurora’s cardiovascular research
program activities, including speakers and educational/
training programs.
Masood Akhtar, MD, former president of
Aurora Cardiovascular Services, created one
of the first accredited electrophysiology
fellowship programs and played a key role
in developing Aurora’s other cardiovascular
fellowship programs.

CardioMEMS HF System
(St. Jude Medical Inc.)
The system wirelessly measures and
monitors pulmonary artery pressure
and heart rate to reduce hospital
readmissions for patients with heart
failure. After it had been studied via
clinical trial at Aurora a few years ago,
the system received FDA approval in
July. Aurora clinicians are developing
a program to implement use of this
device for patients with heart failure.

Since stepping down as president,
Dr. Akhtar has concentrated on
electrophysiology research and teaching
as a clinical professor of medicine for the
University of Wisconsin School of Medicine and Public Health
at Aurora Sinai and Aurora St. Luke’s Medical Centers.

Masood Akhtar, MD
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Cardiovascular volumes – systemwide
Source:
Aurora Smart Chart/HIM Decision Support

2012

2013

2014

Cardiovascular surgery
Coronary artery bypass graft
(CABG) total
CABG on pump
CABG off pump

794

920

926

653

722

768

141

198

158

Valve replacement
Aortic valve replacement
Mitral valve replacement
Other valve replacement

430
364
56

491
373
112

572
446
107

10

6

19

Valve annuloplasty (open)

101

116

101

Cardiac ablation – open (MAZE)

94

100

95

Valve repair
Mitral valve repair
Other valve repair

80
61
19

98
77
21

76
61
15

Patent foramen ovale/atrial
septal defect closure total

60

64

75

2012

2013

2014

10,822
8,485
2,337

10,359
7,959
2,400

9,394
7,049
2,345

Interventional cardiology
Heart catheterization total
Cardiac catheterization
Angiogram without pressures
Coronary intervention

3,109

2,812

2,567

2,952
157

2,653
159

2,441
126

743

432

343

Endovascular aortic valve
replacement

48

55

187

Patent foramen ovale/atrial
septal defect closure total

50

65

60

Balloon valvuloplasty
(percutaneous)

45

37

40

Transapical mitral valve
replacement (TMVR)

7

3

17

Transapical aortic valve
replacement (TAVR)

20

57

14

With stent
Without stent
Myocardial biopsy

2012

2013

2014

Cardioversion

1,259

1,243

1,175

EP study

1,139

1,114

1,130

Pacemaker

1,007

941

1,059

Ablation – percutaneous

1,091

1,062

1,050

Cardiac mapping

963

974

839

Defibrillator

856

830

804

Tilt testing

713

650

553

Lead extraction

50

39

68

Electrophysiology
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2012

2013

2014

2,041
1,063
978
496
292
204
465
178
162
108
54
202
160
42
115
29
86
0
294
278
16
91

1,906
1,024
882
480
307
173
507
165
163
104
59
162
128
34
93
17
76
0
291
275
16
69

1,709
954
755
504
303
201
365
174
172
120
52
172
132
40
99
22
75
2
63
49
14
28

2012

2013

2014

34
37

28
22

44
22

Vascular medicine
Peripheral vascular intervention
With stent
Without stent
Endarterectomy
Carotid endarterectomy
Other endarterectomy
Other endovascular procedure
Lower extremity bypass
Amputation
Below knee
Above knee
Abdominal aortic aneurysm repair
Endovascular
Open
Thoracic aortic aneurysm repair
Endovascular only
Open only
Both
Vessel intervention
Surgical occlusion of vessels
Other vessel resection
Carotid stenting

Heart failure and transplant
Ventricular assist device
Heart transplant

Top 50 ranking
third year running
Continuing the streak, the
cardiology and heart surgery
department at Aurora St. Luke’s
Medical Center, Milwaukee,
was the only heart program in
Wisconsin nationally ranked
by U.S. News & World Report
in its 2014-15 evaluation of the
nation’s best hospitals.
Aurora St. Luke’s cardiology and heart surgery
department ranked 41st nationally among 708
programs that qualified for review. This is the third
year in a row that it was the only heart program in
the state ranked among the nation’s top 50.

Cardiovascular publications
2014 Aurora-authored, peer-reviewed

Journal articles,
book chapters,
monographs
Ahmad MN, Khaliq F, Yousaf H, Bloomgarden DC,
Ammar KA. Can cardiac magnetic resonance
imaging alter management of idiopathic recurrent
pleural effusions? Available at: http://www.scmr.org/
caseoftheweek/2014/7129.html#. Royal, NJ: Society
of Cardiovascular Magnetic Resonance; Epub 2014
Aug 25.
Agarwal A. Sleep apnea and hypertrophic
cardiomyopathy. Available at: http://www.acc.org/
education-and-meetings/patient-case-quizzes/sleepapnea-and-hypertrophic-cardiomyopathy?w_nav=S).
Washington, DC: American College of Cardiology
Foundation. Epub 2014 Jan 16.

Blanck Z. Case 38: Bundle branch reentry ventricular
tachycardia. In: Sra JS, Akhtar M, Natale A, Wilber
DJ (eds). Practical Electrophysiology. Minneapolis,
MN: Cardiotext Publishing; 2014, pp. 368-71.
Blanck Z. Case 39: Interfascicular reentrant ventricular
tachycardia. In: Sra JS, Akhtar M, Natale A, Wilber
DJ (eds). Practical Electrophysiology. Minneapolis,
MN: Cardiotext Publishing; 2014, pp. 372-4.
Choudhuri I. Case 33B: Idiopathic left ventricular
tachycardia. In: Sra JS, Akhtar M, Natale A, Wilber
DJ (eds). Practical Electrophysiology. Minneapolis,
MN: Cardiotext Publishing; 2014, pp. 341-5.
Choudhuri I, Krum D, Agarwal A, Hare J, Belohlavek
M, Ahmad A, Pinninti M, Khandheria BK. Bachmann’s
bundle and coronary sinus ostial pacing accentuate
left atrial electrical dyssynchrony in an acute canine
model. J Cardiovasc Electrophysiol 2014;25:1400-6.

Agarwal A, Sulemanjee NZ, Cheema O, Downey
FX, Tajik AJ. Cardiac sarcoid: a chameleon
masquerading as hypertrophic cardiomyopathy
and dilated cardiomyopathy in the same patient.
Echocardiography 2014;31:E138-41.

Choudhuri I, Sra JS. Case 6: Narrow-complex
tachycardia with features suggesting multiple
tachycardia mechanisms – the importance of
electrophysiology fundamentals. In: Sra JS,
Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 176-81.

Akhtar M, Sra JS. Chapter 3: Physiologic responses
during electrophysiologic evaluation. In: Sra JS,
Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 39-107.

Choudhuri I, MacCarter D, Shaw R, Anderson S,
St Cyr JA, Niazi I. Clinical feasibility of exercisebased A-V interval optimization for cardiac
resynchronization: a pilot study. Pacing Clin
Electrophysiol 2014;37:1499-509.

Akhtar M, Sra JS. Case 19: Preexcited tachycardias:
differential diagnosis, mechanisms, and diagnostic
clues. In: Sra JS, Akhtar M, Natale A, Wilber DJ
(eds). Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 246-57.

Cooley R. Case 4: Noninvasive testing for sudden
cardiac death. In: Sra JS, Akhtar M, Natale A, Wilber
DJ (eds). Practical Electrophysiology. Minneapolis,
MN: Cardiotext Publishing; 2014, pp. 163-8.

Ammar KA, Khandheria BK. Case 62:
Echocardiographic parameters of dyssynchrony. In:
Sra JS, Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 511-5.
Ammar KA, Khandheria BK. Case 72: Threedimensional echocardiography cardiac imaging. In:
Sra JS, Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 564-7.
Arbustini E, Narula N, Tavazzi L, Serio A, Grasso
M, Favalli V, Bellazzi R, Tajik AJ, Fuster V, Narula
J, Bonow RD. The MOGE(S) classification of
cardiomyopathy for clinicians. J Am Coll Cardiol
2014;64:304-18.
Bagai A, Peterson ED, Honeycutt E, Effron MB,
Cohen DJ, Goodman SG, Anstrom KJ, Gupta A,
Messenger JC, Wang TY. In-hospital switching
between adenosine diphosphate receptor inhibitors
in patients with acute myocardial infarction treated
with percutaneous coronary intervention: Insights
into contemporary practice from the TRANSLATEACS study. Eur Heart J Acute Cardiovasc Care 2014
Dec 16 [Epub ahead of print].

Cusmà-Piccione M, Zito C, Khandheria BK, Pizzino
F, Di Bella G, Antonini-Canterin F, Vriz O, Bello VA,
Zimbalatti C, La Carrubba S, Oreto G, Carerj S. How
arterial stiffness may affect coronary blood flow: a
challenging pathophysiological link. J Cardiovasc
Med (Hagerstown) 2014;15:797-802.
De Franco AC, Oldridge N. Health-related quality of
life in patients with acute coronary syndromes and
treated with ticagrelor or clopidogrel. Expert Rev
Pharmacoecon Outcomes Res 2014;14:23-6.
Dhala A. Case 45: Diagnosing catecholaminergic
polymorphic ventricular tachycardia. In: Sra JS,
Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 403-5.
Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R,
Dattilo G, Oreto G, Baldari S, Vita G, Khandheria
BK, Carerj S. The mosaic of the cardiac amyloidosis
diagnosis: role of imaging in subtypes and stages
of the disease. Eur Heart J Cardiovasc Imaging
2014;15:1307-15.
Djelmami-Hani M. Case 7: Slow-fast atrioventricular
nodal reentrant tachycardia. In: Sra JS, Akhtar M,
Natale A, Wilber DJ (eds). Practical Electrophysiology.
Minneapolis, MN: Cardiotext Publishing; 2014, pp. 182-9.

Frommelt PC, Haddadian B, Bajwa T. Case 48:
Anomalous coronary artery and ventricular
arrhythmias. In: Sra JS, Akhtar M, Natale A, Wilber DJ
(eds). Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 416-9.
Gilbert C. Case 54: Cardiac implantable electronic
devices: timing cycles, sensing, and troubleshooting
during pacing. In: Sra JS, Akhtar M, Natale A, Wilber
DJ (eds). Practical Electrophysiology. Minneapolis,
MN: Cardiotext Publishing; 2014, pp. 463-71.
Glower D, Kar S, Trento A, Lim DS, Bajwa T, Quesada
R, Whitlow PL, Rinaldi MJ, Grayburn P, Mack MJ,
Mauri L, McCarthy PM, Feldman T. Percutaneous
mitral valve repair for mitral regurgitation in high-risk
patients: results of the EVEREST II study. J Am Coll
Cardiol 2014;64:172-81.
Hansen TB, Thygesen LC, Zwisler AD, Helmark L,
Hoogwegt M, Versteeg H, Höfer S, Oldridge N. Selfreported health-related quality of life predicts 5-year
mortality and hospital readmissions in patients with
ischaemic heart disease. Eur J Prev Cardiol 2014 May
12 [Epub ahead of print].
Höfer S, Benzer W, Oldridge N. Change in health-related
quality of life in patients with coronary artery disease
predicts 4-year mortality. Int J Cardiol 2014;174:7-12.
Hu D, Barajas-Martinez H, Pfeiffer R, Dezi F, Pfeiffer
J, Buch T, Betzenhauser MJ, Belardinelli L, Kahlig
KM , Rajamani S, Deantonio H, Myerburg RJ, Ito
H, Deshmukh P, Marieb M, Nam GB, Bhatia A,
Hasdemir C, Haissaguerre M, Veltmann C, Schimpf R,
Borggrefe M, Viskin S, Antzelevitch C. Mutations in
SCN10A responsible for a large fraction of Brugada
syndrome cases. J Am Coll Cardiol 2014;64:66-79.
Hummel SL, Katrapati Y, Gillespie BW, DeFranco AC,
Koelling TM. Impact of prior admissions on 30-day
readmissions in Medicare heart failure inpatients.
Mayo Clin Proc 2014;89:623-30.
Jan MF, Tajik AJ. Case 49: Risk stratification of
sudden death in hypertrophic cardiomyopathy. In:
Sra JS, Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 420-33.
Jan MF, Tajik AJ. Obstructive sleep apnea and
hypertrophic cardiomyopathy: obiter dictum or
more? J Am Coll Cardiol 2014;64:2560-2.
Jan MF, Tajik AJ. Zero-hour aortic sclerosis:
auscultatory biomarker or imaging biomarker?
J Am Coll Cardiol 2014;64:1865-6.
Kress DC. Case 28: Hybrid ablation for recurrent left
atrial fibrillation using pericardioscopy and transseptal
approach. In: Sra JS, Akhtar M, Natale A, Wilber DJ
(eds). Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 309-12.
Krum D, Sra JS. Case 73: CT imaging of the left
atrium. In: Sra JS, Akhtar M, Natale A, Wilber DJ
(eds). Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 568-70.

Bhatia A. Case 8: Nonreentrant atrioventricular nodal
tachycardia. In: Sra JS, Akhtar M, Natale A, Wilber DJ
(eds). Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 190-1.

Elias HK, Jan MF, Allaqaband SQ. Role of
endovascular stenting in radiation-induced stenosis
of lower extremity veins. Catheter Cardiovasc Interv
2014 Sep 25 [Epub ahead of print].

Lidell E, Höfer S, Saner H, Perk J, Hildingh C,
Oldridge N. Health-related quality of life in European
women following myocardial infarction: A crosssectional study. Eur J Cardiovasc Nurs 2014 May 12
[Epub ahead of print].

Bhatia A. Case 9: Atrioventricular nodal reentrant
tachycardia with 2:1 AV block. In: Sra JS,
Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 192-4.

Farrell MH, Christopher SA, La Pean Kirschner
A, Roedl SJ, O’Tool FO, Ahmad NY, Farrell PM.
Improving the quality of physician communication
with rapid-throughput analysis and report cards.
Patient Educ Couns 2014;97:248-55.

Maharaj N, Khandheria BK, Libhaber E, Govender S,
Duarte R, Peters F, Essop MR. Relationship between
left ventricular twist and circulating biomarkers of
collagen turnover in hypertensive patients with heart
failure. J Am Soc Echocardiogr 2014;27:1064-71.

Bhatia A. Case 42: Brugada syndrome: different
presentations. In: Sra JS, Akhtar M, Natale A, Wilber
DJ (eds). Practical Electrophysiology. Minneapolis,
MN: Cardiotext Publishing; 2014, pp. 387-92.

Fish J. Arterial Ulcerations. In: Dean S and Satiani B
(eds). Color Atlas and Synopsis of Vascular Disease.
New York, NY: McGraw-Hill, 2014, pp. 425-9.

Nfor T, Allaqaband, S, Bajwa T. Advances in peripheral
arterial and aortic diseases. In: Chatterjee K, Horwitz
PA (eds). Advances in Cardiology. New Delhi, India:
Jaypee Brothers Medical Publishers; 2014, pp. 88-136.
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Niazi I. Case 65: Atrial synchronous His-bundle
pacing. In: Sra JS, Akhtar M, Natale A, Wilber DJ
(eds). Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 529-32.
Niazi I. Case 66: Cardiac resynchronization
therapy in congenital heart disease. In: Sra JS,
Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 533-5.
Oaks M, Michel K, Sulemanjee NZ, Thohan V,
Downey FX. Practical value of identifying antibodies
to cryptic HLA epitopes in cardiac transplantation.
J Heart Lung Transplant 2014;33:713-20.
Ortiz D, Jahangir A, Singh M, Allaqaband S, Bajwa
TK, Mewissen MW. Access site complications after
peripheral vascular interventions: incidence, predictors,
and outcomes. Circ Cardiovasc Interv 2014;7:821-8.
Ortiz D, Siegal EM, Kramer C, Khandheria BK, Brauer
E. Nontyphoidal salmonella cardiac infection: two
case reports and a review of the literature. Tex Heart
Inst J 2014;41:401-6.
Osranek M, Agarwal A, Tajik AJ. David and Goliath:
a clash of flows in apical hypertrophic cardiomyopathy.
Eur Heart J Cardiovasc Imaging 2014;15:1280.
Paterick TE, Bhatia A, Humphries JA, Kramer C,
Umland MM, Khandheria BK, Tajik AJ, Akhtar M.
Guiding the management of ventricular arrhythmias
in patients with left ventricular noncompaction
cardiomyopathy: a knowledge gap. Rev Cardiovasc
Med 2014;15:208-16.

Niazi I, Ryu K, Hood R, Choudhuri I, Akhtar M.
Three-dimensional electroanatomic mapping of the
coronary veins during cardiac resynchronization
therapy implant: feasibility and possible applications.
J Interv Card Electrophysiol 2014;41:147-53.
Razzaque I, Khandheria BK, Jain R, Allaqaband
S, Ammar KA. Synovial sarcoma invades the
left atrium: visualization with three-dimensional
trans-oesophageal echocardiography. Eur Heart J
Cardiovasc Imaging 2015;16:189 [Epub 2014 Oct 9].
Shaikh A, Agarwal A, Treiber S, Tajik AJ. Anomalous
connection of the left upper pulmonary vein to the
vertical vein: an uncommon diagnosis unveiled by
suprasternal notch imaging. Eur Heart J Cardiovasc
Imaging 2014;15:1385.
Shen F, Nfor T, Bajwa T. Recurrent acute myocardial
infarction in patients with immune thrombocytopenic
purpura. J Patient-Centered Res Rev 2014;1:41-5.
Sra JS. Case 21: Left atrial flutters after AF ablation.
In: Sra JS, Akhtar M, Natale A, Wilber DJ (eds).
Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 268-77.
Sra JS. Case 52: Antiarrhythmic drug therapy. In:
Sra JS, Akhtar M, Natale A, Wilber DJ (eds).
Practical Electrophysiology. Minneapolis, MN:
Cardiotext Publishing; 2014, pp. 445-56.
Sra JS. Case 76: Cardiac image integration. In: Sra
JS, Akhtar M, Natale A, Wilber DJ (eds). Practical
Electrophysiology. Minneapolis, MN: Cardiotext
Publishing; 2014, pp. 577-81.

Paterick TE, Gordon T, Spiegel D. Echocardiography:
profiling of the athlete’s heart. J Am Soc
Echocardiogr 2014;27:940-8.
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in external grant funding awarded in 2014
for oncology research studies

Colorectal
(5) 6%
Other
(26) 34%

Lung
(5) 7%
Prostate
(6) 8%

Breast
(21) 27%

Multiple myeloma
(6) 8%

349

Lymphoma
(8) 10%

total oncology clinical trial
enrollments in 2014

77

open oncology clinical trials
as of Dec. 31, 2014

Renal Cell
(4) 1%

(excludes open trials in follow-up)

Gynecology
(9) 2%
Lung
(11) 3%
Prostate
(16) 5%

Breast
(214) 61%

Colorectal
(21) 6%
Misc.
(37) 11%
Hematology
(37) 11%

Yvonne Kidandi, a breast cancer
survivor, challenged herself by
joining Team Phoenix to train for a
triathlon. (See story on page 42.)

~45%

of Aurora’s research
is oncology-related

>10%

of Aurora’s oncology research
is investigator-initiated
aurora.org/research
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Aurora named NCORP community site
Aurora Research Institute received
a highly competitive grant in 2014
to further its efforts of connecting
individuals to cancer research taking
place in their communities.
The National Cancer Institute
(NCI), a component of the National
Institutes of Health, selected 34
health care organizations it felt
best equipped to partner in the
NCI Community Oncology
Research Program, or NCORP.
The program utilizes community
sites to increase the number and
scope of available clinical trials. As
an NCORP community site, Aurora
will implement this nationwide effort
on a local level with $3.9 million in
federal funding over five years.

“Aurora has helped make Wisconsin
a national leader in medical research
and cancer care,” U.S. Sen. Tammy
Baldwin wrote. “By focusing on
community-based care, Aurora
has earned the trust of eastern
Wisconsin families.”
“The talented and hardworking
staff at Aurora Health Care should
be proud of this accomplishment,”
U.S. Rep. Paul Ryan wrote.

NCORP principal investigators
Thomas Saphner, MD, and
Michael Thompson, MD, PhD, are
spearheading the NCORP initiative
throughout Aurora Health Care’s
extensive footprint under the
guidance of the Aurora Research
Institute and Aurora Cancer Care.
“This is a transformational grant
for Aurora,” Dr. Saphner said.
“We are making a statement and
commitment to being a national
player in cancer research.”
One of the first implementation
steps was creating a program
administrator position. Neha
Glandt, a key player in preparing
the NCORP application, was
promoted to the position.

Wisconsin
Illinois

The team, which includes clinical
trials manager Jan DeBartolo,
MSN, then received training at
the charter NCORP meeting in
the nation’s capital. In addition
to NCI-sponsored clinical trials
for cancer treatment, symptom
control and prevention, Aurora
will participate in cancer care
delivery research trials designed
to determine the best use of
resources in cancer care. This
is in addition to any enrollments
in non-NCI-sponsored trials.
With monthly meetings to
track progress and develop
informational materials for
patients, the team is working
toward its goal of ultimately
improving patient outcomes
by sharing and analyzing all
research findings, then
applying that new knowledge
to individual treatment.
“We want the right therapy
delivered to the right patient
at the right location – close to
home,” Dr. Thompson said.

The NCORP team traveled to the nation’s
capital to receive training.
Photo courtesy of Michael Thompson, MD, PhD

39

Annual Report 2014

Additional
extramural funding

NCORP principal
investigators Thomas
Saphner, MD (from
left), and Michael
Thompson, MD, PhD,
receive the Clinical
Trials Research Award
presented by James
Weese, MD, during
the Greater Milwaukee
Clinical Research
Recognition Event.

STUDY:
Improving patient cancer care
delivery with a web-based
platform for multidisciplinary
conference access
AWARD:
$35,000
SOURCE:
Public Service Commission
of Wisconsin
PRINCIPAL INVESTIGATOR:
James Weese, MD

Providing more options to fight cancer
When Virginia Mortenson of Green
Bay was diagnosed with breast
cancer in 2007, she didn’t believe it.
“I have always had dense breast
tissue and I’ve had to go beyond
mammograms a couple times for
screenings, but it never amounted
to anything,” she said.
But this time regular screening, a
second mammogram and biopsy
confirmed – Mortenson faced
stage 1 breast cancer.

chemotherapy plus an estrogeninhibiting medication while others
avoided chemotherapy and only
received the estrogen-inhibiting
medication to try to prevent the
cancer from recurring. Mortenson
received only the inhibitor drug
and stayed on it for five years.
“I avoided chemotherapy. I don’t
think it would have been any
more effective than the inhibitor,”
Mortenson said.

“That was a bit of a shocker,”
Mortenson said. “It all went very
quickly – I scheduled an appointment
with a surgeon, she and her team
were wonderful in explaining what
was happening – it’s a lot to take in.”

“Currently, there is a gap between
when treatments or techniques are
known to be successful and when
they are incorporated as a standard
of care,” said Thomas Saphner, MD,
a principal investigator spearheading
Aurora’s efforts. “A primary goal of
our work on this project will be to
narrow this gap.”
Mortenson is living proof. The
inhibitor she began taking in 2007 is
now available even in generic form.

After surgery and radiation,
Mortenson’s doctor recommended
a test that examines the tumor to
determine likelihood of recurrence.

“I entered the clinical trial so in the
future, women in my position would
have more clear-cut data on which
to make a treatment decision,”
Mortenson said.

Because she tested “in the middle”
for recurrence, Mortenson decided
to enroll in a clinical trial for a chance
to avoid the side effects and damage
caused by chemotherapy’s toxicity.
The trial involved postmenopausal
women with estrogen-positive
breast cancer, which is what she had.
Some women were given traditional

Providing patients with better access
to top clinical trials is a key goal of
Aurora Health Care’s involvement
with the National Cancer Institute
Community Oncology Research
Program, or NCORP. Aurora was
awarded $3.9 million in federal
funding over five years to improve
cancer research and expand patient
access to clinical trials in Wisconsin.

Virginia Mortenson
Photo courtesy of Virginia Mortenson

Dhimant Patel, MD, is Mortenson’s
oncologist. Lori Bowhousen, Kate
McPolin, BSN, and Sarah Peterson,
RN, provided site coordination for
Aurora Research Institute.
aurora.org/research
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TORQUE
Translational Oncology Research:
Quest for Understanding & Exploration
Judy A. Tjoe, MD
Medical Director, TORQUE
Dr. Tjoe leads Aurora Health Care’s translational breast cancer research program through
TORQUE (Translation Oncology Research: Quest for Understanding & Exploration), using
more than 30 years of data from the Cancer Registry and Biorepository and Specimen
Resource Center. With a research component, the Team Phoenix breast cancer survivorship
program started by Dr. Tjoe falls under the TORQUE umbrella.

Investigator-initiated research
TORQUE investigators hope to
find predictors of breast cancer
progression and understand the
role of estrogen receptors (ER) in
development of the disease.
The investigator-initiated research
project led by Judy A. Tjoe, MD,
and Sanjay Kansra, PhD, involves
identification of biomarkers that
could predict development of
breast cancer.
Abnormal cell growth in the ducts
or lobules of the breast (atypical
ductal hyperplasia [ADH] and
atypical lobular hyperplasia
[ALH]) is associated with a
three- to fivefold increased risk
of future breast cancer, and
risk mitigation includes regular
imaging or preventive measures.
The goal of the study is to find
predictors for those at highest
risk for disease progression
to limit aggressive treatment
options, which are associated
with side effects. Findings so far
may have ruled out expression
of ER, progesterone receptors
and human epidermal growth
factor receptor-2 (HER2/neu)
as possible predictors.
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Using a multiplex immunochemistry
technique, their work in patients
with premalignant breast lesions
(ADH and ALH) revealed distinct
findings when compared to a
similar study on patients with
ductal carcinoma in situ that
suggested a combination of three
biomarkers (the cell cycle regulator
p16INK4a, the proliferation antigen
Ki-67 and the stress response
enzyme COX2) could predict

future breast cancer. Additional
study is needed.
Digging deeper, investigators are
pursuing nonclassical ER and
ER-beta as possible biomarkers
to predict future breast cancer.
Maharaj Singh, PhD, and Brittany
Last provide support for these
studies, which are funded by
Genentech Inc. and Rock River
Cancer Research Foundation.

Cancer rehabilitation specialist Leslie J. Waltke, PT, gave a talk on the role and benefits
of cancer rehabilitation at the 2014 China Cancer Congress in Beijing, China. Waltke was
invited to present after publishing a review on exercise and rehabilitation to improve
cancer outcomes in Journal of Patient-Centered Research and Reviews.

Survivorship
program
“It was more of a challenge
than breast cancer,” said Yvonne
Kidandi, breast cancer survivor
and 2014 Team Phoenix athlete.
“You have to show up for
treatments, but you don’t have
to sign up for a triathlon.”
The 14-week Team Phoenix
program, led by breast cancer
surgeon Judy A. Tjoe, MD, and
cancer rehabilitation specialist
Leslie J. Waltke, PT, brings
together breast cancer survivors
to train – under medical guidance
– for a triathlon. The purpose is
to promote adoption of regular
exercise and healthy lifestyle
behaviors that not only counter
many side effects, but ultimately
empower patients and survivors
to take control of their health
after treatment.

Kidandi’s journey
Kidandi was diagnosed in July
2011 at 27. She had a double
mastectomy, reconstruction and
eight cycles of chemotherapy.

Celebrating her birthday and last chemotherapy treatment,
Yvonne Kidandi enjoys a beverage with family and friends.
Photos courtesy of Yvonne Kidandi

Yvonne Kidandi during
cancer treatment.

“My support system was
amazing,” Kidandi said. “All of
the nurses at the Vince Lombardi
Cancer Clinic at Aurora Sinai
Medical Center made the
experience better.”

Research component

Her last treatment was on her
birthday in January 2012, giving
her two reasons to celebrate.

Findings showed that participation
improved quality of life with more
endurance capacity, weight loss
and less fatigue.

“It was truly a new beginning,”
Kidandi said.

“My energy
level is up,
I’m eating
better and I’m
happier.”

After her treatments were
finished, she joined Team Phoenix
to challenge herself to a new
sport. Both athletic and medical
coaches oversee the patients’
gradual progression of increased
exercise intensity, while cancer
rehab physical therapists address
any immediate aches and pains
from training or the original
cancer surgery and radiation.
“Team Phoenix was a positive
change in my life,” Kidandi said.
“I look forward to working out
three to four times a week and
I am aware of the foods I eat.
My energy level is up, I’m eating
better and I’m happier.”

Patients in the Team Phoenix program
volunteer for research efforts done
in collaboration with Marquette
University.

The research is supported by
American Cancer Society and an
Aurora Cancer Care Research
Award (generously funded by
Vince Lombardi Cancer Foundation).
In 2014, Dr. Tjoe received $25,000
in second-year funding. Research
scientists in endocrinology, Hershel
Raff, PhD, and immunology, John
Richards, PhD, are co-investigators.
The goal of their continued research
is to more definitively determine if
markers of inflammation, obesity and
health are influenced by prescribed
exercise in breast cancer survivors
exposed to systemic therapy; and
investigate mechanisms of cancerrelated fatigue and further evaluate
exercise as a means to reduce
cancer-related fatigue in patients
who have undergone treatment.
aurora.org/research
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Early Phase Cancer Research Program
Michael Thompson, MD, PhD
Medical Director, Early Phase Cancer Research Program
Dr. Thompson leads development of early phase (Phase I and II) clinical trials at Aurora
Health Care. These therapeutic trials run through the Early Phase Cancer Research Program
are designed to test new treatments with the primary aim to benefit patients. Based on
statistical power, Phase I trials evaluate safety and Phase II assess efficacy of investigational
treatments before they can be tested against the current standard of care (Phase III studies).

Bile duct cancer (cholangiocarcinoma)
As part of a Phase II clinical trial,
Aurora Health Care researchers
are trying to improve the
response to chemotherapy
in patients with advanced
cholangiocarcinoma, or bile duct
cancer. Cholangiocarcinomas
represent approximately 10-15% of
all primary liver cancers worldwide
and the incidence is growing.
The five-year overall survival with
systemic chemotherapy is about
5% with median survival less than
one year after diagnosis.
Led by principal investigator
Michael Thompson, MD, PhD,

18% of
subjects
were enrolled at Aurora
researchers are testing whether
the drug nab-paclitaxel,
which has proved effective in
advanced breast, pancreatic
and non-small-cell lung cancers,
will improve survival

in subjects with advanced bile duct
cancer by targeting gemcitabine
chemotherapy (clinicaltrials.gov
identifier: NCT02181634; sponsor:
PrECOG LLC).
The goal is to enroll 70 subjects
nationwide. As of March 27, 2015,
Aurora had enrolled 3 of the
17 subjects from the more than
20 participating centers. Enrolling
physicians were Scott Maul, MD,
Corey Shamah, MD, and Umang
Gautam, MD, with support from
coordinators Liz Sieber, RN, BS,
Chris Goebel, BSN, and Kate
McPolin, BSN.

Lung cancer
Aurora Health Care is the only health system in
Wisconsin – one of nine health systems nationally –
participating in an early phase clinical trial on solid
tumors and relapsed small-cell lung cancer.
The Phase I portion of the trial
determined the maximum
tolerated dose of carfilzomib
in combination with irinotecan
chemotherapy. The Phase II
portion of the trial will assess
6-month survival of patients
with relapsed small-cell
lung cancer treated with
this combination therapy
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(clinicaltrials.gov identifier: NCT01941316; sponsor:
Cancer Research and Biostatistics Clinical Trials
Consortium).
Michael Thompson, MD, PhD, is Aurora’s
principal investigator. Michael Mullane, MD,
and coordinator Karen Crone, RN,
enrolled Aurora’s first patient by the
end of 2014. The goal is to enroll 112
subjects nationwide.

Only in
Wisconsin

Can curcumin heal
mouth sores?
Combating the toxic effects of
chemotherapy with a natural
agent is the goal of a collaborative
hybrid effort – an investigatorinitiated clinical trial – led by
sponsor Dhimant Patel, MD.
Oral mucositis is a common
complication of chemotherapy
that causes mouth ulcers. The
ulcers cause pain and nutritional
problems because the person
cannot eat. Also, the open sores
increase risk of infection. In
severe cases, the chemotherapy
dose needs to be reduced, which
interferes with treatment.
Bench research has shown that
curcumin, a chemical found in
the spice turmeric, can reduce
the amount of bacteria and
prevent inflammation.
Dr. Patel and his team want to
learn if a mouthwash made with
curcumin is safe for people to
use and can help with oral
mucositis due to chemotherapy.

With assistance from Nina
Garlie, PhD, director of
Aurora Research Institute’s
Regenerative Medicine Center,
Patel wrote an investigational
new drug application, which
received Food and Drug
Administration approval.
They developed a protocol for
the trial and obtained $25,000
in seed money from Vince
Lombardi Cancer Foundation
in the form of an Aurora Cancer
Care Research Award, which is
administered by the institute’s
Sponsored Programs Office.
Aurora BayCare Medical
Center is the only site for
this early phase (I/II) trial
(clinicaltrials.gov identifier:
NCT02300727). The goal is
to enroll about 38 subjects,
who will be randomized to
receive a pharmacy-prepared
mouthwash with or without
the maximum tolerated dose
of curcumin. Subjects will use
the mouthwash three times a
day for four to six weeks, unless
otherwise advised. An initial
group of subjects will determine
the maximum tolerated dose.

Dhimant Patel, MD, sponsor of a clinical
trial to test curcumin in treatment of oral
mucositis, a chemotherapy complication.

Kate McPolin, RN, Sarah
Peterson, RN, and Corinne
Zipperer, RN, are coordinating
the clinical trial for the institute.

Vaccines
in multiple
myeloma
Through a generous donation
from Vince Lombardi Cancer
Foundation, Michael Thompson,
MD, PhD, received a
2014 Aurora Cancer
Care Research
Award totaling
$25,000 to pursue
a study on the
immune system
response following
vaccination in
patients with
multiple myeloma.
Plasma cells, a
type of white blood cell, create
antibodies to fight infections. In
multiple myeloma, the plasma
cells become cancerous and
unable to create infectionfighting antibodies. Because of
a compromised immune system
response, people with multiple
myeloma become susceptible to
infections, a common reason for
hospitalization or death.
Dr. Thompson is performing a
group of three related studies
with other Aurora investigators.
The first is a retrospective review
to determine Aurora’s vaccination
practice patterns and outcomes.
The second is a prospective
registry to track vaccinations
in myeloma and other blood
cancers. The final component is
a blood sample collection study
to see how people with multiple
myeloma compare to controls in
response to flu and pneumonia
vaccines.
“We believe this work will provide
important information about the
best way and time to vaccinate
patients with multiple myeloma
against flu and pneumonia,”
Dr. Thompson said.
aurora.org/research
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Finding new cancer treatment options
is a personal mission for researcher
Senior research scientist Santhi Konduri, PhD, has a
personal vendetta against breast cancer – it claimed
her aunt’s life.
“It has happened in my family, and I’m trying to see
if this research can help. Will it make a difference for
people like her?” she said.
Winner of two Aurora Cancer Care Research
Awards in 2014, Konduri and co-investigator George
Bobustuc, MD, have found that a new combination of
drugs may decrease
breast and pancreatic
“We really
tumor growth without
undesirable side
need new drug
effects to healthy
combinations to
cells. Their continued
preclinical evaluation
prolong the lives
could be translated
of these patients.” into new treatment
options in the future.
The key appears to be disulfiram.
“Disulfiram is actually an FDA-approved drug for
alcoholism; it creates an aversion for alcohol and
reverses the inclination to drink,” said Dr. Konduri,
principal investigator. “Recently, it has also shown
anticancer properties, and when it is combined
with chemotherapeutic drugs (temozolomide and
cyclophosphamide/gemcitabine and paclitaxel), we
can reduce the dosage of chemotherapeutic drugs.”

Santhi Konduri, PhD, reviews cancer cells through a microscope
in a laboratory near Aurora St. Luke’s Medical Center.

This is critical as reducing the dose will decrease
both unpleasant side effects and cellular/organ
damage caused by chemotherapy’s toxicity.
There are only two drugs with FDA approval to treat
pancreatic cancer and the survival rates are quite low.
“It’s a very severe disease, partly because people
don’t often notice the symptoms until after the
disease has spread to other organs,” she said. “We
really need new drug combinations to prolong the
lives of these patients.”
Vince Lombardi Cancer Foundation generously
supports the Aurora Cancer Care Research Award
program. Dr. Konduri received a total of $50,000.

Laboratory capabilities spur collaboration
Aurora Research Institute’s ability to study white
blood cell (monocyte) function in human samples
spurred collaboration with Duke University School
of Medicine cancer researchers.
Immunotherapy researcher John Richards, PhD,
developed a method to simultaneously characterize
how therapeutic antibodies stimulate various
immune cells to kill cancer cells.
His multiplex flow cytometry assay has been used
to study human mononuclear cells important to the
immune system’s response against cancer as well as
destruction of tumors.
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Visiting Duke researcher Donald McDonald, PhD,
wanted to test the hypothesis that inhibitors to the
gene CaMKK2 may improve immune cell-mediated
killing of tumors. When the gene is deleted in mice,
the mice do not develop tumors. In an ongoing
collaboration, Dr. McDonald provides CaMKK2
inhibitors to be tested with Dr. Richards’ assay.
“The door has been opened for immunotherapies,”
Dr. Richards said. “They get the person’s immune
system to fight the cancer.”
The goal of immunotherapy cancer research is,
ultimately, to develop new drugs that spur the immune
system to eliminate tumors or keep tumors in check.

Researchers look for predictors to detect
early heart damage due to chemotherapy
breast cancer who are
being treated with
doxorubicin and/or
trastuzumab – drugs known
to have cardiotoxic effects –
for two years beginning
with the start of treatment.
Echocardiography and blood
tests are being used to
determine cardiac function
and to evaluate potentially
predictive biomarkers.

Chemotherapy is a primary
weapon in the arsenal against
cancer, but some drugs used
to treat cancer have the
potential to cause damage
to the heart.
Principal investigator
Rubina Qamar, MD, and
co-investigator Scarlet Shi,
PhD, are trying to find early
prediction methods for
patients with breast cancer
who are at greater risk for
developing heart disease
from chemotherapy.
“We hope that early detection
in the future leads to early
intervention and improves
long-term complications from
cardiotoxicities,” Dr. Qamar said.
In this study, the researchers
are following 150 patients with

The goal is to detect early
signs of injury to the heart
before permanent damage
occurs, and monitor and
modify treatment without
impacting the effectiveness
of cancer therapy.
“The results will help guide
cardio-oncology specialists
in making treatment
decisions,” Dr. Shi said.

Echocardiogram and strain imaging (bull’s-eye inset)
shows early cardiotoxic effects of chemotherapy in a
patient with cancer.

The researchers received Aurora Cancer
Care Research Awards totaling $50,000 over
two years to support this research. Vince
Lombardi Cancer Foundation generously
supports the award program.

Reviews highlight cardiotoxic drugs,
new diagnostic techniques
Both cardiologist Bijoy Khandheria, MD, and medical
oncologist Charles Bomzer, MD, served as guest
editors of the cardio-oncology theme issue of
Journal of Patient-Centered Research and Reviews.
Dr. Bomzer provided a
review, “Cardiovascular
toxicity of common
chemotherapy drugs
used to treat breast
cancer: an overview.”
His review identified
the most commonly
used drugs to treat
breast cancer and
provided an overview
of their potential
adverse impact on the
cardiovascular system.

Under Dr. Khandheria’s mentorship, Italian author
Fausto Pizzino, MD, provided a review, “Diagnosis
of chemotherapy-induced cardiotoxicity,” which
highlighted new techniques to diagnose cardiotoxicity
due to chemotherapy.
Their review notes that use of left ventricular ejection
fraction – as recommended by guidelines – is not
sensitive in detecting early cardiac damage. Techniques
like identifying biomarkers may hold promise for the
future, but larger controlled trials are needed.
Both articles stress the importance of close
collaboration between cardiologists and oncologists
for the correct management of patients who are
treated with drugs that have potentially harmful
effects on the cardiovascular system. Fostering this
collaboration is one of the fundamental principles
of Aurora Health Care’s Center for Cardio-Oncology
Research and Innovation.
aurora.org/research
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Study tests radiation therapy plus hormone
suppression against prostate cancer
preventing prostate cancer
recurrence (clinicaltrials.gov
identifier: NCT00567580).

External beam radiation therapy
is the standard of care for men
with prostate cancer as it destroys
cancer cells and shrinks tumors.

“Some patients treated with
hormone suppression drugs
and radiation have a greater
chance of not having the
cancer return when compared
to men treated with radiation
alone,” Dr. Pincus said.

But how do you prevent the cells
from growing back?
Growing evidence shows that
reducing male hormone levels
prevents cancer cell growth.
Principal investigator Mitchell
Pincus, MD, and his team are
studying whether hormone
suppression, when added to
radiation therapy, is effective in

“Treating the pelvic lymph nodes
can result in increased side
effects, so the benefits need to
be understood,” Dr. Pincus said.
Kerri Cwiklinski, RN, coordinates
the clinical trial for Aurora
Research Institute.

The clinical trial also is testing
whether it is more beneficial
to include the pelvic lymph
nodes when applying radiation
therapy to the prostate bed.

Reducing male
hormone levels
prevents cancer
cell growth

Oncology volumes (new cases) – systemwide
Source: Cancer Registry

2012

2013

2014*

Primary site of disease
Oral cavity
Lip
Tongue
Oropharynx
Hypopharynx
Other
Digestive system
Esophagus
Stomach
Colon
Rectum
Anus/anal canal
Liver
Pancreas
Other
Respiratory system
Nasal/sinus
Larynx
Lung/bronchus
Other
Blood and bone marrow
Bone
Connect/soft tissue
Skin
Breast

*Complete data not available at time of publication
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2012

2013

2014*

Brain (benign)
Brain (malignant)
Other
Endocrine
Thyroid
Other
Lymphatic system
Unknown primary
Other/ill-defined

448
52
230
92
46
28
801
760
35
6
570
327
226
17
197
6
75
116
190
145
45
333
72
43

443
45
237
108
37
16
854
819
28
7
591
371
199
21
171
13
71
87
158
130
28
312
66
40

578
75
291
127
63
22
943
899
38
6
593
329
242
22
376
101
124
151
243
161
82
317
90
40

Total

6,816

6,872

7,592

Primary site of disease
118
6
38
4
5
65
1,094
84
78
344
158
30
99
193
108
847
6
38
789
14
540
9
43
338
1,173

131
4
43
9
5
70
1,036
76
79
318
155
21
82
200
105
860
4
45
795
16
503
6
31
376
1,294

163
5
51
10
10
87
945
80
79
328
146
23
77
189
23
956
6
34
894
22
545
15
51
460
1,277

Female genital
Cervix uteri
Corpus uteri
Ovary
Vulva
Other
Male genital
Prostate
Testis
Other
Urinary system
Bladder
Kidney/renal
Other
Brain & central nervous system

Oncology publications
2014 Aurora-authored, peer-reviewed

Journal articles,
book chapters,
monographs
Baumgardner DJ, Rogers A. Primary care
for melanoma: should we be screaming for
screening? J Patient-Centered Res Rev 2014;
1:33-40.
Bomzer CA. Cardiovascular toxicity of common
chemotherapy drugs used to treat breast
cancer: an overview. J Patient-Centered Res
Rev 2014;1:133-6.
Bomzer CA, Khandheria BK. Cardio-oncology:
success breeds new challenges, opportunities.
J Patient-Centered Res Rev 2014;1:113.
Burkard ME, Wisinski KB, Njiaju UO, Donohue
S, Hegeman R, Stella A, Mansky P, Shah V,
Goggins T, Qamar R, Dietrich L, Kim K, Traynor
AM, Tevaarwerk AJ. Feasibility of 4 cycles of
docetaxel and cyclophosphamide every 14 days
as an adjuvant regimen for breast cancer: a
Wisconsin Oncology Network study. Clin Breast
Cancer 2014;14:205-11.
Khan A, Malone ML, Bomzer C. Splenic marginal
zone lymphoma involving the breast: lessons
in patient-centered care. J Am Geriatr Soc
2014;62:405-7.
Khan AS, Fowler KJ, Chapman WC. Current
surgical treatment strategies for hepatocellular
carcinoma in North America. World J
Gastroenterol 2014;20:15007-17.
Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L,
Flynn KA, Atherton P, Seisler D, Qamar R, Lewis
GC, Grothey A. Phase III randomized, placebocontrolled, double-blind study of intravenous
calcium and magnesium to prevent oxaliplatininduced sensory neurotoxicity (N08CB/Alliance).
J Clin Oncol 2014;32:997-1005.
Mullane MP. The molecular biology and
treatment of malignant melanoma with
BRAFV600 mutations. J Patient-Centered Res
Rev 2014;1:21-6.
Oaks M, Rein N, Richards JO, Shaffer J.
Autoantibodies to the NY-ESO-1 tumor antigen
in metastatic melanoma: sialylation of the Fc
region of immunoglobulin G induces differential
expression signatures of inflammatory
molecules during dendritic cell differentiation
and maturation. J Patient-Centered Res Rev
2014;1:171-87.
Paranjpe A, Zhang R, Ali-Osman F, Bobustuc
GC, Srivenugopal KS. Disulfiram is a direct and
potent inhibitor of human O6-methylguanineDNA methyltransferase (MGMT) in brain tumor
cells and mouse brain and markedly increases
the alkylating DNA damage. Carcinogenesis
2014;35:692-702.
Rice S, Kozak KR, Mohindra P. Scalp
angiosarcoma: discussion of a management
plan. Applied Radiation Oncology
2014;(September):20-3. Published online at:
http://appliedradiationoncology.com/
wp-content/uploads/2013/09/ARO_09-14_
RiceROC.pdf.

Rosiak J, Humphreys C. A case of complicated
survivorship care. J Adv Pract Oncol 2014;5:64-8.
Santhosh-Kumar CR, Gray D, Fisher DJ. Pulsed
erlotinib as sole treatment of leptomeningeal
carcinomatosis: can we avoid the use of
intrathecal therapy? World J Oncol 2014;5:237-9.
Shaikh A, Agarwal A, Treiber S, Tajik AJ.
Anomalous connection of the left upper
pulmonary vein to the vertical vein: an
uncommon diagnosis unveiled by suprasternal
notch imaging. Eur Heart J Cardiovasc Imaging
2014;15:1385.
St Germain D, Denicoff AM, Dimond EP,
Carrigan A, Enos RA, Gonzalez MM, Wilkinson
K, Mathiason MA, Duggan B, Einolf S, McCaskillStevens W, Bryant DM, Thompson MA, Grubbs
SS, Go RS. Use of the National Cancer Institute
Community Cancer Centers Program screening
and accrual log to address cancer clinical trial
accrual. J Oncol Pract 2014;10:e73-80.
Sud A, Wham D, Catalano M, Guda NM.
Promising outcomes of screening for pancreatic
cancer by genetic testing and endoscopic
ultrasound. Pancreas 2014;43:458-61.
Thompson MA. Melanoma: attacking on many
fronts. J Patient-Centered Res Rev 2014;1:8-10.
Thompson MA. Social media in clinical trials.
Am Soc Clin Oncol Educ Book 2014:e101-5.
Thompson MA, Westin JR, Hagemeister FB.
Bone mineral density screening should be
routine in lymphoma patients. (letter) Ann
Oncol 2014;25:913-4.
Waltke L. An overview of cancer rehabilitation
and exercise in the literature: promoting
increased referrals to improve oncology
outcomes. J Patient-Centered Res Rev
2014;1:137-41.
Weber JS, Levit LA, Adamson PC, Bruinooge
S, Burris HA 3rd, Carducci MA, Dicker AP,
Gönen M, Keefe SM, Postow MA, Thompson
MA, Waterhouse DM, Weiner SL, Schuchter LM.
American Society of Clinical Oncology Policy
Statement Update: The Critical Role of Phase I
Trials in Cancer Research and Treatment.
J Clin Oncol 2015;33:278-84.

Abstracts
Barry-Weers A, Huibregtse C, Ihde S,
Bjegovich-Weidman M, Weese JL. Getting quality
data back to frontline providers. J Clin Oncol
(Meeting Abstracts) 2014;32(30_suppl):196.
Engel AA, Cybulski AN, Robinson K, Piacentine
LB, Tjoe JA, Waltke LJ, Papanek PE, Ng AV.
Psychosocial and physiological effects of
triathlon training in breast cancer survivors.
Med Sci Sports Exerc 2014;46(5S):543-4.
Feldt A, Godden J. Implementation of pharmacy
services in 22 oncology clinics. J Clin Oncol
(Meeting Abstracts) 2014;32(30_suppl):145.

Poggi L, Godden J, Yoder S. A standardized
approach for managing chemotherapyinduced rash. J Clin Oncol (Meeting Abstracts)
2014;32(30_suppl):86.
Rathod H, Yoder S. Interventions to optimize the
use of colony-stimulating factors. J Clin Oncol
(Meeting Abstracts) 2014;32(30_suppl):92.
Reid BB, Rodriguez KN, Thompson MA,
Matthews GD. An analysis of cancer-specific
Twitter conversations among physicians in
2013. J Clin Oncol (Meeting Abstracts)
2014;32(15_suppl):e17644.
Rice S, Liang E, Geye H, Kimple RJ. Skin cancers
of the head and neck: a 21-year single institution
experience. Int J Radiat Oncol Biol Phys
2014;90:S562.
Rice S, Mohindra P, McHaffie DR, Jarrard DF, Graf
AK, Adkison J, Ritter MA. Long term outcomes
with hypofractionated radiotherapy (HFRT) for
clinically localized prostate cancer: 70 Gy at
2.5 Gy per fraction. Int J Radiat Oncol Biol Phys
2014;90:S53.
Santhosh-Kumar CR. Barriers to clinical trial
accrual in a community cancer clinic. J Clin Oncol
(Meeting Abstracts) 2014;32(30_suppl):91).
Steensma DP, Abedi M, Attar EC, Bejar R,
Cogle CR, Garcia-Manero G, Grinblatt DL, Ma X,
Maciejewski JP, Pollyea DA, Roboz GJ, Savona M,
Scott BL, Sekeres MA, Thompson MA, Zernovak
O, Sugrue MM, Swern AS, Nifenecker M, Erba
HP. Connect MDS and AML: The myelodysplastic
syndromes (MDS) and acute myeloid leukemia
(AML) disease registry. J Clin Oncol (Meeting
Abstracts) 2014;32(15_suppl):TPS7126.
Tjoe JA, Ihde SE, Greer DM, Weese JL. Improving
quality metric adherence in minimally invasive
breast biopsy among surgeons across a
multihospital organization. J Am Coll Surg
2014;219:e151-2.
Tjoe JA, Neitzel G, Singh M, Last B, Marx J,
Kansra S. Does expression of estrogen receptor,
progesterone receptor, and HER2 in atypical
breast lesions predict a subsequent clinically
significant event? J Clin Oncol (Meeting
Abstracts) 2014;32(26_suppl):34.
Tjoe JA, Neitzel G, Singh M, Last BT, Kansra S.
Expression pattern of estrogen, progesterone
and HER2/neu receptors in atypical breast lesions
does not predict subsequent clinically significant
event. J Patient-Centered Res Rev 2014;1:152.
Tjoe JA, Singh M, Last B, Neitzl GF, Marx JJ,
Jewett C. Breast atypia: timing of progression
to subsequent clinically significant event.
J Patient-Centered Res Rev 2014;1:57.
Tjoe JA, Waltke LJ, Engel A, Cybulski A, Robinson
K, Piacentine L, Papanek PE, Ng AV. “Surgerychemotherapy-radiation, followed by a different
kind of triathlon”: medically directed group
exercise program is unique and effective among
overweight and obese breast cancer survivors.
J Patient-Centered Res Rev 2014;1:150-1.

Owens WL. Major complication rate after
mastectomy with implant reconstruction in a
community hospital setting. J Patient-Centered
Res Rev 2014;1:55.
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Neurosciences
research
Amin Kassam, MD
Vice President, Aurora Neurosciences
Dr. Kassam leads the Aurora Neuroscience Innovation Institute team, a multidisciplinary
group of specialists who coordinate care for neurological disorders at Aurora.

Neurosciences Research Work Team
Julie Basquin, MS

Vani Nilakantan, PhD

Carol Tutino, BSN, MS

Nina Garlie, PhD (CHAIR)

Sara Planton, BSN

Kurt Waldhuetter

Amin Kassam, MD

Natalie Polinske, MS

Randall Lambrecht, PhD

Bob Stoltz, MBA, MT

49

Annual Report 2014

Epilepsy
(5) 28%
Multiple
sclerosis
(3) 18%

NeuroOncology
(3) 18%

18

Interventional
radiology
(3) 18%
Surgical/
Stroke
(3) 18%

17

total neurosciences clinical
trial enrollments in 2014

open neurosciences clinical
trials as of Dec. 31, 2014

Surgical/Stroke
(8) 44%

Interventional
radiology
(3) 17%
Epilepsy
(1) 6%
Sisters Sarah Socha and Nicole
Borley share a birth date and a
diagnosis – multiple sclerosis.
(See story on page 53.)

Neuro-Oncology
(6) 33%

~5%

of Aurora’s research is
related to neurosciences

~5%

of Aurora’s neurosciences
research is investigator-initiated
aurora.org/research
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Neurosurgeon leads course
on latest techniques
Aurora Research Institute in 2014
renovated space in the lower level
of the Milwaukee Heart Institute to
accommodate the course, which
includes hands-on simulation
laboratory sessions.

Amin Kassam, MD, leads one of the
quarterly 6 Pillar Approach courses at
Aurora Sinai Medical Center.

Learning brain surgery from
Neurosciences Vice President
Amin Kassam, MD, well, it’s not
brain surgery.
Dr. Kassam leads a two-day
course on his minimally invasive
6 Pillar Approach to brain surgery
quarterly in the new Aurora
Research Institute Innovation
Learning Center.
Neurosurgeons, neuroradiologists
and neurologists from around
the world attend to learn the
parafascicular approach to remove
tumors and clots from areas deep
within the brain, or white matter. The
approach pulls together the latest
technologies to target treatment.
The course emphasizes economic
resource optimization through
surgical biometrics.

In 2015, new addition to the
neurosciences team Richard Rovin,
MD, signed on as co-director for
the course. Dr. Rovin serves as
clinical research director for Aurora
Neuroscience Innovation Institute.
Participants earn a maximum
15.5 AMA PRA Category 1 Credits.
Aurora Health Care is accredited
by the Wisconsin Medical Society.
The event is presented through
collaboration between Aurora and
Academic Event Management.
The course is supported in part
by educational grants from NICO
Corp., Synaptive Medical, Hitachi
Aloka Medical Ltd., KARL STORZ
Endoscopy-America Inc. and KLS
Martin Group.

Clinicians from around the world attend the
6 Pillar Approach course to learn the latest
developments in brain surgery.

Abstract
highlights
The Society of Vascular and
Interventional Neurology
invited interventional
neurologist Akram Shhadeh,
MD, to present two abstracts
at its seventh annual meeting
in November 2014.
“One abstract reflects our
experience with treating
ruptured brain aneurysms
with a pipeline flow
diverter device,” said
Dr. Shhadeh, medical director
of Endovascular Surgical
Neuroradiology for Aurora
Neuroscience Innovation
Institute. “The second
one reflects the benefit of
interventional stroke treatment
in young patients with no
evidence of penumbra on
CT perfusion.”
“Treatment of ruptured
aneurysm with pipeline”
showed that a self-expanding
embolization device was safe
and effective in treating two
patients with ruptured brain
aneurysms not amenable to
other endovascular or surgical
options. Further study is
needed to validate this option.
“IA stroke therapy benefits
despite lack of ‘penumbra’ on
CT perfusion” showed that
intra-arterial therapy within
eight hours was beneficial
in two patients despite a
matched lesion without
potentially salvageable
tissue, or penumbra, visible
with computed tomography
perfusion imaging.
Ayman Gheith, MD, Rehan
Sajjad, MD, Elizabeth Marriott,
MD, Molly Zahour, NP, Megan
Dibb, NP, and Amin Kassam,
MD, were co-authors of the
abstracts.
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Aurora coordinates national study
to evaluate new way to remove brain clots
Each year, nearly 130,000 people in the United
States die from stroke.
Intracerebral hemorrhage is a type of stroke that
occurs when a blood vessel in the brain bursts, most
often due to high blood pressure. The pressure from
the blood leaking inside the brain can damage brain
tissue and lead to permanent disability and death.
Aurora Health Care, under the leadership of
Neurosciences Vice President Amin Kassam, MD,
launched a multicenter research study to assess
the outcomes of a unique, minimally invasive
surgical approach to safely remove clots in study
subjects with intracerebral hemorrhage in deep
areas of the brain.
Aurora St. Luke’s Medical Center, Milwaukee, is the
coordinating site for the research study, known as
Minimally Invasive Subcortical Parafascicular Access
for Clot Evacuation, or MiSPACE. Up to 12 sites
nationwide will participate in the program.
“MiSPACE provides an important opportunity
to study the clinical and economic impact of a
minimally invasive approach to patients with
hemorrhagic stroke,” said Sara Planton, BSN,
director of the Clinical Trials Department for
Aurora Research Institute. “Under Dr. Kassam’s
direction, Aurora St. Luke’s will serve as the
national hub and coordinating site for this
important, multicenter trial.”

The goal of the study is to assess clinical outcomes
in up to 50 study subjects surgically treated for
subcortical intracerebral hemorrhage. A systems
approach will be used that integrates five core
competencies for safe and consistent use at
30- and 90-day increments.
As an additional measure, investigators also will
perform an economic analysis, comparing inpatient
care costs of patients who undergo the unique
surgical approach to those managed with drugs
or conventional surgical treatment.
“The problem we have today is that a ‘wait and see’
approach to hemorrhage resolution does not always
result in the best outcome for the patient,” Dr. Kassam
said. “It is our hope that by using this new, integrated
surgical approach of subcortical parafascicular access
with early intervention, we will provide a better end
result with less trauma to the patient and improved
functional outcomes.”
Lynda Yanny, BSN, and Jennifer Mathieu are
coordinating the research study for the institute.

Expanding clinical trial access
Stroke is the fourth leading cause
of death in the United States.
Principal investigator Elizabeth
Marriott, MD, received a federal
cooperative grant making Aurora
Health Care the first StrokeNet
satellite site in Wisconsin.
The National Institutes of Health
Stroke Centers Network, or
StrokeNet, is a network of 25
regional coordinating centers and
its satellite sites working together

to address the three prongs of stroke
research: prevention, treatment and
recovery.

than 30 health systems, or satellites,
in the region to expand patient
access to stroke clinical trials.

The University of Wisconsin-Madison,
a regional coordinating center,
entered agreements with more

“We are pleased to combine the
latest advances in stroke care with
our extensive research team to
bring the best available care to
our patients,” Dr. Marriott said.

First
satellite in
Wisconsin

1

st

Clinical trials manager Carol
Tutino, BSN, MS, is coordinating
the program for Aurora Research
Institute.
aurora.org/research

52

Neurosciences research

Sisters provide unique
data for clinical trials
Born three years apart, sisters
Nicole Borley, 26, and Sarah
Socha, 23, coincidentally share
a birth date.
Though there is no evidence of
hereditary risk, they also share
a disease – multiple sclerosis
(MS).
Both diagnosed at 18, these
Green Bay residents have
different manifestations of
this unpredictable disease of
the central nervous system.
However, the same Food and
Drug Administration-approved
drug, Tysabri (natalizumab,
Biogen Idec), seems to work
for both women.
Both also agreed to participate
in observational clinical trials
led by principal investigator
James Napier, MD, so
researchers can learn more
about the disease and impact
of the drug (clinicaltrials.gov
identifiers: NCT00477113 and
NCT01070836).
“I thought I might as well
contribute to science,” Borley
said. “How often do two sisters
have the same disease and
need the same drug? We can
provide that kind of data.”
“I was fascinated by the whole
process,” Socha said. “It was
something new and different.
Why wouldn’t I do it?”

Sisters Nicole Borley (left) and Sarah
Socha share a birth date and a multiple
sclerosis diagnosis.
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“How often do two
sisters have the same
disease and need the
same drug?”

First diagnosis
Borley, who gave birth to a girl
at the end of April, first knew
something was wrong when she
had vision problems with her left
eye. After going in for a checkup
and then to a specialist, she
found out she had optic neuritis,
an inflammation of the optic
nerve. Further testing – including
magnetic resonance imaging –
showed lesions on her brain. Her
diagnosis was MS.
With no previous medical history,
Borley was stunned.
“I was numb,” said Borley, who
had graduated high school the
previous month. “I had never

heard of MS. I didn’t know if I was
dying or if it was something that
could be fixed.”
After being hospitalized for a
week, steroid therapy brought
back the lost sight in her left eye
after three months.
Borley tried different drugs, but
flare-ups continued – numbness
and tingling in her arms, legs
and feet. When the latest drug
stopped working, Borley was
prescribed Tysabri.
“More lesions were showing up
on my brain,” Borley said. “I had
more than 40 lesions and a black
hole was forming.”

Second diagnosis
Because of her sister’s experience,
Socha was suspicious when she
went numb along her left side from
her shoulder to her foot.
She underwent testing.
“They wanted to rule out other
things,” Socha said.
But Socha, a freshman in college at
the time, was called home to receive
her diagnosis.
“I stole Nicole’s appointment,” said
Socha, who had steroid therapy for
five days on an outpatient basis.
After suffering side effects from
the first drug she tried, Socha was
prescribed Tysabri.
Though the sisters began getting
the monthly infusions together
at Aurora BayCare Medical
Center, Socha had to switch to a
different schedule because she
is JC antibody positive, which
means she is more susceptible to
a fatal complication – progressive
multifocal leukoencephalopathy, a
brain infection that can cause death
in three days. Now she goes every
seven weeks.
“I have decided to continue this
treatment even though the risks
are extremely high,” Socha said.
“Bottom line is this medicine is
very effective in keeping my MS
flare-ups under control.”

“Their contribution to
research has been helpful
in trying to control the risks
associated with Tysabri.”
“Their contribution to research has
been helpful in trying to control the
risks associated with Tysabri,”
Dr. Napier said. “The information
we have gathered has allowed
us to extend Tysabri to those
previously who may not have been
able to receive it. I consider their
contributions very valuable.”

Sarah Socha (center) leads her team, Team Coco Loco, during
a National Multiple Sclerosis Society MS Walk in Green Bay.
Photos courtesy of Nicole Borley and Sarah Socha

Differences
The difference in how the
disease manifests, particularly in
members of the same family, is
shown in stark contrast between
the two sisters.
“Between Nicole and I, it shows
that it can be so different,”
Socha said.
Borley was able to complete
college, got married and works
as a high school math teacher.
Though she has about 20 more
lesions than her sister, she was
primarily symptom-free until her
pregnancy. After going off the
drug for six months, she was
prescribed Tysabri during her
third trimester and took medical
leave because of flare-ups in
her dominant right hand and
weakness in her right leg.
Socha, who withdrew from
college and is limited to working
less than 20 hours a week as
a PartyLite consultant, needs
a walking stick to get around
a store. She hopes to one
day return to college and is
considering a degree in medical
transcription.

can’t,” Borley said. “It doesn’t mean
my body is healed (for lack of
symptoms).”
“My symptoms are more physically
seen,” Socha said. “The walking
stick shows something is physically
wrong.”

Giving back
No matter how differently the
disease affects the women they are
committed to making a difference
in the course of MS. Through the
Brown County MS Walk, the family
has raised more than $73,500 over
nine years for the National Multiple
Sclerosis Society.
Co-captains of Team Coco Loco, the
sisters have pulled together as many
as 100 members for the annual walk.
“We’ll always do the walk,” Borley
said.
Jennifer Homa, MS, is coordinating
the clinical trials for Aurora Research
Institute. Both trials are expected to
wrap up in 2015.

“Some people you can really
tell they have MS, some you
aurora.org/research
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Brain cancer stem cell bank creation
to spur new treatment options
Building on Aurora Research
Institute’s infrastructure,
Neurosciences Vice President
Amin Kassam, MD, is creating
a brain cancer stem cell bank.

(right) Patient-derived
glioblastoma cells grown
in a cancer stem cellenriching medium.

His team is prospectively collecting
multiple types of brain tumor
tissue, including glioblastoma
multiforme samples, and storing
them in the Biorepository and
Specimen Resource Center (BSRC),
managed by Natalie Polinske, MS.
The bank will provide a needed
resource for the research
community to use in development
of new treatments for brain cancer.
Current standard of care for brain
tumors includes chemotherapy,
radiation therapy and surgery.
However, long-term survival after
treatment is a matter of months
due to relapse, possibly because
of remaining cancer stem cells.
“It is thought that the cells
are at the root cause of tumor
development and their elimination
is critical for effective eradication
of tumors in the long term,”
Dr. Kassam said.
To initiate this research at Aurora,
project coordinator Nina Garlie,
PhD, director of the Regenerative
Medicine Center, collaborated with
scientific advisor Aaron Cheung,
PhD, of Synaptive Medical and
principal investigator Dr. Kassam

Senior research associate Deb Donohoe cultures brain cancer stem cells at the
Regenerative Medicine Center.

to prepare an application for
necessary seed money. They were
successful in winning a $25,000
Aurora Cancer Care Research Award.
Vince Lombardi Cancer Foundation
generously funds the program.
Polinske wrote a protocol and
obtained Institutional Review
Board approval to collect leftover
brain tumor samples for research
purposes. After the patients consent
to the research study, senior
research scientist Chang-Hyuk
Kwon, PhD, and senior research
associate Deborah Donohoe identify
and characterize cancer stem cells.
They will deposit a portion of the
stem cells in the BSRC for future
research. The remaining stem cells

Samples are stored in an ultra-low-temperature
freezer (-80 C) in the Biorepository and
Specimen Resource Center.
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will be studied to develop new
therapeutic techniques.
Jennifer Mathieu and Carol
Halliday, RN, lead subject enrollment.
Richard Rovin, MD, and Melanie
Fukui, MD, are co-investigators.

Additional
intramural funding
STUDY:
Inflammatory markers and
oral HPV infection: is there a
correlation?
AWARD:
$25,000, one year
SOURCE:
Vince Lombardi Cancer
Foundation (via Aurora Cancer
Care Research Awards)
PRINCIPAL INVESTIGATOR:
Martin Corsten, MD

Researchers study brain
cancer drug as part
of international trial
Aurora St. Luke’s Medical
Center is the only site in
Wisconsin participating in an
international clinical trial to
study a new immunotherapy
drug in the fight against brain
cancer.
Principal investigator George
Bobustuc, MD, and his team
are studying the impact of the
vaccine, DCVax-L (Northwest
Biotherapeutics, Bethesda,
Md.), on survival in subjects
with newly diagnosed
glioblastoma multiforme,
an aggressive type of brain
cancer, compared to controls
(clinicaltrials.gov identifier:
NCT00045968).
The drug is composed of the
subject’s immune system
cells (autologous dendritic
cells) that have been modified
with a tumor antigen (pulsed
with tumor lysate antigen) to

provoke an immune system
response against relapse.
After the tumor has been
surgically removed, subjects
undergo standard of care
treatment – radiation therapy
and chemotherapy – as part
of this Phase III trial. Two
out of three subjects are
randomized to also receive
the investigational vaccine,
while the remaining subjects
receive a placebo.
Jennifer Mathieu and Lynda
Yanny, BSN, are coordinating
the clinical trial for Aurora
Research Institute.

2012

2013

2014

Cases
Epilepsy cases

3,052

3,239

3,209

Total stroke cases

1,712

2,394

2,433

Ischemic stroke

880

1,316

1,509
552

Transient ischemic attack stroke

428

576

Hemorrhagic stroke

404

502

372

236

339

387

Interventional radiology cases*

*Number of individual patients

2014 Aurora-authored,
peer-reviewed

Journal articles,
book chapters,
monographs

Only site in
Wisconsin

Neurosciences volumes
– systemwide
Source: Aurora Smart Chart and Medipac

Neurosciences
publications

French JA, Baroldi P, Brittain ST, Johnson JK;
PROSPER Investigators Study Group. Efficacy and
safety of extended-release oxcarbazepine (Oxtellar
XR™) as adjunctive therapy in patients with
refractory partial-onset seizures: a randomized
controlled trial. Acta Neurol Scand 2014;129:143-53.
Gont A, Hanson JE, Lavictoire SJ, Daneshmand
M, Nicholas G, Woulfe J, Kassam A, Da Silva VF,
Lorimer IA. Inhibition of glioblastoma malignancy
by Lgl1. Oncotarget 2014;5:11541-51.
Labib MA, Prevedello DM, Carrau R, Kerr EE,
Naudy C, Abou-Al Shaar H, Corsten M, Kassam
A. A road map to the internal carotid artery in
expanded endoscopic endonasal approaches to
the ventral cranial base. Neurosurgery 2014;10
Suppl 3:448-71; discussion 471.
Kelly K, Johnson-Obaseki S, Lumingu J, Corsten
M. Oncologic, functional and surgical outcomes
of primary transoral robotic surgery for early
squamous cell cancer of the oropharynx: a
systematic review. Oral Oncol 2014;50:696-703.
Khatri BO, Foley JF, Fink J, Kramer JF, Cha C, You
X, Warth JD, Foulds P. The TRUST (EvaluaTion of
Bladder Function in Relapsing-Remitting MUltiple
Sclerosis Patients Treated with Natalizumab)
observational study. Int J MS Care 2014;16:40-7.
Paranjpe A, Zhang R, Ali-Osman F, Bobustuc
GC, Srivenugopal KS. Disulfiram is a direct and
potent inhibitor of human O6-methylguanine-DNA
methyltransferase (MGMT) in brain tumor cells and
mouse brain and markedly increases the alkylating
DNA damage. Carcinogenesis 2014;35:692-702.

Abstracts
Bobustuc GC, Ticku J, Patel A, Srivenugopal
KS, Konduri SD. O6 methylguanine DNA
methyltransferase inhibition sensitizes pancreatic
cancer cells to temozolomide. In: Proceedings
of the 105th Annual Meeting of the American
Association for Cancer Research, April 5-9, 2014,
San Diego. Philadelphia: AACR; 2014, #810.
Shhadeh A, Gheith A, Sajjad R, Marriott E, Zahour
M, Dibb M, Kassam A. Treatment of ruptured
aneurysm with pipeline. Society of Vascular and
Interventional Neurology 7th Annual Meeting
Abstract Supplement (http://www.svin.org/files/
public/SVIN%202014%20Final%20Abstract%20
Supplement.pdf) Epub November 2014:Poster 17.
Shhadeh A, Gheith A, Sajjad R, Marriott E, Zahour
M, Dibb M, Kassam A. IA stroke therapy benefits
despite lack of “penumbra” on CT perfusion.
Society of Vascular and Interventional Neurology
7th Annual Meeting Abstract Supplement (http://
www.svin.org/files/public/SVIN%202014%20
Final%20Abstract%20Supplement.pdf) Epub
November 2014:Poster 76.

aurora.org/research
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Additional strategic
research
Aurora Research Institute investigators engage in
additional strategic research that includes:

Precision Medicine

Orthopedics

Women’s Health

Aurora UW Medical Group

Center for Urban Population Health

Miscellaneous

>$265,000
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in external grant funding awarded in 2014
for additional strategic research

Sleep medicine
(1) 5%

Gastrointestinal
(3) 14%

Women’s health
(1) 5%

Orthopedics
(4) 19%

Asthma
(1) 5%
Humanitarian
use device
(9) 42%

Emergency dept.
(1) 5%
Pulmonology
and critical care
(1) 5%

123

21

total additional strategic
research clinical trial
enrollments in 2014

open additional strategic
research clinical trials
as of Dec. 31, 2014

Sleep medicine
(1) 1%
Pulmonology
and critical care
(1) 1%

Orthopedics
(43) 36%

Radiology
(38) 31%

Humanitarian
use device
(17) 12%

Congestive
heart failure
(70) 11%

Asthma
(20) 17%
Subject Hero Award
winner Norman J.
Schmidt shares his
experience with research.
(See story on page 62.)

>25%

of Aurora’s research fits in the
additional strategic category

~45%

of Aurora’s additional strategic
research is investigator-initiated
aurora.org/research
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PRECISION MEDICINE RESEARCH

Study incorporates genetic testing
to personalize
prescription
of drugs
Inpatient
CDS for Clopidogrel/CYP2C19
Inpatient
CDS for Clopidogrel/C
Inpatient CDS for Clopidogrel/CYP2C19

In collaboration with Vanderbilt University,
principal investigator Michael Michalkiewicz, PhD,
and his team are studying the impact of genetic
test results incorporated in the electronic health
record on prescription of three common stroke
prevention and two cancer therapy drugs.
The precision medicine study uses patients’
genetic characteristics to guide prescription of
the best drug for the individual that increases
drug effectiveness while at the same time
reduces the risk of potential adverse effects.
From its National Institutes of Health grant,
Vanderbilt awarded Aurora Health Care more than
$400,000 over about four years to test whether
genetic testing results in better outcomes for
patients in need of these particular drugs.

$400K
over four years
starting in 2015

A clinical decisionmaking support tool
will aid physicians
with selection of
the proper genetic
test before they

Clopidogrel Intermediate Metabolizer Rules
Genetic testing has been performed
and indicates this patient may be at risk
for inadequate anti-platelet response to
clopidogrel (Plavix®) therapy
Treatment modification is recommended if not otherwise contraindicated:
P
 rescribe prasugrel (EFFIENT) 10 mg daily and stop clopidogrel (PLAVIX),

start date 10 AM
P
 rescribe ticagrelor (BRILINTA) 180 mg x1 dose, start date 10 AM, followed by

90 mg twice daily
1

Modified screenshot of the electronic health record tool after
genetic test results identified a mutation.

prescribe warfarin, clopidogrel or simvastatin for
stroke prevention or erlotinib or vemurafenib for
some lung cancers and melanoma. After the results
1
are incorporated in the electronic health record,
the tool will inform the provider about the proper

Precision medicine clinical trial
Rubina Qamar, MD, is principal investigator of
a clinical trial that offers precision medicine for
subjects with non-small-cell lung cancer, the most
frequent type of lung cancer.
Aurora Health Care is participating in the LungMAP clinical trial, which utilizes genomic profiling to
determine the most appropriate of five investigational
treatment options for the specific individual with
advanced squamous cell lung cancer (clinicaltrials.
gov identifier: NCT02154490).
“Squamous cell carcinoma represents about a
quarter of all lung cancer diagnoses, but there are
currently few treatment options beyond surgery
for the disease,” Dr. Qamar said. “The trial will use
genomic profiling to match patients to one of five
59
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different investigational treatments – four targeted
therapies and an anti-PD-L1 immunotherapy – that
are designed to target the genomic alterations
found to be driving the growth of their cancer.
This innovative approach to clinical testing should
improve patient access to promising drugs.”

Additional extramural funding
drug and dose based on the
individual patient’s genetic
test results.

“This project introduces
information technology and
organizational platforms for
implementing personalized
treatment based on a patient’s
genetic characteristics,”
Dr. Michalkiewicz said. “That
means a provider will have the
information to suggest a switch to
an alternate therapy for a patient
TTGTGCTCTGTCTCTCATGTTTGCTTCTCCT
with a gene-drug interaction.”

STUDY:
Health Profession
Opportunity Grant
AWARD:
$112,975
SOURCE:
Milwaukee Area Workforce
Investment Board
PRINCIPAL INVESTIGATORS:
Naomi Dolohanty, MHRLR
Mary Cieslak-Duchek, RN

the mutations in the CYP2C19 gene before Clopidogrel

TCTGGGAGAGGAAAACTCCCTCCTGGCCCCA
Following implementation of the
AAATATCCTACAGATAGATATTAAGGATGTC
tool, researchers will evaluate
changes in prescribing patterns
TCTCAAAAATCTATGGCCCTGTGTTCACTCT
by providers and improvements
ATGGTGGTGCTGCATGGATATGAAGTGGTGA
in outcomes for patients who
were genotyped.
TGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
Key personnel include
ACAGAGGATTTGGAATCGTTTTCAGCAATGG
Arshad Jahangir, MD, Michael
Thompson, MD, PhD, Ahmed
CGGCGTTTCTCCCTCATGACGCTGCGGAATT
Dalmar, MD, Scarlet Shi, PhD,
CATTGAGGACCGTGTTCAAGAGGAAGCCCGC
Anthony DeFranco, MD, and
Charles Bomzer, MD.
GAAAAACCAAGGCTTCACCCTGTGATCCCAC
CCCTGCAATGTGATCTGCTCCATTATTTTCC
AGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGTAAGCACCCCCTGGATCCAGATATGCAA

GATTATTTCCC

G/CGGAACCCATAACAAA

TTTATGGAAAGTGATATTTTGGAGAAAGTAA
GGACATCAACAACCCTCGGGACTTTATTGAT
AGAAGGAAAAGCAAAACCAACAGTCTGAATT
ATCACTGCAGCTGACTTACTTGGAGCTGGGA
CCTGAGATATGCTCTCCTTCTCCTGCTGAAG
AAGTCCAGGAAGAGATTGAACGTGTCATTGG
ATGCAGGACAGGGGCCACATGCCCTACACAG
CCAGAGATACATCGACCTCATCCCCACCAGC
GTGACGTTAAATTCAGAAACTACCTCATTCC
In this CYP2C19 gene fragment,
a G/C mutation is identified, suggesting
prescription of prasugrel instead of clopidogrel.
ACTTCCCTCACTTCTGTGCTACATGACAACA
GATGTTTGACCCTCGTCACTTTCTGGATGAA
TAACTACTTCATGCCTTTCTCAGCAGGAAAA

STUDY:
PeriData Maintenance and
Service
AWARD:
$55,640
SOURCE:
University of
Wisconsin-Milwaukee
PRINCIPAL INVESTIGATOR:
Andrew Marek

STUDY:
Development of the Lakeland
Rural Training Track
AWARD:
$53,267
SOURCE:
University of Wisconsin
Department of Family
Medicine’s Wisconsin
Rural Physician Residency
Assistance Program
PRINCIPAL INVESTIGATOR:
John Brill, MD

STUDY:
Next steps in physicians’
training in geriatrics
AWARD:
$19,200 second-year funding

STUDY:
Innovative programs
(Integrative Medicine in
Residency Program) to help
support resident, faculty and
staff education along with
patient engagement
AWARD:
$13,000
SOURCE:
Weil Foundation Grant
PRINCIPAL INVESTIGATORS:
Kristen Reynolds, MD
Rebecca Schultz, NP

STUDY:
Improving diabetes quality
reports for persons with
multiple chronic conditions
AWARD:
$7,468
SOURCE:
University of
Wisconsin-Madison
PRINCIPAL INVESTIGATOR:
Jennifer Fink, PhD

STUDY:
Nurse-initiated music
therapy in the immediate
postoperative period: an
evaluation of the impact of
music on pain medication
doses in the recovery room
AWARD:
$1,000
SOURCE:
University of WisconsinMilwaukee’s Eta Nu Chapter
of Sigma Theta Tau
International
PRINCIPAL INVESTIGATOR:
Matthew Beier, MS, RN

SOURCE:
Donald W. Reynolds
Foundation (via subaward
by Medical College of
Wisconsin)
PRINCIPAL INVESTIGATORS:
Michael Malone, MD
Deborah Simpson, PhD

aurora.org/research
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ORTHOPEDIC RESEARCH

FDA approves new
shoulder replacement device
Whether it’s to address a trauma
or chronic debilitation, many
people benefit from shoulder
joint replacement.
In the 60 years since the
first shoulder replacement,
the design of the device has
changed dramatically to prevent
complications.
Aurora Health Care orthopedists
R. Sean Churchill, MD, and
Joseph Davies, MD, wrapped
up testing in November 2014
for the latest design, a stemless
device called the Simpliciti total
shoulder replacement system
(Tornier, Bloomington, MN).

The device received U.S. Food
and Drug Administration approval
early in 2015 as research results
from 157 patients at 14 centers
nationwide showed outcomes
after two years similar to those
of previous models with a stem.
It is the first stemless shoulder
replacement system available in
the United States.
“Shoulder replacement is nothing
new, and over time, the stem has
shortened up,” Dr. Churchill said.
“The question became, can we
make it even better.”
Previous shoulder replacement
devices had stems that went half
way down the shoulder bone
– to the weakest spot – and a
curved piece that fit in the joint.
Fractures at that weak spot
were frequent, requiring a
second shoulder replacement
with a stem inserted along the
full length of the bone.
Though newer models have
shorter stems, the Simpliciti

1st
FDA-approved stemless shoulder
replacement system implanted

in the
world

system abandoned it for a coating
that allows bone to grow into the
device. Any shoulder bone breaks
can be treated naturally.
“Orthopedists are all about trying
to conserve bone because you
are always looking at not this
procedure, but the one down
the road,” Dr. Churchill said.
Churchill implanted the first
FDA-approved stemless shoulder
implant in the world March 17 at
Aurora Medical Center in Grafton.
Sue Truchan, BSN, coordinated
the clinical trial for Aurora
Research Institute.

Orthopedist R. Sean
Churchill, MD, explains
how the stemless shoulder
replacement system works.

Stemless Simpliciti total
shoulder replacement system
(Tornier, Bloomington, MN)
Photo courtesy of Tornier
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Pathway to more options
“Research – if you
can be in it and help
someone out – why
not do it?”
During a routine checkup after
having his knee replaced in January
2012, Norman J. Schmidt admitted
to shoulder pain.

The bionic man also received
a new hip in February 2014 at
Aurora Medical Center in Grafton.
“Research – if you can be in it and
help someone out – why not do
it?” said Schmidt, who received
the Aurora Research Institute’s
Subject Hero Award at the Greater

Milwaukee Clinical Research
Recognition Event in September.
“Testimony like that from Mr.
Schmidt makes it all worthwhile,”
said Randall Lambrecht, PhD,
president of the institute. “It shows
we are fulfilling our purpose of
providing options for patients.”

Norman J. Schmidt accepts the Subject Hero
Award for his participation in research from
physician R. Sean Churchill, MD.

His physician, Joseph Davies, MD,
referred him to R. Sean Churchill, MD,
at Aurora Medical Center in Grafton
for a clinical trial testing a new shoulder
replacement option, the Simpliciti
total shoulder replacement system.
Schmidt fit the requirements for the
trial and consented to participate.
After a successful surgery, Schmidt
returned for regular checkups to test
range of motion and monitor pain.
“Every day I wake up without pain
and it is just great,” Schmidt said.
“And I don’t know what I would have
done without him (Dr. Churchill).”

Orthopedic volumes – systemwide
Source: Aurora Smart Chart and 3M/Clintrac

2012

2013

2014

2,734
1,386

2,713
1,440

2,904
1,705

374

628

812

864
449
307
373

646
516
358
491

544
506
428
389

431

652

384

274

266

364

712

880

322

Inpatient Procedure*
Total knee replacement
Total hip replacement
Hip replacement with ceramic-onpolyethylene bearing surfaces
Packed cell transfusion
Fusion or refusion of 2-3 vertebrae
Insert spinal fusion device
Excision or destruction of intervertebral disc
Open reduction of tibia and fibula fracture
with internal fixation
Hip replacement with metal-onpolyethylene bearing surfaces
Injection into joint

2012

2013

2014

3,646
2,989
798
833
373
320
290
372
264
204

956
936
280
272
184
122
61
104
82
63

4,969
4,557
1,543
1,514
735
703
652
641
574
410

Outpatient Procedure*
Knee arthroscopy/surgery
Shoulder arthroscopy/surgery
Carpal tunnel surgery
Arthroscopic rotator cuff repair
Wrist endoscopy/surgery
Incise finger tendon sheath
Drain/inject joint/bursa
Arthroscopy biceps tenodesis
Removal of support implant
Revise ulnar nerve at elbow

*Top orthopedic procedures performed in 2014
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WOMEN’S HEALTH RESEARCH

Weight loss during pregnancy in obese
women improves maternal, fetal outcomes
Aurora challenges
weight gain
recommendations
for obese women
during pregnancy
Pregnancy for obese women
comes with increased risks.
However, the Institute of
Medicine recommends weight
gain for all women, the amount
depending on prepregnancy
body mass index.
Aurora Health Care research, led
by principal investigator David
Merrill, MD, and co-investigator

Callie Cox-Bauer, MD, challenges
the recommendation for obese
women, with findings showing
that weight loss during pregnancy
improves outcomes for obese
women and their infants.
Dr. Merrill and his team compared
outcomes of obese women who
lost weight during pregnancy to
those who had gained weight and
documented newborn outcomes.
Obese women who lost weight
were less likely to need cesarean
delivery or develop preeclampsia.
Though there was an increase
in small-for-gestational-age
newborns, there was a significant
decrease in neonatal intensive
care unit admissions and a

decrease in poor neonatal
outcomes.
The researchers found that it
may be safe for obese women
to lose weight during pregnancy
with appropriate surveillance by
a health care provider.
Danielle Greer, PhD, and
Kiley Bernhard, MPH,
contributed to this research.
Dr. Cox-Bauer presented the
findings at the American
College of Obstetricians and
Gynecologists Joint District VI,
VIII and IX 2014 Annual Meeting
and at the American College of
Obstetricians and Gynecologist
2015 National Meeting, receiving
the Donald F. Richardson
Memorial Prize.

Tool may predict risk for postcesarean
incision site infection
Knowing which women who
undergo cesarean section are
more likely to develop an infection
at the incision site could lead
to fewer infections and better
postpartum recovery.
Danish Siddiqui, MD, led a team of
researchers in the development of
a risk stratification tool to identify
women whose postpartum course
may be complicated by infections
of their cesarean incision.
After comparing two established
models, Dr. Siddiqui and his team
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found that use of chorioamnionitis an infection of amniotic fluid, body
mass index and surgery duration
was a more simplified model for
predicting infection based on a highrisk population. Further research is
ongoing to validate the model.
Nicole Salvo, MD, Dakisha Lewis, MD,
Kiley Bernhard, MPH, Danielle Greer,
PhD, and Chris Van Mullem, MS, RN,
contributed to this research. Dr. Lewis
presented the findings at the Central
Association of Obstetricians and
Gynecologists 2014 Annual Meeting.

high
risk
moderate
risk
low
risk

Researchers publish findings on
vitamin D, preeclampsia in Endocrine
There is conflicting evidence on whether
vitamin D deficiency leads to preeclampsia,
a pregnancy complication associated with
high blood pressure.
Principal investigator Danish Siddiqui, MD,
and co-investigator Ahmed Dalmar, MD,
compared vitamin D and calcium levels
in women with preeclampsia to those
without on the first day after childbirth.
The researchers simultaneously tested
both the inactive (25-hydroxyvitamin D)

and active (1,25-dihydroxyvitamin D) forms of
vitamin D, something not routinely reported in
the medical literature.
Regardless of type, vitamin D levels did not differ
between women who had preeclampsia and
those who did not on the first day after childbirth.
The findings were published in Endocrine.
Hershel Raff, PhD, Suneet Chauhan, MD,
and Maharaj Singh, PhD, contributed to this
research.

Women’s Health volumes – systemwide
2012

2013

2014

Breast Health Procedures
Mammography
Screening
Diagnostic
Digital (%)

2013

2014

107,981
75,177
41,195

111,818
90,591
45,972

112,864
89,138
47,351

18,918
8,045
6,747

17,436
7,610
6,915

17,262
7,202
6,727

Gynecology (Primary Diagnostic) Visits
148,202
122,601
25,601
87%

158,709
131,683
27,026
96%

154,539
128,080
26,459
100%

Breast ultrasound

15,471

16,155

17,534

Core biopsy
Ultrasound-guided
Stereotactic
MRI-guided
Undifferentiated

3,180
1,941
1,036
72
131

3,456
2,146
1,188
29
93

3,373
2,203
1,096
41
33

Breast MRI

1,258

1,372

1,419

337

391

412

Needle localization
Obstetrics/Newborn
Hospital deliveries
C-section (%)

12,855
25.7%

12,883
26.2%

12,184
27.3%

Hospital newborns

13,258

13,246

12,523

1,355
1,036
319
15.4
58.0

1,425
1,101
324
15.7
62.2

1,406
1,027
379
16.0
61.7

29,236
2,090

36,850
3,003

37,987
3,305

Hospital newborn NICU admissions
Level III unit
Level II unit
Average length of stay (days)
Average daily census
Maternal Fetal Medicine
Ultrasounds
Office visits

2012

Other disorders of female
genital tract
Routine gynecologic exam
Contraceptive management
Inflammatory disease of female
pelvic organs
Benign gynecology
General fertility management

Surgical Gynecology (Primary Procedures)
Hospital procedures
Outpatient
Inpatient
Cancer (%)

6,846
5,366
1,480
8.8%

6,227
5,082
1,145
8.2%

6,445
5,675
770
8.6%

Hysterectomy
Outpatient (%)
Laparoscopic (%)
Laparoscopic assist (%)
Robotic assist (%)
Open (%)
Cancer (%)

2,466
60.2%
55.2%
11.4%
24.2%
16.6%
10.5%

2,151
68.3%
55.2%
10.9%
27.8%
15.5%
11.7%

2,200
77.4%
58.7%
11.2%
26.6%
14.5%
13.7%

1,563
835
692
36

1,697
986
669
42

1,732
1,092
607
33

Urogynecology
Urogynecology surgical procedures
Prolapse
Incontinence
Revision mesh

Source: IDX, EpicPB, Medipac, EpicHB 2012-14
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Aurora UW Medical Group
Dennis Baumgardner, MD
Research Director, Aurora UW Medical Group
Dr. Baumgardner leads the Aurora UW Medical Group research core, which is responsible
for supporting, growing and coordinating research and scholarly activity among faculty,
students, residents and fellows. Areas of research focus include health care quality
improvement and health services, medical education, cardiology, geriatrics, women’s health,
healthy lifestyles, health disparities, epidemiology, asthma and other specific diseases.

What’s your worry?
A patient’s greatest health fear may
be cancer, but her doctor would rather
she focus on her cholesterol levels.

I’m
I’m
concerned
concerned
about ...
about ...

I’m
I’m
concerned
concerned
about ...
about ...

Disagreement on health
priorities between patient
and doctor is common.
Apparently, disagreement on health
priorities is pretty common. In
about three of five cases, patients
and physicians disagreed about the
patient’s greatest health concern,
according to research led by principal
investigator Dennis Baumgardner, MD,
and presented by Jessica Kram, MPH,
at the 2014 Wisconsin Research and
Education Network Annual Meeting.
To determine the difference in
opinions, Dr. Baumgardner and
his team reviewed patients’ charts
and noted a most important health

Elizabeth Quiroz, MD, Dennis Baumgardner,
MD, and Jessica Kram, MPH, present the
findings of their study at Aurora Health
Care’s Quality Roundtable

concern before entering the
exam room. During the exam,
the physician asked the patient
his or her greatest health
concern. A total of 94 patients
participated in the study.
Of the people who disagreed,
the majority (83%) were more
concerned about a different
particular medical disorder than
the doctor had identified. The
other patients who disagreed
either were worried about
finances or violence or had no
fears at all.
Men and women equally
disagreed with their doctor.
Younger patients were more
likely to identify the same
health concern as their doctor,
but difference in age was not
statistically significant.
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Patients with high blood
pressure were twice as likely as
patients with other diseases to
have a different concern than
their doctor.
“People value a doctor who is
sensitive to individual needs,”
Dr. Baumgardner said. “This
study has shown there is
potential to identify and address
unmet patient concerns and,
hopefully, direct that person to
relevant health interventions.”
Co-investigators Elizabeth
Quiroz, MD, Kiley Bernhard, MPH,
Mark Ledesma, MD, and Keren
Rosner, MD, contributed to this
study, which also was presented
at Aurora Health Care’s Quality
Roundtable.

Measuring delirium
After showcasing their findings at
the American Geriatrics Society
2014 Annual Meeting, Center
for Senior Health and Longevity
medical director Michael
Malone, MD, Ariba Khan, MBBS,
MPH, and their team published
a manuscript, “Innovative
approach to measure delirium in
hospitalized older adults using the
electronic medical record,” in the
Journal of the American Geriatrics
Society earlier this year.

Using the Acute Care for the
Elderly (ACE) Tracker clinical
decision-making support tool
within the electronic health
record, collaborators compared
the delirium marker feature to
the standard delirium assessment
in hospitalized adults 65 years
and older.
The delirium marker combines
delirium symptoms documented
by nurses, use of physical

restraints and pharmacological
treatment for delirium.
They found that further work
to improve the sensitivity of an
automated delirium measure may
make it more clinically useful.
Michelle Simpson, PhD, RN,
Maharaj Singh, PhD, Mary Hook,
PhD, RN-BC, and Yan Geng, MD,
contributed to this study, which
was also presented locally at
Aurora Scientific Day.

Aurora Scientific Day
Aurora Scientific Day, an annual conference held
in May, is an opportunity for students, residents,
fellows, teaching and research faculty, and other
allied health professionals at Aurora Health Care
to present research findings.

Sanjay Kansra, PhD, presents his study, “Curcumin
(diferuloylmethane) induces apoptosis and blocks migration of
human medulloblastoma cells,” at Aurora Scientific Day 2014.

In 2014, more than 130 people supported research
by attending the presentations – 16 judged posters,
13 general posters, 14 oral presentations, two
Rieselbach distinguished paper sessions and two
innovation projects.

Rieselbach distinguished papers
•D
 evelopment and validation of a risk score to
predict access site hematomas after peripheral
vascular interventions – Daniel Ortiz, MD
•D
 iabetes mellitus is an independent predictor of
early mortality in patients at risk of sudden cardiac
death – Mahek Mirza, MD

Judged Posters
1st place – Anton Strunets, MD
Increased risk of bleeding with no additional stroke
reduction benefit in patients with atrial fibrillation
on ASA and dabigatran or ASA and rivaroxaban
combination therapy
2nd place – Rayan Yousefzai, MD
Hypertrophic cardiomyopathy with aortopathy: a
novel association
3rd place – Mahek Mirza, MD
Noninvasive approach assessing atrial mechanics
and serum biomarkers of collagen turnover provides
a surrogate for fibrosis and atrial fibrillation

Oral Presentation
1st place – Anushree Agarwal, MD
Elevated troponin as a risk marker in hypertrophic
cardiomyopathy
2nd place tie – Luke O’Rourke, DO
Association of fetal abdominal-head circumference size
difference with shoulder dystocia: a multi-center study
2nd place tie – Rayan Yousefzai, MD
Effect of pulmonary hypertension on patients with
aortic stenosis who undergo transcatheter aortic
valve replacement
3rd place – David Krum, MS
Determining three-dimensional catheter location
using single plane fluoroscopy only
aurora.org/research
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Center for Urban Population Health
Ron Cisler, PhD
Director, Center for Urban Population Health
Dr. Cisler leads the Center for Urban Population Health, a collaboration of Aurora Health
Care, University of Wisconsin School of Medicine and Public Health, and University of
Wisconsin-Milwaukee. The mission of the center is to advance population health research
and education to improve the health of urban communities.

What is population health research?
Population health research focuses on identifying the determinants
of health, disease and well-being in a particular population;
designing and implementing preventive or treatment interventions;
and measuring their effectiveness against health outcomes of the
community.
The emphasis is health outcomes research and patient engagement
at the intersection of primary care and community health.

Partners
•h
 ealth centers, hospitals and clinics

• governmental institutions

•c
 ommunity-based organizations

• coalitions and networks

•a
 cademic centers and institutions

Dementia wellness project
Alzheimer’s disease is the most
common cause of dementia. About
1 in 7 seniors in Wisconsin have
Alzheimer’s disease. Currently,
65% of Wisconsin’s 74,000 nursing
home residents have dementia,
mostly due to Alzheimer’s
disease, and the estimated cost
of Medicaid-supported long-term
care for Wisconsin residents with
Alzheimer’s disease was about
$1.6 billion in 2010.
Because Alzheimer’s disease is
primarily a disease of old age,
its prevalence and associated
cost are projected to increase
exponentially given the
unprecedented expansion in
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the elder segment of the U.S.
population. African American
baby boomers are at greater
risk than non-Hispanic whites
of similar ages for Alzheimer’s
disease or other dementias.
The prevalence of Alzheimer’s
disease and other dementias
among older African Americans
is roughly double than that
among non-Hispanic whites, and
is significantly higher than that
among Hispanics.
In partnership with Milwaukee
Health Services Inc. and the
Wisconsin Alzheimer’s Institute,
UW School of Medicine and Public
Health has launched the Dementia

Wellness Project for Underserved
African American Elders.
The program aims to improve the
health and well-being of underserved
urban elders and their families by
addressing health behaviors, access
to care and social and economic
factors. Funded by the Wisconsin
Partnership Program, this project
expands the role of the Dementia
Diagnostic Clinic Network.
Bruce Hermann, PhD, is principal
investigator with Tito Izard, MD,
from Milwaukee Health Services Inc.
Teresa Skora is project manager with
support from center staff: Michelle
Corbett, Gina Green Harris and
Stephanie Houston.

In 2014:
2014
extramural
funding
sources

State and local
foundations
22%
State and local
contracts
54%
Federal
24%

22 = $1.4
million

grants and
contracts
awarded

Pediatric asthma research

Obesity intervention

African Americans suffer a
disproportionate burden of
asthma morbidity compared to
other ethnicities. One possible
explanation for such racial
differences in asthma is that
African Americans respond
differently to asthma therapies
as compared to other ethnicities.

According to the Centers for
Disease Control and Prevention,
62.8% of Milwaukee residents
are overweight or obese. Ethnic
and racial minority groups are
disproportionately affected
by obesity, particularly African
Americans, with 36.8% obese
compared to 25.2% of whites.

The Best African American
Response to Asthma Drugs
(BARD) trial is comparing four
treatment combinations for
asthma. Each participant receives
a peak flow meter and must
complete a daily asthma symptom
diary. There are 15 to 18 visits over
a 16-month period. Participants, or
the parents of minors, complete
questionnaires asking about
environmental factors, income
and quality-of-life issues.
This study is open to enrollment
for anyone who has an asthma
diagnosis and at least one African

American
grandparent
and is a
nonsmoker,
on a daily
controller
medication
and at least 5 years old.
The objective of a second
asthma study, STep-up Yellow
Zone Inhaled CorticosteroidS
to Prevent Exacerbations
(STICS), is to determine in
children receiving low-dose
inhaled corticosteroids whether
quintupling the dose at the onset
of symptoms reduces the rate
of severe asthma exacerbations
treated with oral corticosteroids.
This study is open to children
of all ethnicities from 5 to 11
years of age. Similar to BARD,
the STICS study provides all
study medication, education and
monitoring of asthma symptoms.
The studies are sponsored by
AsthmaNet and being conducted
in partnership with the Aurora
Research Institute Clinical Trials
Department, Aurora UW Medical
Group and the University of
Wisconsin-Madison.
Lisa Sullivan-Vedder, MD, is
the principal investigator and
Stacie Snap and Mary BriggsSedlachek, RN, are coordinators
for both studies.

Interventions have shown limited
success at weight reduction in
patients from these populations.
The Health Outcomes and Patient
Engagement (HOPE) Research
Collaborative has been working to
develop MyLIFE: a patient-centered
obesity intervention for African
American women. The MyLIFE
project, funded by Center for
Urban Population Health, intends
to examine the effect of a patientcentered obesity intervention
that addresses both individual
and community resource issues.
Clinically, patients will be engaged
in a multidisciplinary manner in
areas of primary care, behavioral
health, exercise and nutrition.
HOPE partners are Aurora Health
Care, Aurora UW Medical Group,
Marquette University, Medical
College of Wisconsin and University
of Wisconsin-Milwaukee.
Ron Cisler, PhD, is principal
investigator and Danielle Greer,
PhD, Mike Farrell, MD, and Maharaj
Singh, PhD, are co-investigators.
aurora.org/research
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Study reaches milestone with training
of 900 nurses, nurse leaders in 2014
In year two of a three-year study,
about 850 nurses and 50 nurse
leaders at Aurora St. Luke’s
Medical Center learned how to
use a new evidence-based clinical
decision-making support tools
in the electronic health record
(EHR) system to improve patient
outcomes.
Mary Hook, PhD, RN-BC, leads the
Knowledge-Based Nursing (KBN)
Impact Study, funded by a $1.6
million Department of Defense
grant from the U.S. Army Medical
Research and Materiel Command.
The KBN initiative uses technology
to accelerate the adoption of best
practices in patient care, which
include conducting standardized
assessments to detect risks and
symptoms, intervening with
tailored strategies to address
unique patient needs and
engaging patients in their care.

Epic-based EHR system. After
performing baseline assessments
last year, investigators found
knowledge gaps and intervened
with various implementation
methods to study the best way to
improve use of the best practices.
Researchers are hoping to
eliminate knowledge gaps and
increase use of best practices
to achieve improved outcomes.
The next steps call for a
postintervention assessment and
possibly replicating the study at
other Aurora Health Care sites.
Maharaj Singh, PhD, contributes
biostatistical support.

Best practices for:
-Delirium risk
-Medication nonadherence
-Pain
-Fall risk and fall-related injury
-Pressure ulcer risk
-Depressive/suicidal symptoms

Patient outcomes
-Mortality
-Length of stay
-30-day readmission
-Patient satisfaction
-Adverse outcomes for falls
and pressure ulcers
-Patient-reported use of
recommended care practices

“Researchers have found that
simply giving information about
best practices does not change
practice,” Dr. Hook said. “Changes
must be adopted, implemented
and maintained over time to get
the best outcomes. We hope that
this study transforms care.”
KBN best practices in six key areas
were incorporated in Aurora’s

Mary Hook, PhD, RN-BC, leads a training session for nurses on how to use a new evidencebased clinical decision-making support tools as part of a Knowledge-Based Nursing initiative.

Endocrinologist publishes seminal review
The Journal of Physiology invited
Hershel Raff, PhD, director of the
Endocrine Research Laboratory at
Aurora St. Luke’s Medical Center,
to write a review on Cushing’s
syndrome, a condition caused by
too much of the stress hormone
cortisol remaining in the body for
too long.
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Dr. Raff, an endocrinologist with
ties to both Aurora Research
Institute and Medical College of
Wisconsin (MCW), collaborated
with MCW endocrinologist Ty
Carroll, MD, to publish “Cushing’s
syndrome: from physiological
principles to diagnosis and
clinical care.”

“It is the culmination of my 30 years
doing clinical research at Aurora
St. Luke’s,” Dr. Raff said.
The review highlights a translational
research approach to the
condition by first providing a basic
physiologic understanding before
new diagnostic methods and
treatment options can be explored.

Researchers work to develop risk
stratification tool for acute kidney injury
In partnership with Mayo Clinic,
University of Wisconsin-Milwaukee
and Milwaukee Kidney Associates,
Aurora Research Institute
investigators are working to
develop a risk stratification tool for
early diagnosis and management
of acute kidney injury (AKI).
Principal investigator Vani
Nilakantan, PhD, is leading this
research for the institute.
“This study uses clinical
information and mathematical
computerized approaches for
AKI risk prediction in hospitalized
older adults,” Dr. Nilakantan said.
“The overall result will be a clinical
decision-making support tool to
help providers with early diagnosis
and management of AKI.”
Findings presented at the
American Medical Informatics

Association 2015 Annual
Symposium showed that certain
laboratory measures in the
electronic health record were
the strongest predictors for
AKI in older hospitalized adults.
Further research is underway
to utilize novel machine
learning techniques to improve
prediction accuracy.
Additional research in this area
focused on predicting incidence
of AKI in older patients, after
cardiac intervention, was
accepted for presentation at the
American College of Cardiology
2015 Scientific Session and
selected for presentation during
the Geriatric Cardiology Section.

risk for AKI, highlighting the
importance of continuous
monitoring of older patients
undergoing invasive surgeries.
Ruth Perez, Chris Cho, MS,
Andy Marek and Robyn Shearer,
MS, as well as Rohit Kate, PhD,
Debesh Mazumdar, MD, Kalyan
Pasupathy, PhD, and Rashmi
Prasad, PhD, contributed to the
studies.

The study found that older
patients who need valve and
bypass surgery are at highest

Gastroenterology research changes practice
As part of collaboration with the University of
Minnesota, gastroenterologist Nalini Guda, MD,
led research comparing biopsy techniques –
conventional fine needle aspiration to the new
wet suction technique.
The study showed that the new wet suction
technique obtained better tissue samples.
The findings were presented at Digestive Diseases
Week and published in Gastrointestinal Endoscopy
– “‘Wet suction technique (WEST)’: A novel way
to enhance the quality of EUS-FNA aspirate.
Results of a prospective, single-blind, randomized,
controlled trial using a 22-gauge needle for
EUS-FNA of solid lesions.”

The new technique obtained better
tissue samples for diagnosis.

“This research is changing practice,” Dr. Guda
said. “The need to bring patients back for a repeat
procedure because of inadequate tissue for
diagnosis has decreased.”
Aurora Health Care biostatistician Maharaj Singh, PhD,
and gastrointestinal pathologist Timothy Wallace, MD,
contributed to the study.
Aurora’s gastrointestinal researchers also had the
distinction of securing access to data from the
American College of Surgeons National Cancer
Data Base. The intent of the study is to determine
whether improvements in technology for tumor
detection and staging have reduced nationally the
number of unsuccessful surgeries in patients with
pancreatic cancer.
“We are excited to have an opportunity to analyze
the data,” Dr. Guda said. “It is a difficult disease,
and every bit of what we can do for early detection,
treatment and palliation will help.”
aurora.org/research
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Additional strategic publications
2014 Aurora-authored, peer-reviewed

Journal articles,
book chapters,
monographs
Abejuela-Matt VL. Bedbugs biting back? A
multifactorial consideration of bedbug resurgence.
J Patient-Centered Res Rev 2014;1:93-8.
Agger WA, Siddiqui D, Lovrich SD, Callister SM,
Borgert AJ, Merkitch KW, Mason TC, Baumgardner
DJ, Burmester JK, Shukla SK, Welter JD, Stewart
KS, Washburn MJ, Bailey HH. Epidemiologic
factors and urogenital infections associated with
preterm birth in a midwestern U.S. population.
Obstet Gynecol 2014;124:969-77.
Baumgardner DJ. Blastomycosis. In: Domino FJ,
Baldor RA, Golding J, Grimes JA (eds). 5-Minute
Clinical Consult 2015, 23rd Edition. Philadelphia:
Lippincott Williams & Wilkins, 2014.
Baumgardner DJ. From breast cancer to bedbugs
– really? J Patient-Centered Res Rev 2014;1:69.
Baumgardner DJ. What is PFAPA and why does it
matter? J Patient-Centered Res Rev 2014;1:161-3.
Baumgardner DJ. Why patient-centered?
J Patient-Centered Res Rev 2014;1:7.
Bernhard KA, Siddiqui DS, Leonard KM, Chauhan
SP. American College of Obstetricians and
Gynecologists practice bulletins: ascertaining their
citation, influence, and utilization. Am J Perinatol
2014;31:373-82.
Biddison LD, Berkowitz KA, Courtney B, De Jong
CM, Devereaux AV, Kissoon N, Roxland BE, Sprung
CL, Dichter JR, Christian MD, Powell T. Ethical
considerations: care of the critically ill and injured
during pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e145S-e155S.
Bodager J, Gessert T, Bruder ED, Gehrand A, Raff
H. Adrenocortical sensitivity to ACTH in neonatal
rats: correlation of corticosterone responses and
adrenal cAMP content. Am J Physiol Regul Integr
Comp Physiol 2014;307:R347-53.
Bose D, Bauer CC, Bernhard K, Baumgardner DJ.
Application of the Breastfeeding Personal Efficacy
Beliefs Inventory and acknowledgment of barriers
for improving breastfeeding initiation rates in an
urban population. J Patient-Centered Res Rev
2014;1:77-84.
Capezuti EA, Malone ML, Katz PR, Mezey MD (eds).
The Encyclopedia of Elder Care, Third Edition. New
York, NY: Springer, 2014.
Carek PJ, Simpson D, Yarris LM. Comments:
authors’ response to letters regarding “defining
the scholarly and scholarship common program
requirements”. (letter) J Grad Med Educ 014;6:392.
Castro M, King TS, Kunselman SJ, Cabana MD,
Denlinger L, Holguin F, Kazani SD, Moore WC, Moy
J, Sorkness CA, Avila P, Bacharier LB, Bleecker E,
Boushey HA, Chmiel J, Fitzpatrick AM, Gentile D,
Hundal M, Israel E, Kraft M, Krishnan JA, LaForce
C, Lazarus SC, Lemanske R, Lugogo N, Martin RJ,
Mauger DT, Naureckas E, Peters SP, Phipatanakul
W, Que LG, Sheshadri A, Smith L, Solway J,
Sullivan-Vedder L, Sumino K, Wechsler ME, Wenzel
S, White SR, Sutherland ER; National Heart,
Lung, and Blood Institute’s AsthmaNet. Effect of
vitamin D3 on asthma treatment failures in adults
with symptomatic asthma and lower vitamin D
levels: the VIDA randomized clinical trial. JAMA
2014;311:2083-91.

71

Annual Report 2014

CCSC Task Force on Critical Care Educational
Pathways in Internal Medicine (inc. Siegal E).
Training internists to meet critical care needs in
the United States: a consensus statement from the
Critical Care Societies Collaborative (CCSC). Criti
Care Med 2014;42:1272-9.
Chintamaneni K, Bruder ED, Raff H. Programming
of the hypothalamic-pituitary-adrenal axis by
neonatal intermittent hypoxia: effects on adult
male ACTH and corticosterone responses are
stress specific. Endocrinology 2014;155:1763-70.
Courtney B, Hodge JG Jr, Toner ES, Roxland BE,
Penn MS, Devereaux AV, Dichter JR, Kissoon N,
Christian MD, Powell T. Legal preparedness: care
of the critically ill and injured during pandemics
and disasters: CHEST consensus statement. Chest
2014;146:e134S-e144S.
Christian MD, Devereaux AV, Dichter JR, Rubinson
L, Kissoon N. Introduction and executive summary:
care of the critically ill and injured during
pandemics and disasters: CHEST consensus
statement. Chest 2014;146:8S-34S.
Christian MD, Sprung CL, King MA, Dichter
JR, Kissoon N, Devereaux AV, Gomersall CD.
Triage: care of the critically ill and injured during
pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e61S-e74S.
Cleveland M, Holder C, Khan A, Jencius A. The
team approach to interdisciplinary care. In: Malone
ML, Capezuti EA, Palmer RM (eds). Acute Care
for Elders: A Model for Interdisciplinary Care. New
York: Humana Press, 2014, pp. 9-19.
Dalmar A, Raff H, Chauhan SP, Singh M, Siddiqui
DS. Serum 25-hydroxyvitamin D, calcium and
calcium-regulating hormones in preeclamptics and
controls during first day postpartum. Endocrine
2015;48:287-92 [Epub 2014 May 23].
Danto-Nocton ES, Holder C, Ramsden R, Macias
Tejada J, Steliga A, Padua K. How to develop, start,
and sustain an acute care for elders unit. In: Malone
ML, Capezuti EA, Palmer RM (eds). Acute Care
for Elders: A Model for Interdisciplinary Care. New
York: Humana Press, 2014, 97-115.
Devereaux AV, Tosh PK, Hick JL, Hanfling D, Geiling
J, Reed MJ, Uyeki TM, Shah UA, Fagbuyi DB,
Skippen P, Dichter JR, Kissoon N, Christian MD,
Upperman JS. Engagement and education: care
of the critically ill and injured during pandemics
and disasters: CHEST consensus statement. Chest
2014;146:e118S-e133S.
Dichter JR, Kanter RK, Dries D, Luyckx V, Lim
ML, Wilgis J, Anderson MR, Sarani B, Hupert N,
Mutter R, Devereaux AV, Christian MD, Kissoon
N. System-level planning, coordination, and
communication: care of the critically ill and injured
during pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e87S-e102S.
Dries D, Reed MJ, Kissoon N, Christian MD,
Dichter JR, Devereaux AV, Upperman JS. Special
populations: care of the critically ill and injured
during pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e75S-e86S.
Einav S, Hick JL, Hanfling D, Erstad BL, Toner
ES, Branson RD, Kanter RK, Kissoon N, Dichter
JR, Devereaux AV, Christian MD. Surge capacity
logistics: care of the critically ill and injured during
pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e17S-e43S.

Farrell MH, Christopher SA, Kirschner AL, Roedl SJ,
O’Tool FO, Ahmad NY, Farrell PM. Improving the
quality of physician communication with rapidthroughput analysis and report cards. Patient Educ
Couns 2014;97:248-55.
Fink JT, Morris GL 3rd, Singh M, Nelson DA, Walker
RE, Cisler RA. Discordant documentation of
obesity body mass index and obesity diagnosis in
electronic medical records. J Patient-Centered Res
Rev 2014;1:164-70.
Geiling J, Burkle FM Jr, Amundson D, DominguezCherit G, Gomersall CD, Lim ML, Luyckx V, Sarani
B, Uyeki TM, West TE, Christian MD, Devereaux
AV, Dichter JR, Kissoon N. Resource-poor settings:
infrastructure and capacity building: care of the
critically ill and injured during pandemics and
disasters: CHEST consensus statement. Chest
2014;146:e156S-e167S.
Geiling J, Burkle FM Jr, West TE, Uyeki TM,
Amundson D, Dominguez-Cherit G, Gomersall
CD, Lim ML, Luyckx V, Sarani B, Christian MD,
Devereaux AV, Dichter JR, Kissoon N. Resourcepoor settings: response, recovery, and research:
care of the critically ill and injured during
pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e168S-e177S.
Gentile D. Pain management. In: Weinstein S, Hagle
M (eds). Plumer’s Principles & Practice of Infusion
Therapy, Ninth Edition. Philadelpia, PA: Lippincott,
Williams & Wilkins, 2014, pp. 651-83.
Greer DM, Baumgardner DJ, Bridgewater FD, Frazer
DA, Kessler CL, LeCounte ES, Swain GR, Cisler RA.
Milwaukee Health Report 2013: Health Disparities in
Milwaukee by Socioeconomic Status. Available at:
http://www.cuph.org/uploads/2/5/8/0/25803255/
mhr_2013_final.pdf. Milwaukee, WI: Center for
Urban Population Health; 2013, pp. 1-56.
Gusic ME, Baldwin CD, Chandran L, Rose S,
Simpson D, Strobel HW, Timm C, Fincher RM.
Evaluating educators using a novel toolbox:
applying rigorous criteria flexibly across institutions.
Acad Med 2014;89:1006-11.
Hanson L, VandeVusse L. Supporting labor progress
toward physiologic birth. J Perinat Neonatal Nurs
2014;28:101-7.
Hanson L, Vandevusse L, Duster M, Warrack S,
Safdar N. Feasibility of oral prenatal probiotics
against maternal group B Streptococcus vaginal
and rectal colonization. J Obstet Gynecol Neonatal
Nurs 2014;43:294-304.
Hanson L, VandeVusse L, Harrod KS. Health
education during pregnancy. In: Jordan RG,
Engstrom JL, Marfell J, Farley CL (eds). Prenatal
and Postnatal Care: A Woman-Centered Approach.
Ames, IA: Wiley-Blackwell, 2014, pp. 312-24.
Haq C. Compassion in medicine. Fam Med
2014;46:549-50.
Hasan L, Singh M, Khan A, Lung J, Malone M, Karst
A. The unique needs of older adults readmitted to
the hospital. J Am Geriatr Soc 2014;62:1378-80.
Henderson JB, Sorser SA, Atia AN, Catalano MF.
Repair of esophageal perforations using a novel
endoscopic suturing system. Gastrointest Endosc.
2014;80:535-7.
Hick JL, Einav S, Hanfling D, Kissoon N, Dichter
JR, Devereaux AV, Christian M. Surge capacity
principles: care of the critically ill and injured
during pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e1S-e16S.

Hollingsworth T. Which clinical guidelines should
be implemented for management of osteopenia
in primary care? A Clin-IQ. J Patient-Centered Res
Rev 2014;1:201-3.
Hudson J. Recurrent aphthous stomatitis:
diagnosis and management in primary care.
J Patient-Centered Res Rev 2014;1:197-200.
Kennelly P, Malloy E. Peace profile: Afghan peace
volunteers. Peace Review: A Journal of Social
Justice 2014;26:137-40.
Kim SJ, Lee JH, Kim S, Nakagawa S, Bertelson H,
Lam J, Yoo JW. Associations between the 2007
Medicare reimbursement reduction for bone
mineral density testing and osteoporosis drug
therapy patterns of female Medicare beneficiaries.
Patient Prefer Adherence 2014;8:909-15.
Kim SJ, Lee JH, Nakagawa S, Bukowy E, Biswas
A, Han B, Cho Y, Shin HP, Yoo JW. Predictors of
hospitalization among newly admitted skilled
nursing facility residents: rethinking the role of
functional decline. J Patient-Centered Res Rev
2014;1:70-6.
Kim SJ, Park EC, Kim S, Nakagawa S, Lung J,
Choi JB, Ryu WS, Min TJ, Shin HP, Kim K, Yoo
JW. The association between quality of care and
quality of life in long-stay nursing home residents
with preserved cognition. J Am Med Dir Assoc
2014;15:220-5.
Kim SJ, Yoo JW, Lee SG, Kim TH, Han KT, Park
EC. Governmental designation of spine specialty
hospitals, their characteristics, performance and
designation effects: a longitudinal study in Korea.
BMJ Open 2014;4:e006525.

Malone ML, Yoo JW, Goodwin JS. An introduction
to the acute care for elders. In: Malone ML,
Capezuti EA, Palmer RM (eds). Acute Care for
Elders: A Model for Interdisciplinary Care. New
York: Humana Press, 2014, pp. 1-7.
May T, Zusevics KL, Derse A, Strong KA, Jeruzal
J, La Pean Kirschner A, Farrell MH, Spellecy R.
The limits of traditional approaches to informed
consent for genomic medicine. HEC Forum
2014;26:185-202.
Niezgoda JA, Hardin ST, Kubat N, Acompanado J.
The management of intractable pain with adjuvant
pulsed electromagnetic field therapy. Adv Skin
Wound Care 2014;27:205-9.
Orgill BD, Simpson D. Toward a glossary of
competency-based medical education terms.
J Grad Med Educ 2014;6:203-6.
Ornelas J, Dichter JR, Devereaux AV, Kissoon N,
Livinski A, Christian MD. Methodology: care of
the critically ill and injured during pandemics and
disasters: CHEST consensus statement. Chest
2014;146:35S-41S.
Osborne K, Hanson L. Labor down or bear down:
A strategy to translate second-stage labor
evidence to perinatal practice. J Perinat Neonatal
Nurs 2014;28:117-26.
Pfaff NF. The new hypertensive guidelines for
pregnancy: what every nurse should know.
J Perinat Neonatal Nurs 2014;28:91-3.
Raff H. Cushing syndrome: update on testing.
Endocrinol Metab Clin North Am 2014 Dec 9
[Epub ahead of print].

Trivedi H, Szabo A, Zhao S, Cantor T, Raff H.
Circadian variation of mineral and bone parameters
in end-stage renal disease. J Nephrol 2014 Aug 20
[Epub ahead of print].
Turkal N, Lambrecht RS. Welcome to the Journal of
Patient-Centered Research and Reviews. J PatientCentered Res Rev 2014;1:6.
Voegeli M, Wolf M, Smith TC, Sokn E, Schrant H.
Advancing the pharmacy practice model through
statewide resident collaboration. Am J Health Syst
Pharm 2014;71:612, 614.
White SB, Tutton SM, Rilling WS, Kuhlmann RS,
Peterson EL, Wigton TR, Ames MB. Percutaneous
in utero thoracoamniotic shunt creation for fetal
thoracic abnormalities leading to nonimmune
hydrops. J Vasc Interv Radiol 2014;25:889-94.
Williams HC, Rogers A. A rendezvous with an
unexpected diagnosis. J Patient-Centered Res Rev
2014;1:46-7.
Winkler BE, Hartig F, DuCanto J, Koch A, Georgieff
M, Lungwitz YP, Muth CM. Helicopter-based inwater resuscitation with chest compressions: a pilot
study. Emerg Med J 2014 Sep 26 [Epub ahead of
print].
Woller TW, Knoer S, Daniels R. Strategic
considerations for centralization of services across
the pharmacy enterprise. Am J Health Syst Pharm
2015;72:74-7 [Epub 2014 Dec 15].
Wong RY, Vollbrecht M, Pagel P. How to
disseminate the ACE model of care beyond one
unit. In: Malone ML, Capezuti EA, Palmer RM (eds).
Acute Care for Elders: A Model for Interdisciplinary
Care. New York, NY: Humana Press, 2014 pp. 117-129.

Koch PE, Simpson D, Toth H, Marcdante K,
Densmore E, Young S, Weisgerber M, Morzinski JA,
Havas N. Clinical clerkship students’ perceptions
of (un)safe transitions for every patient. Acad Med
2014;89:477-81.

Raff H, Auchus RJ, Findling J, Nieman L. Urine free
cortisol in the diagnosis of Cushing’s syndrome: is
it worth doing and, if so, how? J Clin Endocrinol
Metab 2014 Nov 25:jc20143766 [Epub ahead of
print].

Konkel K, Hussussian C. Technique tip: avoiding
wound complications after a large opening wedge
osteotomy of the distal tibia using a soft-tissue
expander. Foot Ankle Int 2014;35:631-5.

Raff H, Carroll T. Cushing’s syndrome: from
physiological principles to diagnosis and clinical
care. J Physiol 2014 Dec 5 [Epub ahead of print].

Attam R, Arain MA, Bloechl SJ, Singh M, Wallace T,
Henderson JB, Catalano MF, Guda NM. Wet suction
FNA technique: a novel technique for EUS-FNA.
Results of a prospective, randomized and blinded
study. Gastrointest Endosc 2014;79:AB110.

Raff H, Gehrand A, Bruder ED, Hoffman MJ,
Engeland WC, Moreno C. Renin knockout rat:
control of adrenal aldosterone and corticosterone
synthesis in vitro and adrenal gene expression.
Am J Physiol Regul Integr Comp Physiol.
2015;308:R73-7.

Baumgardner DJ, Bernhard KA, Egan G.
Weather and environmental exposures in human
blastomycosis: Northern Wisconsin. J PatientCentered Res Rev 2014;1:147.

Kovach CR, Woods DL, Devine EC, Logan BR,
Raff H. Biobehavioral measures as outcomes: a
cautionary tale. Res Gerontol Nurs 2014;7:56-65.
Kunz JH, Greenley RN, Mussatto KA, Roth-Wojcicki
B, Miller T, Freeman ME, Lerand S. Personal
attitudes, perceived social norms, and health-risk
behavior among female adolescents with chronic
medical conditions. J Health Psychol 2014;
19:877-86.
Lee JH, Kim SJ, Lam J, Kim S, Nakagawa S, Yoo
JW. The effects of shared situational awareness on
functional and hospital outcomes of hospitalized
older adults with heart failure. J Multidiscip Healthc
2014;7:259-65.
Lewis J. A systematic literature review of the
relationship between stretching and athletic injury
prevention. Orthop Nurs 2014;33:312-20.

Raff H, Sharma ST, Nieman LK. Physiological
basis for the etiology, diagnosis, and treatment of
adrenal disorders: Cushing’s syndrome, adrenal
insufficiency, and congenital adrenal hyperplasia.
Compr Physiol 2014;4:739-69.
Singh K, Malone ML. The future of acute care
for elders. In: Malone ML, Capezuti EA, Palmer
RM (eds). Acute Care for Elders: A Model for
Interdisciplinary Care. New York: Humana Press,
2014, pp. 245-9.

Lung J, Khan A, Malone ML. Pyogenic liver abscess
in a frail older adult. J Am Geriatr Soc 2014;
62:408-9.

Soryal S, Boltz M, Wilber S, Malone ML. How
to improve care for seniors in the emergency
department. In: Malone ML, Capezuti EA, Palmer
RM (eds). Acute Care for Elders: A Model for
Interdisciplinary Care. New York: Humana Press,
2014, pp.217-31.

Maley A, Olasz EB. Skin disease in solid organ
transplant recipients. The Dermatologist
2014;22:28-34.

Sullivan GM, Simpson D. Graduate medical
education needs new ideas. J Grad Med Educ
2014;6:193-4.

Maley A, Rhodes A. Cutaneous melanoma:
preoperative tumor diameter in a general
dermatology outpatient setting. Dermatol Surg
2014;40:446-54.

Sullivan GM, Simpson D, Cook DA, Delorio
NM, Andolsek K, Opas L, Philibert I, Yarris LM.
Redefining quality in medical education research:
a consumer’s view. J Grad Med Educ 2014;6:424-9.

Malone M, Capezuti E, Malsch A. Do more with less.
J Am Geriatr Soc 2014;62:1977-8.

Tillett J. Mentoring leaders in perinatal nursing.
J Perinat Neonatal Nurs 2014;28:3-5.

Malone ML, Capezuti EA, Palmer RM (eds). Acute
Care for Elders: A Model for Interdisciplinary Care.
New York: Humana Press, 2014.

Tosh PK, Feldman H, Christian MD, Devereaux AV,
Kissoon N, Dichter JR. Business and continuity
of operations: care of the critically ill and injured
during pandemics and disasters: CHEST consensus
statement. Chest 2014;146:e103S-e117S.

Abstracts

Baumgardner DJ, Chaturvedi S, Li X. My
chrysosporium is a scedosporium. J PatientCentered Res Rev 2014;1:48-9.
Bernhard KA, Siddiqui DS, Louks HA, Chauhan SP.
Gynecologic surgeons: profiling at a glance.
J Patient-Centered Res Rev 2014;1:55-6.
Brown D, Denson K, Duthie EH, Denson S,
Simpson D, Manzi G, Rehm J, Wessel B, Padua K,
Collaboratives M. Geriatrics education is also a
“team sport.” J Am Geriatr Soc 2014;62:S110-1.
Bunce K, Varade S. Does the presentation of an
after visit summary improve patient satisfaction:
physician versus other team members? J PatientCentered Res Rev 2014;1:49-50.
Carlton PK, Hartlaub J. Intensive counseling and
behavioral interventions for weight loss in primary
care. J Patient-Centered Res Rev 2014;1:53.
Cox Bauer CM, Bose D, Bernhard KA, Baumgardner
DJ. Feasibility of using the Breastfeeding Efficacy
Beliefs Inventory for improving breastfeeding
initiation rates in an urban population. J PatientCentered Res Rev 2014;1:48.
Dalmar A, Chua TY, Singh M. Weight loss after
laparoscopic adjustable gastric banding: the role
of race, BMI and age. J Patient-Centered Res Rev
2014;1:61.
Denson K, Manzi G, Foy P, Vasudev B, Malmsten
C, Rehm J, Brown D, Simpson D, Duthie E. Using
teaching objective structured clinical examination
(OSCEs) to expand fellows’ perceptions around
quality care for older adults. J Am Geriatr Soc
2014;62:S205.

aurora.org/research

72

Additional strategic research
Dunbar S, Englund J. Young athlete with bilateral
exertional calf pain. J Patient-Centered Res Rev
2014;1:50.
Even L, Sen L, Leonhardt KK, Simpson D, Mundh
I. Utilizing resident council leaders to improve the
culture of patient care through systematic design
of our clinical learning environment. J PatientCentered Res Rev 2014;1:148-9.
Fink J, Morris GL 3rd, Singh M, Nelson D, Walker
R, Cisler RA. Obesity remains underdiagnosed:
discordant documentation of obesity body mass
index and obesity diagnosis in patients’ electronic
medical record. J Patient-Centered Res Rev
2014;1:142.
Fink J, Smith D, Singh M, Ihrke D, Cisler RA.
Employee wellness program: participation rates
among obese employees and selection patterns of
available alternative activities. J Patient-Centered
Res Rev 2014;1:146-7.
Forgie M, Bernhard KA, Salvo NP. Tdap
immunization in pregnancy: provider compliance
with CDC guidelines. J Patient-Centered Res Rev
2014;1:152-3.
Garbett DL, Joshi MJ, Patel AR, Garbett TM.
Factors influencing post-spinal puncture
headaches or leaks. J Patient-Centered Res Rev
2014;1:143.
Guda NM, Gupta N, Klyve D, Allen JI, Deas TM,
Huang L, Ketover SR, Etzkorn KP, Gutta KG, Morris
S, Sharma P, Hernandez LV. Temporal trends in the
detection of right-sided colon polyps: summary
data of large GI practices. Gastrointest Endosc
2014;79:AB117.
Guda NM, Freeman ML, Catalano MF, Romagnuolo
J, Pfau PR, Dua KS, Cote GA, Mullady D, Tarnasky
PR, Whitcomb DC, Wilcox CM, Johnson CD.
Recurrent acute pancreatitis significantly impairs
the quality of life. Validation of RAPQOLI.
Gastroenterology 2014;S621-2.
Haflund O, Amin P, Iqbal A. Azathioprine
hypersensitivity mimicking sepsis in a patient
with Crohn’s disease. J Patient-Centered Res Rev
2014;1:49.
Handler H, Bernhard KA, Baumgardner DJ.
Assessment of resident knowledge and comfort
with menopause and openness to integrative
therapies: the short term impact of evidence based
menopause hand-out. J Patient-Centered Res Rev
2014;1:57.
Hasan M, Karst A, Khan A, Malone M, Lung J, Singh
M. The unique needs of older patients who are
re-admitted to the hospital. J Patient-Centered Res
Rev 2014;1:53-4.
Hirsch DM, Bose D, Baumgardner DJ, Garland
JS. Maternal group B streptococcus colonization
and neonatal morbidity in premature preterm
rupture of membranes. J Patient-Centered Res Rev
2014;1:59.
Johnson KT, Bernhard KA, Baumgardner DJ.
Demographic features of Aurora blastomycosis
cases, 2007-2013. J Patient-Centered Res Rev
2014;1:151-2.
Kaiser ML, Halsey J. Evaluation of sleep inducing
medications as a contributor to adverse events in
the elderly. J Patient-Centered Res Rev 2014;1:57-8.
Katers KM, Dalhgren MJ. Optimizing stress ulcer
prophylaxis in critical care patients. J PatientCentered Res Rev 2014;1:50-1.
Khan A, Hook ML, Pagel P, Vollbrecht MA, Singh
M. Electronic data modeling to predict 30-day
hospital readmission for older adults. J PatientCentered Res Rev 2014;1:142-3.
Khan A, Hook M, Pagel P, Vollbrecht M, Singh M,
Malsch A, Malone ML. Electronic data modeling
to predict 30-day hospital readmission for older
adults. J Am Geriatr Soc 2014;62:S63-4.

73

Annual Report 2014

Khan A, Simpson M, Singh M, Geng Y, Malone ML.
Validation of delirium instrument generated by
the electronic health record in hospitalized older
adults. J Am Geriatr Soc 2014;62:S63.
Khan A, Simpson M, Singh M, Malone ML, Hook ML.
Using the electronic health record as an innovative
approach to measure delirium in older hospitalized
patients. J Patient-Centered Res Rev 2014;1:143.
Khan A, Singh M, Aziz A, Siddiqi A. A survey of
concerns in end-of-life care: perspective from
Pakistan. J Am Geriatr Soc 2014;62:S198.
Kim RE, Gupta N, Vennalaganti P, Repici A, Parasa
S, Guda NM, Sharma P. Computer aided diagnosis
using narrow band imaging (NBI) – a novel
objective tool for differentiating tubular adenoma
and hyperplastic colon polyps. Gastrointest
Endosc 2014;79:AB474.
Kumar S, Pedersen R. Impact of donation after
cardiac death (DCD) allografts on incidence and
severity of recurrent hepatitis C (HCV) and graft
survival post liver transplantation (LT) for HCV.
Hepatology 2014;60:370A.
Louks H, Fixmer J, Baumgardner DJ. Clinical
approach to non-resolving pneumonia: a survey
of Wisconsin primary care clinicians. J PatientCentered Res Rev 2014;1:48
Lung J, Khan A, Singh K, Malone M, Singh M. An
electronic medical record marker for delirium in
hospitalized elderly. J Patient-Centered Res Rev
2014;1:59-60.
Macias J, Khan A, Malone ML. Delirium days as a
quality indicator for medical surgical units in six
hospitals. J Am Geriatr Soc 2014;62:S69.
Mackinnon J, Muntz M, Mitchell J, Simpson D,
Kuester J, Gilligan MA, Kay C, Bernstein R. Valueadded tasks for early clinical learners (ECL) on a
continuity rotation in the patient centered medical
home. Central Group on Educational Affairs 2014
Spring Conference Program (https://www.aamc.
org/download/374286/data/cgeafinalprogram.
pdf). Cleveland, OH: Association of American
Medical Colleges, 2014:97.
Matias S, Patel B, Palla K, Handu D, Imam S,
Freeman S. Does geriatric service admission
decrease a veterans drug burden index? J Am
Geriatr Soc 2014;62:S144.
Mehl SJ, Anderson A, Gunn L, Stearns J, Simpson
D. Team competencies in patient care. J PatientCentered Res Rev 2014;1:54-5.
Morris GL 3rd, Chapman K, Nelson D, Cisler RA,
Walker R. Wisconsin physician survey on diagnosis
and treatment of obesity. J Patient-Centered Res
Rev 2014;1:147-8.
Nilakantan V, Last B, Singh M, Dalmar A, Shi Y.
Racial disparities in graft loss following kidney
transplantation – a single center experience.
J Patient-Centered Res Rev 2014;1:56.
Nilakantan V, Singh M, Perez R. Racial disparity in
kidney transplantation: a review and meta-analysis.
J Patient-Centered Res Rev 2014;1:146.
Olowoyeye O, Bernhard K, Baumgardner DJ.
Clinical approach to non-responsive pneumonia
diagnosed in the primary care office: a
retrospective feasibility study. J Patient-Centered
Res Rev 2014;1:51-2.
Padua K, Simpson D, Denson K, Malone M, Rehm
J, Manzi G, Barbieri KA, Siddiqui A, Finn T, Duthie
E. It’s an elephant! Lessons learned in “mobilizing”
geriatric fast facts for education. J Am Geriatr Soc
2014;62:S205-6.
Ray V, Mead-Meucci J, Pelner M, Singh M. A
decade of early intervention for psychiatric
patients in hospital emergency departments by a
behavioral health intake team. J Patient-Centered
Res Rev 2014;1:144.

Reynolds K, Sullivan Vedder L, Baumgardner DJ,
Bidwell J, Frederick T, Simpson D. Calculating
time/effort to develop medical specialty-approved
board (re)certification modules for part IV practice
performance assessment. J Patient-Centered Res
Rev 2014;1:145-6.
Salvo N, Siddiqui DS, Bernhard K, Chauhan S, Chen
H-Y. Outcome of different routes of hysterectomy
by uterine weight in overweight and obese patients.
J Patient-Centered Res Rev 2014;1:54.
Siegel R, Bernhard K, Baumgardner DJ. Resident
physician recognition of obesity and patient
education in a family medicine residency clinic
within an underserved community. J PatientCentered Res Rev 2014;1:60-1.
Siegel R, Bernhard KA, Baumgardner DJ. Obese
patients’ compliance and satisfaction with
educational intervention: O.N.E. Packet. J PatientCentered Res Rev 2014;1:153.
Simpson D, Anderson A, Kelly C, Brill JD, Stearns
J. Aligning training with the 2020 physician’s job
description. J Patient-Centered Res Rev 2014;1:52.
Simpson D, Siddiqui D, Bidwell J, Battiola R, Greer
D. Aligning clinical teaching evaluation forms with
physician competencies. Ottawa 2014 Abstract
Book: Transforming Healthcare Through Excellence
in Assessment and Evaluation (http://media.wix.
com/ugd/bd1cfc_8ef41237a92847fc87354972c9b
d22d8.pdf). Ottawa, Canada: Ottawa Conferences,
2014:132.
Simpson D, Wilkerson LA, Hafler JP. Faculty
development strategies focused on assessment: not
boring!! Ottawa 2014 Abstract Book: Transforming
Healthcare Through Excellence in Assessment and
Evaluation (http://media.wix.com/ugd/bd1cfc_8e
f41237a92847fc87354972c9bd22d8.pdf). Ottawa,
Canada: Ottawa Conferences, 2014:34.
Singh M, Dalmar A. Use of guided imagery for
reduction of pain and anxiety and improved quality
of sleep in patients undergoing surgery: a review
and meta-analysis. J Patient-Centered Res Rev
2014;1:146.
Singh M, Kohler L, Davies J. The effect of using
guided mental imagery for patients receiving knee
or hip replacement. J Patient-Centered Res Rev
2014;1:51.
Singh M, Kohler L, Davies J, Reynolds K. The use of
guided mental imagery for patients receiving knee
or hip replacement surgery. J Altern Complement
Med 2014;20:A67.
Sorser SA, Atia A, Khan NM, Labinski J, Guda NM,
Catalano MF. The stack sign: an important anatomic
landmark in the training of endosonographic
evaluation of the pancreas. Gastrointest Endosc
2014;79:AB308.
Sorser SA, Mayer A, Atia A, Henderson JB, Ali
S, Khan NM, Labinski J, Guda NM, Catalano
MF. Abdominal cutaneous nerve entrapment
syndrome (acnes): an overlooked cause of
abdominal pain in PTS referred for the evaluation
of type III sphincter of oddi dysfunction (SOD) &
unexplained abdominal pain. Gastrointest Endosc
2014;79:AB159-60.
Stearns MA, Haq C, Brill JR, Anderson A, Simpson
D. Training physicians to care for urban populations:
a win-win for health systems. J Patient-Centered
Res Rev 2014;1:144.
Teshome M, Belete H. An unusual case of recurrent
pneumonia. J Patient-Centered Res Rev 2014;1:52.
Yu H, Hararah M, Kwok B, Brill JR, Ames D.
Chronic illness management in teams of urban
multidisciplinary scholars: CIMTUMS. J PatientCentered Res Rev 2014;1:145.

Aurora St. Luke’s programs
rank among nation’s top 50
The gastroenterology and
gastrointestinal (GI) surgery
department at Aurora St. Luke’s
Medical Center, Milwaukee, was
the highest ranking GI program in
Wisconsin among those nationally
ranked by U.S. News & World
Report in its 2014-15 evaluation of
the nation’s best hospitals.
Aurora St. Luke’s gastroenterology
and GI surgery department

ranked 39th nationally among 1,586
programs that qualified for review.
Aurora St. Luke’s cardiology and
heart surgery (see page 33), diabetes
and endocrinology, geriatrics and
pulmonology departments also
ranked nationally among the top
50 hospitals in their respective
categories, contributing to the
tertiary care facility’s ranking as one
of the best hospitals in the state.

Aurora BayCare Medical Center
(Green Bay) and Aurora West
Allis Medical Center also were
listed as among the best
hospitals in Wisconsin.

Research Media and Publishing
The Research Media and Publishing team
supports production of the Aurora Research
Institute Patient-Centered Research Annual
Report and Aurora Health Care’s scientific
journal, Journal of Patient-Centered Research
and Reviews.
Publication is an important research outcome.
The team also provides editing and design
services for research manuscripts and other
research communications.

Thank you!
To the Research Subject Protection Program for its management of the institutional review
boards, review of all human subject research submissions and regulatory guidance and support.
To the institutional review board members for the countless volunteer hours they dedicate
to ensure the safety and welfare of subjects participating in Aurora research.
Together, these groups help Aurora achieve the highest level of
professional and ethical standards in human subject research.
To all the caregivers who contributed data, content and feedback to this report.
The hard work and dedication of Aurora’s caregivers are evident on each page.
aurora.org/research
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